# Dissertation for the award of the degree <br> "Doctor rerum naturalium" <br> of the Georg-August-Universität Göttingen 

# Crystal Structure \& <br> Characterization of the SCOC Coiled Coil Domain 

submitted by

## Caroline Anna Julie Behrens

from Hamburg-Altona

within the doctoral program<br>Biomolecules: Structure - Function - Dynamics of the Georg-August University School of Science (GAUSS)



Göttingen 2013

## Members of the Thesis Committee

Dr. Karin Kühnel (1st Reviewer)
Department of Neurobiology, Max Planck Institute for Biophysical Chemistry
Prof. Dr. Michael Thumm (2nd Reviewer)
Department of Biochemistry II, University of Göttingen
Prof. Dr. Markus Zweckstetter
Research Group Structure Determination of Proteins Using NMR, Max Planck Institute for Biophysical Chemistry

Prof. Dr. Marina Rodnina
Department of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry

Date of the oral examination: August $7^{\text {th }}, 2013$

## Affidavit

Herewith I declare that I have written this Dissertation independently and without any sources or aids other than quoted.

Göttingen, June $14^{\text {th }}, 2013$
(Caroline Anna Julie Behrens)

## Abstract

Autophagy is a conserved eukaryotic process for the degradation of cytosolic content. An expanding double layered membrane takes up part of the cytoplasm and matures to an autophagosomal vesicle. The autophagosome fuses with the lysosome, where its content is degraded. The short coiled coil protein (SCOC) forms a complex with fasciculation and elongation protein zeta 1 (FEZ1). Their complex is involved in autophagy regulation. Here, I present the crystal structure of the functional important human SCOC coiled coil domain (residues 78-159), which was determined at $2.8 \AA$ resolution. SCOC forms a parallel left handed coiled coil dimer. I observed two distinct dimers in the crystal structure with a 3 -molecule asymmetric unit, showing that SCOC is conformational flexible. Importantly, several of the canonical hydrophobic a/d-heptad core positions are occupied by well conserved, polar and charged residues. I assumed that these non-canonical residues might have a strong effect on the stability and oligomerization state of SCOC. The influence of the residues was investigated by characterising mutant SCOC constructs. The double core mutations E93V/K97L and N125L/N132V led to a change from dimer to either trimer or tetramer formation and the thermostabilities of these mutants were dramatically increased. Moreover, I present the formation of a stable homogeneous complex of SCOC with the coiled coil domain of FEZ1. A minimal FEZ1 region (residues 227-290) was sufficient for interaction with SCOC. Complex formation with the SCOC double core mutants was impaired, showing that dimerization of SCOC is essential for interaction with FEZ1. In addition I identified SCOC surface residue R117 as important for binding.

The human pathogen Shigella flexneri escapes autophagy by a sophisticated mechanism involving the Shigella flexneri proteins VirG and IcsB-IpgA. VirG is an autotransporter protein, consisting of a signal sequence, a passenger domain (residues $52-758$ ) and a transmembrane domain. I established a purification protocol for the VirG (52-758) under denaturing conditions. First crystallization trials of refolded VirG passenger domain yielded spherulites and microcrystalline structures. Initial studies of IcsB-IpgA indicate, that IcsB contains flexible and presumably unfolded regions, while its chaperone IpgA is well structured and stable.

## Acknowledgements

First of all, I would like to thank my supervisor Dr. Karin Kühnel for her advice and support during my thesis. Her door was always open for discussion and I am very thankful for her guidance into the field of protein crystallography. Furthermore, I would like to thank Prof. Dr. Reinhard Jahn for financial support during the first year of my PhD , for the infrastructure in his department that allowed me to pursue my research, and for general scientific and personal advice. Next, I would like to express my gratitude towards Dr. John Chua, Beyenech Binotti and Brigitte Barg-Kues for the tremendous efforts they made during our collaboration on the SCOC-FEZ1 interaction. Dagmar Diezmann and Michaela Hellwig have provided crucial and excellent technical support, which I appreciated a lot.

I am very thankful to all those who have helped me with several methods that I conducted during the course of my thesis. My thanks goes to Dr. Matias Hernandez for teaching me how to use the SEC-MALLS equipment. I am very grateful for help with nucleotide analysis that was made possible by Dr. Corinna Pohl and Prof. Dr. Marina Rodnina. My gratitude goes to Prof. Dr. Markus Zweckstetter and Dr. Stefan Bibow for two-dimensional NMR analysis. Dr. Danilo Meyer and Prof. Dr. Kai Tittmann provided advice and equipment for the ITC measurements, for which I am very thankful. A special thanks goes to Dr. Vlad Pena and Dr. Ashwin Chari for the extensive discussions and helpful advice on crystallography methods and X-ray data collection. I would also like to express my gratitude towards the staff of beamline X10SA at the SLS.

Thanks a lot to all my friends and colleagues in the Jahn department for a nice and supportive working atmosphere, and to Frieder for routine and quick daily support with lab equipment and the coffee machine. Janina and Saskia, working with you was a professional and personal gain. Andreea, thanks for being the most helpful bench partner I can imagine. Thanks to Birk for constant coffee delivery during the writing process!

Last but not least I would like to thank GGNB for the financial support during my thesis, and moreover also for the many possibilities I was able to experience by learning new methods, skills and friends in graduate school.

Finally, I would like to thank my parents and my siblings for just being as awesome as you are! Our family support system has been the greatest gift through the last year(s). Thank you, Andreas - not only for Linux and ETEX assistance - but for everything else.

## Contents Overview

1 Introduction ..... 1
1.1 General introduction to Autophagy ..... 1
1.2 SCOC and its interaction partners ..... 7
1.3 Shigella flexneri and Autophagy ..... 11
2 Materials and Methods ..... 17
2.1 Materials ..... 17
2.2 Methods ..... 32
3 SCOC and its interaction partners ..... 57
3.1 Characterization \& structure determination of the SCOC coiled coil domain ..... 57
3.2 Interaction of SCOC's coiled coil domain with Arl1 and FEZ1 ..... 99
3.3 Discussion ..... 110
3.4 Outlook ..... 115
4 Shigella flexneri and Autophagy ..... 117
4.1 Characterization of VirG ..... 117
4.2 Characterization of IcsB-IpgA ..... 124
4.3 Discussion and Outlook ..... 130
A Appendix ..... 133
A. 1 DNA sequences of synthetic genes ..... 133
A. 2 Crystallization conditions of SCOC ccd constructs ..... 135
A. 3 Supplementary Figures ..... 143
A. 4 Computational Methods ..... 145
A. 5 Mass spectrometry results ..... 160
Bibliography ..... 163

## Contents

1 Introduction ..... 1
1.1 General introduction to Autophagy ..... 1
1.1.1 Subtypes of Autophagy ..... 1
1.1.2 The autophagic core machinery ..... 4
1.2 SCOC and its interaction partners ..... 7
1.2.1 SCOC: an Arl1 effector ..... 7
1.2.2 SCOC interaction with Arl1 ..... 7
1.2.3 SCOC interaction with FEZ1 ..... 8
1.2.4 Coiled coil domains: features, stability and oligomer- ization state ..... 10
1.2.5 Aims ..... 10
1.3 Shigella flexneri and Autophagy ..... 11
1.3.1 Selective Autophagy: Xenophagy ..... 11
1.3.2 Escape of intracellular Shigella flexneri from au- tophagy ..... 12
1.3.3 The autotransporter protein VirG ..... 13
1.3.4 The secretion protein IcsB-IpgA ..... 15
1.3.5 Aims ..... 15
2 Materials and Methods ..... 17
2.1 Materials ..... 17
2.1.1 Enzymes ..... 17
2.1.2 Kits ..... 17
2.1.3 Columns for Chromatography ..... 18
2.1.4 Antibodies ..... 18
2.1.5 Buffers, media and antibiotics ..... 19
2.1.6 DNA constructs ..... 23
2.1.7 Oligonucleotides ..... 28
2.2 Methods ..... 32
2.2.1 Molecular cloning ..... 32
2.2.1.1 PCR ..... 32
2.2.1.2 DNA agarose gel electrophoresis and gel extraction purification ..... 34
2.2.1.3 Restriction digest ..... 34
2.2.1.4 Ligations ..... 34
2.2.1.5 Transformation ..... 35
2.2.1.6 Plasmid purification ..... 35
2.2.1.7 Mutagenesis ..... 35
2.2.2 Expression and Purification ..... 36
2.2.2.1 Expression analysis ..... 36
2.2.2.2 Minimal expression for selenomethione-labelling ..... 37
2.2.2.3 Minimal expression for ${ }^{15} \mathrm{~N}$-labelling ..... 37
2.2.2.4 Expression and purification of Strep-tagged SCOC (78-159) domain and mutants ..... 37
2.2.2.5 Expression and purification of His-tagged SCOC constructs ..... 38
2.2.2.6 Expression and purification of GST-SCOC fusion proteins ..... 40
2.2.2.7 Expression and purification of Arl1 (15- 181) Q79L 41
2.2.2.8 Coexpression and copurification of SCOC- FEZ1 complexes ..... 42
2.2.2.9 Expression and denaturing purification of VirG (353-758) ..... 43
2.2.2.10 Expression and denaturing purification of VirG passenger domain (52-758) ..... 45
2.2.2.11 Expression and purification of $\operatorname{IcsB}-\operatorname{IpgA}$ complexes ..... 46
2.2.3 Biochemical methods ..... 47
2.2.3.1 SDS-PAGE and Western blot ..... 47
2.2.3.2 Limited proteolysis ..... 48
2.2.3.3 N-terminal sequencing ..... 48
2.2.3.4 GST-Pulldown ..... 49
2.2.3.5 Nucleotide-dependent Arl1-Pulldown ..... 49
2.2.3.6 Isothermal titration calorimetry ..... 50
2.2.3.7 Circular Dichroism spectroscopy ..... 50
2.2.3.8 SEC-MALLS ..... 51
2.2.3.9 Crystallization ..... 51
2.2.3.10 Flash cooling of protein crystals ..... 53
2.2.4 Computational methods ..... 53
2.2.4.1 Structure determination of SCOC ccd ..... 53
2.2.4.2 Sequence alignment of SCOC ..... 55
3 SCOC and its interaction partners ..... 57
3.1 Characterization \& structure determination of the SCOC coiled coil domain ..... 57
3.1.1 Generation of SCOC constructs for crystallization ..... 57
3.1.2 Expression and Purification of SCOC constructs ..... 60
3.1.2.1 Expression and Purification of SCOC (78- 159) ..... 60
3.1.2.2 Expression and Purification of SCOC (78- 132) and SCOC (112-159) ..... 62
3.1.2.3 Expression and Purification of SCOC (78- 141) and SCOC (78-151) ..... 64
3.1.2.4 Expression and Purification of GST-tagged SCOC constructs ..... 66
3.1.3 Biochemical and biophysical characterization of SCOC coiled coil domain ..... 66
3.1.3.1 Limited proteolysis of SCOC coiled coil domain ..... 66
3.1.3.2 Pull-down experiments for the identifica- tion of novel SCOC binding partners ..... 71
3.1.3.3 Analysis of secondary structure and sta- bility of SCOC coiled coil domain by CD spectroscopy ..... 72
3.1.3.4 Characterization of oligomerization state of SCOC coiled coil domain by SEC-MALLS measurements ..... 73
3.1.4 Crystallization of SCOC coiled coil domain ..... 73
3.1.4.1 Crystallization screening of SCOC (78- 159) ..... 76
3.1.4.2 Refinement of the crystallization condi- tions of SCOC (78-159) crystals ..... 76
3.1.4.3 Screening of other SCOC ccd constructs ..... 80
3.1.4.4 Crystallization of selenomethionine-labelled SCOC crystals ..... 80
3.1.4.5 Crystals grown with in situ proteolysis ..... 80
3.1.5 Structure determination ..... 81
3.1.6 Structure of SCOC's coiled coil domain ..... 85
3.1.7 Biophysical characterization of SCOC's mutants ..... 91
3.2 Interaction of SCOC's coiled coil domain with Arl1 and FEZ1 99
3.2.1 Insights into SCOC-FEZ1 complex formation ..... 99
3.2.1.1 Approaches to find a minimal FEZ1 bind- ing domain ..... 99
3.2.1.2 Coexpression and copurification of SCOC- FEZ1 ccd complexes ..... 101
3.2.1.3 Characterization of SCOC-FEZ1 complexes ..... 102
3.2.2 Interaction of SCOC with Arl1 ..... 104
3.2.2.1 Expression, purification and nucleotide ex- change of Arl1 ..... 104
3.2.2.2 Arl1-Pulldown experiments ..... 106
3.2.2.3 Analytical gel filtration ..... 107
3.2.2.4 ITC ..... 108
3.3 Discussion ..... 110
3.3.1 Characterization and structure of SCOC ccd ..... 110
3.3.2 Interaction with FEZ1 and Arl1 ..... 111
3.4 Outlook ..... 115
4 Shigella flexneri and Autophagy ..... 117
4.1 Characterization of VirG ..... 117
4.1.1 Expression and purification of VirG (353-758) ..... 117
4.1.2 Expression and purification of VirG (52-758) ..... 120
4.1.3 Analysis of refolding and secondary structure by CD spectroscopy ..... 120
4.1.4 Crystallization of VirG ..... 121
4.2 Characterization of IcsB-IpgA ..... 124
4.2.1 Expression and purification of IcsB-IpgA ..... 124
4.2.2 Limited proteolysis of IcsB-IpgA ..... 126
4.2.3 Crystallization of IcsB-IpgA ..... 127
4.2.4 Analysis of IcsB-IpgA by heteronuclear NMR spec- troscopy ..... 127
4.3 Discussion and Outlook ..... 130
A Appendix ..... 133
A. 1 DNA sequences of synthetic genes ..... 133
A.1.1 SCOC isoform 1 ..... 133
A.1.2 Arl1 full length Q79L ..... 133
A.1.3 VirG passenger domain (52-758) ..... 133
A.1.3.1 part 1 ..... 133
A.1.3.2 part 2 ..... 134
A. 2 Crystallization conditions of SCOC ccd constructs ..... 135
A. 3 Supplementary Figures ..... 143
A.3.1 Elution Profiles ..... 143
A.3.2 Purification of SCOC ccd-FEZ1 ccd complexes ..... 143
A. 4 Computational Methods ..... 145
A.4.1 COILS results ..... 145
A.4.2 HHpred results ..... 149
A.4.3 XDS input file ..... 153
A.4.4 Systematic absences by CORRECT.LP ..... 154
A.4.5 List of Se positions by Phenix ..... 158
A.4.6 T-COFFEE alignment across species ..... 158
A. 5 Mass spectrometry results ..... 160
Bibliography ..... 163

## List of Figures

1.1 Autophagosome formation ..... 2
1.2 Different subtypes of autophagy and possible membrane sources for membrane biogenesis ..... 3
1.3 Chronology of autophagosome biogenesis in mammals ..... 5
1.4 Complexes involved in initiation and nucleation of autophagy ..... 6
1.5 Crystal structure of GTP-Arl1 (PDB 1UPT) ..... 8
1.6 Helical wheel scheme of a parallel dimeric coiled coil ..... 11
1.7 Mechanism of Shigella flexneri's escape from xenophagy ..... 13
1.8 Secretion mechanism of type Va autotransporters ..... 14
1.9 Crystal structure of VirG (591-758) ..... 15
3.1 Overview of SCOC constructs used for crystallization ..... 58
3.2 Disorder prediction for SCOC Isoform 1 by IUpred [101, 102] ..... 58
3.3 Purification of SCOC (78-159) ..... 61
3.4 Purification of SCOC (78-132) ..... 62
3.5 Purification of SCOC (112-159) ..... 63
3.6 Purification of SCOC (78-141) ..... 64
3.7 Purification of SCOC (78-151) ..... 65
3.8 Purification of GST-SCOC full length ..... 67
3.9 Purification of GST-SCOC (78-159) ..... 68
3.10 Limited proteolysis of SCOC $(78-159)$ ..... 69
3.11 Limited proteolysis of SCOC $(78-159)$ by Trypsin and Subtilisin 70 ..... 70
3.12 GST-Pulldown of GST-SCOC (78-159) ..... 71
3.13 CD measurements of $\mathrm{SCOC}(78-159)$ ..... 73
3.14 SEC-MALLS experiments of SCOC (78-159) ..... 74
3.15 Exemplary crystallization hits of SCOC ccd constructs from 96-well plate screening ..... 75
3.16 Effect of streak seeding ..... 76
3.17 Crystals in hanging drops grown in 24 -well format ..... 77
3.18 Crystals obtained from refinement with grid and random screens 79 ..... 79
3.19 Crystals grown by in situ proteolysis ..... 82
3.20 Phenix Xtriage analysis ..... 86
3.21 Polygon plot by Phenix ..... 87
3.22 Ramachandran plot of all non Pro/Gly residues of SCOC L105M (78-159) ..... 87
3.23 Structure of SCOC coiled coil ..... 88
3.24 Two distinct SCOC dimers in the crystal structure ..... 90
3.25 Surface charge of SCOC ..... 91
3.26 SCOC conservation degree on the surface ..... 92
3.27 Sequence alignment of human SCOC isoforms and homologues ..... 92
3.28 Helical wheel diagram of the SCOC dimer ..... 93
3.29 Stabilizing interactions of non-canonical core positions ..... 94
3.30 CD spectra of SCOC mutants ..... 95
3.31 Thermal unfolding CD curves ..... 96
3.32 Analytical gel filtration elution profiles of SCOC mutants ..... 97
3.33 Elution profiles and corresponding molecular weights de- termined by SEC-MALLS are shown for all SCOC mutants ..... 98
3.34 FEZ1 domain ..... 99
3.35 Test coexpression of Strep-SCOC (78-159) with His-FEZ1 ccd constructs ..... 100
3.36 Copurification of wt Strep-SCOC (78-159) with His-FEZ1 (226-290) ..... 101
3.37 Coexpression of Strep-SCOC (78-159) constructs with His- FEZ1 (227-290) ..... 102
3.38 Analytical gel filtration of SCOC (78-159) —FEZ1 (227- 290) complex ..... 103
3.39 SEC-MALLS measurements of wt SCOC (78-159)—FEZ1 (227-290) complex ..... 103
3.40 Purification of Q79L Arl1 (15-181) ..... 105
3.41 Analysis of bound nucleotide ..... 106
3.42 His-Arl1 pulldown with SCOC (78-159) ..... 106
3.43 Analytical gel filtration ..... 107
3.44 ITC titration of SCOC ( $615 \mu \mathrm{M}$ ) into Arl1 ( $50 \mu \mathrm{M}$ ) ..... 109
3.45 Co-immunoprecipitation of full length FEZ1 tagged N- terminally with a V5 epitope and various EmGFP-SCOC (78- 159) variants from transfected 293 cell lysates using an anti-GFP antibody ..... 113
3.46 SCOC complexes in autophagy and beyond ..... 114
4.1 Purification of VirG (353-758) ..... 118
4.2 Purification of VirG (52-758) ..... 119
4.3 CD spectrum of VirG (353-758) at $20^{\circ} \mathrm{C}$ ..... 121
4.4 CD spectrum of VirG (52-758) in 1 M urea at $20^{\circ} \mathrm{C}$ ..... 121
4.5 96-well plate screening of VirG (353-758) ..... 122
4.6 96-well screening of VirG (52-758) ..... 123
4.7 Purification of IcsB-IpgA ..... 125
4.8 Limited proteolysis of IcsB-IpgA by Trypsin and Chymotrypsin ..... 126
4.9 Two-dimensional HSQC spectrum of IcsB-IpgA ..... 128
4.10 Two-dimensional TROSY spectra of IcsB-IpgA and IpgA ..... 129
A. 1 Elution profiles of SCOC-FEZ1 copurification ..... 143
A. 2 Schägger gels of copurifications of mutant SCOC ccd-FEZ1 ccd ..... 144

## List of Tables

2.1 Enzymes ..... 17
2.2 Kits ..... 17
2.3 Columns ..... 18
2.4 Antibodies ..... 19
2.5 Composition of 1 L minimal media for ${ }^{15} \mathrm{~N}$-labelling (mod- ified from Studier [90]) ..... 21
2.6 Composition of 1 L minimal media for selenomethionine- labelling (modified from Studier [90]) ..... 22
2.7 Composition of 1 L ZYM-50502 media [90] ..... 23
2.8 DNA constructs used in this study ..... 24
2.9 Oligonucleotides ..... 29
2.10 PCR reaction $50 \mu \mathrm{~L}$ ..... 32
2.11 PCR temperature cycling ..... 33
2.12 Restriction digest reaction setup ..... 34
2.13 Mutagenesis PCR reaction ( $25 \mu \mathrm{~L}$ ) setup ..... 35
2.14 Mutagenesis PCR Temperature cycling ..... 36
2.15 Composition of Arl1-Pulldown reactions ..... 49
3.1 N-terminal sequencing results ..... 70
3.2 SCOC peptides detected by mass spectrometry in band 5 ..... 72
3.3 Exemplary crystallization conditions of SCOC ccd con- structs from 96-well plate screening ..... 74
3.4 Crystallization conditions in 24 well plate screens ..... 77
3.5 Exemplary crystallization conditions of Random and Grid screens78
3.6 Exemplary crystallization conditions of in situ proteolysis ..... 83
3.7 Data collection ..... 83
3.8 Diffraction data and refinement statistics ..... 84
3.9 Summary of biophysical characterization of SCOC mutants ..... 93
3.10 FEZ1 fragments comprising the C-terminal ccd ..... 100
3.11 Summary of SCOC ccd crystallization ..... 111
3.12 Chrystallization probability of yeast FEZ1 homologues 116
4.1 Crystallization conditions of VirG (353-758) from 96-well plate screens122
4.2 Crystallization conditions of VirG (52-758) from 96-well screens 124

## List of Abbreviations

| aa | Amino acid |
| :--- | :--- |
| ccd | coiled coil domain |
| CD | Circular Dichroism |
| CV | Column volume |
| cvt | cytoplasm to vacuole |
| fwd | Forward |
| GdnHCl | Guanidinium Hydrochloride |
| GDP | guanosine diphosphate |
| GDPNHP | Guanosine-5'-[( $\beta, \gamma)$-imido]triphosphate |
| GST | glutathione-S-transferase |
| GTP | guanosine triphosphate |
| HSQC | Heteronuclear single quantum coherence spectroscopy |
| IPTG | Isopropyl $\beta$-D-1-thiogalactopyranoside |
| ITC | Isothermal titration calorimetry |
| kb | Kilo base |
| MAD | Multi wavelength anomalous diffraction or dispersion |
| MCS | multiple cloning site |
| MWCO | molecular weight cut off |
| NaAc | Sodium Acetate |


| PBS | Phosphate buffered saline |
| :--- | :--- |
| PCR | Polymerase chain reaction |
| PDB | Protein DataBase |
| PEG | poly ethylene glycol |
| rev | Reverse |
| rpm | Rounds per minute |
| RT | Room temperature, $22-25^{\circ} \mathrm{C}$ |
| SAD | Sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| SDS-PAGE | Sight Scaterer <br> SEC-MALLS |
| TROSY | Transverse relaxation optimized spectroscopy |
| wt | wild-type |
| $(v / v)$ | Volume per volume |
| $(w / v)$ | Weight per volume |

## 1 Introduction

### 1.1 General introduction to Autophagy

Autophagy is a fundamental eukaryotic cellular pathway for the degradation of cellular components such as proteins and membrane organelles. The evolutionary conserved self-eating mechanism occurs at a low basal level and becomes activated under stress conditions. It serves as an adaptive catabolic process and provides energy for the cell.

Autophagy was first described in mammals during the 1950s [1-3], however the term "autophagy" was established by Christian De Duve in 1963 [4], when he observed vesicles with a double membrane engulfing degraded cytoplasmic content in EM images. Although autophagy was initially investigated in mammals, milestones for autophagy-related research were genetic screens in yeast in the 1990s [5-8]. To date, 36 autophagy related genes (Atg) were identified [9], (reviewed e.g. by Mizushima et al. [10]).

During macroautophagy biogenesis, the best characterized autophagic subtype, a growing isolation membrane, also called phagophore, enwraps its cytoplasmic content. Fusion of its ends leads to the formation of an autophagosome, whose outer membrane then fuses with the lysosome in animal cells. Contents are degraded by lysosomal hydrolases (Figure 1.1). In yeast, the autophagosome initiates at the phagophore assembly site (PAS) next to the vacuole, to which Atg proteins are initially recruited. The emerging autophagosome fuses with the vacuole.

### 1.1.1 Subtypes of Autophagy

There are specific and non-specific subtypes of autophagy (see Figure 1.2). Macroautophagy, hereafter referred to as autophagy, connotes the bulk degradation of cytoplasmic content [10, 12]. It occurs at a basal level and is important for mediating cellular homeostasis by degrading protein aggregrates and damaged or excess organelles which are too large to be processed by the proteasome. Thus autophagy is crucial for maintaining quality control of es-


Figure 1.1: Autophagosome formation
After induction and nucleation of autophagy, the isolation membrane is expanding. Cytoplasmic content is engulfed and the autophagosome matures. Upon fusion with the lysosome, its content is degraded. Figure is cited from Kraft \& Martens [11].
sential cell components [11]. Impaired autophagy has been linked to cancer and to aging, furthermore to a number of neurodegenerative diseases caused by protein aggregrates, such as Parkinson, Alzheimer and Huntington's disease $[12,13]$. Selective types of autophagy include the targeted degradation of mitochondria (mitophagy [14]), of ribosomes (ribophagy [15]) and the removal of peroxisomes (pexophagy [9]). Xenophagy, a defense mechanism against invading pathogens, will be discussed in more detail in Section 1.3.1. The yeastspecific cytoplasm-to-vacuole targeting pathway (Cvt) is a biosynthetic pathway and selectively delivers a-mannosidase and proaminopeptidase I to the vacuole [16]. Proaminopeptidase becomes activated in the vacuole through processing. Selective autophagy pathways are mediated by specific adaptors, e.g. p62, Optineurin or Atg36 [17].

In higher eukaryotic species chaperone-mediated autophagy occurs, where


Figure 1.2: Different subtypes of autophagy and possible membrane sources for membrane biogenesis
Subtypes of autophagy are depicted, e.g. canonical macroautophagy, xenophagy and mitophagy. Delivery of cytoplasmic content through invagination of the lysosomal membrane into the lumen is called microautophagy, whereas in chaperone-mediated autophagy, cargo is specifically recognized by chaperones and translocated across the lysosomal membrane. Lipid sources include the ER, Golgi, plasma membrane and mitochondria. Figure is cited from Mizushima et al. [10].
cargo is specifically recognized by chaperones via the consensus motif KFERQ. Chaperone-substrate complexes bind to a receptor at the membrane. The unfolded cargo is transported across the lysosomal membrane and degraded [18].

During microautophagy, cargo is directly engulfed by invaginations of the lysosomal membrane [19].

The source of lipids for the growing isolation membrane has been debated in the field for some time [20-22]. Several cellular compartments have been identified as the membrane source. Autophagosomes originate close to the ER and EM tomograph images showed direct connections between isolation membrane and ER [23-25]. Nevertheless, other sources of membrane precursors are reported, among them mitochondria [26], the Golgi apparatus [27] and the plasma membrane [28]. The membrane source might depend on the specific conditions, e.g. autophagy subtype and how autophagy is induced. Cells may be able to use a combination of compartments for autophagosomal biogenesis [11].

### 1.1.2 The autophagic core machinery

All autophagy subtypes share a common molecular machinery for the induction, nucleation and maturation of autophagosomes. The autophagic core machinery consists of four main groups [12]:
(I) unc-51-like kinase (ULK) complexes (Atg1 in yeast)
(II) ubiqutin-like conjugation systems Atg8 and Atg12
(III) class III phosphatidylinositol 3-kinase (PtdIns3K) (yeast Vps34) complex including Beclin1 (yeast Atg6) and ultraviolet irradiation resistanceassociated gene (UVRAG) (yeast Vps38)
(IV) the transmembrane protein Atg9 and associated proteins.

A chronology of events during mammalian autophagosome biogenesis is depicted in Figure 1.3. Autophagy is initiated through the activation of ULK1 kinase after it dissociates from the target of rapamycin (TOR) complex 1 (TORC1) (Figure 1.4). Several phosphorylation events occur in the ULK1 complex, their biological implications are not yet completely understood. The next key event in autophagosome biogenesis is the recruitment of the Beclin1PtdIns3K complex (Vps34, p150, Beclin1 and Atg14). UVRAG, which is also part of different Beclin1 complexes [30-34], is a positive regulator of autophagy


Figure 1.3: Chronology of autophagosome biogenesis in mammals
Autophagy proteins are recruited in a hierarchical manner to the isolation membrane and most of them associate only transiently with it. Figure is cited from Weidberg et al. [29].


Figure 1.4: Complexes involved in initiation and nucleation of autophagy
(A) ULK1 complexes involved in initiation and regulation of autophagy. Under nutrient starvation, ULK1 and mAtg13 are dephosphorylated, mTOR dissociates and FIP200 and Atg13 are phosphorylated by ULK1. (B) PtdIns3K complexes comprising Beclin1 and UVRAG. PtdIns3K complexes are involved in clearance (Rubicon complex) or formation of autophagosomes (Atg14L and UVRAG complex). Figures were modified from Yang \& Klionsky [12].
(Figure 1.4). Phosphatidylinositol-3-phosphate is produced by PtdIns3K complex. Further expansion of the isolation membranes depends on the two ubiquitin-like conjugation systems. The Atg12-Atg5-Atg16L conjugate is generated by E1 and E2-like enzymes Atg7 and Atg10 forming a bond between Atg12 and Atg5, which further associates with Atg16L. LC3, the mammalian Atg8 homologue, is covalently linked to phosphatidylethanolamine by the action of E1- and E2-like enzymes Atg7 and Atg3, requiring also C-terminal processing of LC3 by Atg4 [29, 35]. Lipidated LC3 localizes to both sides of the isolation membrane, whereas the Atg12-Atg5-Atg16L complex associates with the outer side of the isolation membrane. Atg9 plays another key role in autophagy. It shuttles in vesicles between autophagosomes and Golgi/endosomes, thereby supplying membrane precursors to the autophagosome [12]. Shortly before or after completion of autophagosome formation Atg12-Atg5-Atg16L dissociates from the surface. The "naked" autophagosome then fuses with the
lysosome where its content is degraded and recycled.

### 1.2 SCOC and its interaction partners

### 1.2.1 SCOC: an Arl1 effector

Human short coiled coil protein (SCOC) is an effector of the Golgi resident Arf-like GTPase 1 (Arl1) [36] and endogenous SCOC colocalizes with Arl1 at the Golgi [36]. In addition, SCOC was recently identified as a positive regulator of autophagy in a genome-wide siRNA screen [35]. SCOC is widely expressed in the human body, most abundantly in the brain, heart and skeletal muscle [36]. Su et al. [37] observed enrichment of human SCOC mRNA in fetal brain, indicating a role for SCOC in mammalian nervous system development.
At least four different human isoforms share the well conserved C-terminal coiled coil domain of SCOC, but they differ in their N-termini resulting from alternative splicing (see Figure 3.27). The coiled coil domain (ccd) is identical for isoforms 1,2 and 3 , whereas isoform 4 is missing residues $85-112$. Homologues of SCOC are found in many eukaryotes with the ccd being conserved across species (Section A.4.6). The C. elegans orthologue of SCOC, UNC-69a, and the yeast orthologue, Slo1p, have been described in literature [37, 38]. However, the $S$. cerevisiae homologue is less well conserved than other eukaryotes [37]. SCOC does not seem to be a conserved GTPase effector, since yeast Slo1p interacts with Arl3p in a nucleotide-independent manner and not with Arl1p [38]. A deletion of Slo1p did not affect viability of the cells or impair the known function of Arl3p [38]. UNC-69 does not interact with any of the C. elegans Arl homologues [37].

### 1.2.2 SCOC interaction with Arl1

Arl1 is a small GTPase (181 residues) that is involved in membrane trafficking. Arl1 is essential for the translocation of GRIP-domain containing golgins, large coiled coil proteins important for Golgi structure and trafficking, to the Golgi [39]. In yeast, activated Arl1p recruits the golgin Imh1p via interaction with its GRIP domain to the trans-Golgi network. GTP is hydrolyzed upon recycling of Imh1p to the cytosol [40]. Arl1 is also involved in the activation of Arf1 by targeting the guanine nucleotide exchange factors BIG1 and BIG2 to the Golgi [41].

Three crystal structures of human Arl1 are deposited in the Protein Data

Bank (PDB) (PDB accession numbers 1UPT [39], 1R4A [42], 4DCN [43]). Arl1 was crystallized in complex with the GRIP domain of Golgin-245 (1UPT and $1 R 4 \mathrm{~A}$ ), and in complex with the Arfaptin2 BAR domain.
The crystal structure in complex with the Golgin-245 GRIP domain (1UPT) is depicted in Figure 1.5.


Figure 1.5: Crystal structure of GTP-Arl1 (PDB 1UPT)
(A) Structure of GTP-Arl1 in complex with the GRIP domain of Golgin245. The homodimer consisting of two Arl1 molecules (cyan) and two GRIP domains (light orange and orange) is depicted with two GTP molecules (red) and $\mathrm{MgCl}_{2}$ ions (light green) (B) Detailed view of Arl1. GTP is coloured red, switch 1 region purple, switch region 2 green and the interswitch region orange.

The GRIP domain oligomerizes to a homodimer with each molecule binding to an Arl1 molecule. Arl1 features a fold typical for Arf family GTPases: six $\beta$-strands are enwrapped by five $\alpha$-helices. The molecule has two switch and one interswitch region which change their conformation between nucleotide binding states. Interfaces between Arl1 and the GRIP domain occur between $\alpha$-helices of the GRIP domain and the switch regions, explaining specificity for GTP-bound Arl1 [39].

### 1.2.3 SCOC interaction with FEZ1

Mammalian SCOC interacts with fasciculation and elongation protein zeta 1 (FEZ1) [36, 44], a protein that is essential for kinesin-1 mediated transport along axons. C. elegans orthologue of SCOC UNC-69 interacts with UNC-76,
the FEZ1 orthologue. Deletion of UNC-69 resulted in defects of axon growth, guidance and their fasciculation, and an abnormal presynaptic organization was observed, implying a function of the UNC-69-UNC-76 complex in axonal transport of vesicles [37].

Human FEZ1 (392 residues) is a mainly natively unfolded protein with a conserved coiled coil domain in the C-terminal half of the protein [45].

FEZ1 acts as an adaptor in kinesin-1 mediated axonal transport to nerve terminals by binding to both the heavy chain of the motor protein kinesin$1[46,47]$ and its cargo, for example as recently shown for Syntaxin 1a and Munc18 containing transport vesicles [48]. Phosphorylation of FEZ1 regulates cargo [49] and kinesin binding [48]. Mutations of the C. elegans FEZ1 orthologue UNC-76 lead to severe defects in axon growth and fasciculation [50], similar to the phenotype when its binding partner UNC-69 was deleted. Importantly, UNC-69 function was rescued when human SCOC gene was expressed under the UNC-69 promoter, implying that the function is conserved [37]. In vitro interaction of both proteins was confirmed by GST-pulldown experiments. Point mutation of L287 or deletion of UNC-76 residues 281-299 abolished the interaction, proving that the conserved coiled coil of UNC-76 is responsible for binding [37]. Similarily, McKnight et al. [35] show interaction of SCOC ccd with FEZ1 ccd by pulldown experiments and co-immunoprecipitation. Mutation of leucines in the C-terminal coiled coil of FEZ1 led to disruption of the SCOC-FEZ1 complex in the pulldown experiments.

A distinct regulatory role in autophagy has also been attributed to SCOC and FEZ1 [35]. Axonal transport in fruit fly is regulated by the phosphorylation of UNC-76 by UNC-51/Atg1 [49, 51]. Human orthologues of FEZ1 and ULK1 also interact, and their complex formation is modulated by SCOC [35]. FEZ1 interacts with both the kinase and the proline-serine rich domain of ULK1. Their interaction is nutrient-independent, but a depletion of SCOC leads to reduced complex formation [35]. The FEZ1-ULK1 complex inhibits autophagy induction, and ULK1 is released upon binding of SCOC to FEZ1 [35]. SCOC-FEZ1 also forms a complex with UVRAG [35]. Under starvation conditions, this interaction is reduced, but can be stabilized in the presence of FEZ1.

Summing up, SCOC-FEZ1 complex formation is mediated through the coiled coil domains of SCOC and FEZ1 [35, 44]. Together they interact with ULK1 and UVRAG, implying a regulatory function of SCOC in the crosstalk between these two essential autophagy complexes.

### 1.2.4 Coiled coil domains: features, stability and oligomerization state

$\alpha$-helical coiled coil domains are one of the most common protein structures found in diverse protein families [52]. Despite their rather simple fold, proteins containing coiled coils exhibit a large variety of functions, among them transcription factors, proteins involved in vesicular transport or scaffolding proteins. Besides facilitating protein homo-oligomerization, coiled coils are also very important for mediating protein-protein interactions. The coiled coil interaction network in S. cerevisiae was characterized through yeast two-hybrid assays. In this study 3495 pairwise interactions were identified among 598 predicted coiled coil regions in 453 proteins, which are extensively involved in the organization of the cellular machinery [53].

Coiled coils are formed by at least two $\alpha$-helices that are wound around each other forming a superhelical structure reviewed in Lupas \& Gruber [54]. The sequence pattern underlying the supercoiled structure is characterized by a heptad repeat pattern $(a, b, c, d, e, f, g)_{n}[54,55]$, where positions a and d are occupied by mostly apolar amino acids like leucine, valine and isoleucine. These residues form the hydrophobic core of coiled coils, determining the fold into an $\alpha$-helix with a hydrophobic site, due to the winding of $\sim 3.6$ residues per turn. Oligomerization of two or more such helices results in energetically favored burial of the hydrophobic a/d residues. Complementary packing of a and $d$ residues in the hydrophobic core combined with electrostatical interactions of $e$ and $g$ residues determines structural stability and specificity (see Figure 1.6) [56]. Hence, in the ideal case, e and g are charged residues, and the remaining three residues $\mathrm{b}, \mathrm{c}$ and f , facing the surface-exposed sites of the helix, are preferably hydrophilic [57].

Although the prediction of coiled coils has become a reliable bioinformatical tool [58], it is still difficult to predict the oligomerization state based on sequence data. The nature of the amino acids at the a/d-positions is important for determining the oligomerization state of a coiled coil protein [55, 56, 59].

### 1.2.5 Aims

SCOC and FEZ1 interact via their coiled coil domains. Their complex has been implicated in the regulation of the first steps of autophagy. FEZ1 interaction with ULK1 is modulated by SCOC, and SCOC itself interacts with UVRAG. Moreover, an analogous complex in C. elegans is involved into the kinesin-dependent transport along axons. Also, SCOC does interact with


Figure 1.6: Helical wheel scheme of a parallel dimeric coiled coil Hydrophobic interactions between residues a and d stabilize the core. Ionic interactions between residues e and $g$ give specificity to the coiled coil.

Golgi-resident Arl1. How can such a small protein exhibit so many different functions? SCOC contains only one functional domain, thus, the answer to the diversity of interactions and functions must rely in the nature of SCOC coiled coil. Hence, it was my aim to determine the SCOC ccd structure by X-ray crystallography. This included the expression and purification of SCOC constructs suitable for crystallography. These constructs were further characterized by biophysical and biochemical methods, providing insights into the stability and oligomerization state of SCOC. In addition, the interactions of SCOC with FEZ1 and Arl1 were analyzed with different methods.

### 1.3 Shigella flexneri and Autophagy

### 1.3.1 Selective Autophagy: Xenophagy

Autophagy is of great medical interest since it is not only a major target of cancer research, but also plays an important role in the innate and adaptive immunity response of higher eukaryotes (reviewed in Levine et al. [60], Deretic \& Levine [61]). Xenophagy is, like other selective autophagy pathways, mediated through autophagy adaptors. Adaptors function by binding both the autophagic cargo and to a LC3 protein family member by a LC3-interacting
region (LIR). Sequestosome 1 (SQSTM1/p62) [62], nuclear dot protein 52 kDa (NDP52) [63-65], optineurin (OPTN) [66, 67], and neighbor of BRCA1 gene 1 (NBR1) [68] are adaptor proteins involved in the autophagic clearance of pathogens $[69,70]$. All of these adaptors contain a ubiquitin binding domain, by which they recognize their ubiquitinated substrate [70].

Xenophagy plays a role in intracellular infections with various bacteria, e.g. Shigella, Mycobacteria, Salmonella, Listeria, and Legionella [69]. The escape mechanisms of pathogens as well as the host cell's defensive mechanism are diverse. For example, Mycobacterium tuberculosis survives in phagosomal compartments after invading the host cell by arresting fusion of the phagosome with the lysosome [71, 72]. Virulent Mycobacteria strains can also resist and inhibit autophagy, but this inhibition can be overcome by the induction of autophagy through various stimuli [73, 74].

In Salmonella infection, the bacterium survives in a Salmonella-containing vacuole, in which $S$. typhimurium can replicate [75]. It secrets several effectors through its type III secretion system (TTSS), which results in bacteria invading the cytosol. S. typhimurium in the cytosol are rapidly polyubiquitinated and then recognized by the respective cargo adaptor NDP52 [63, 69].

### 1.3.2 Escape of intracellular Shigella flexneri from autophagy

Shigella flexneri is a human pathogen causing bacillary dysentery Shigellosis. This mucosal bacterium has versatile instruments that circumvent the host cell immune response (reviewed in Ashida et al. [76]). It disrupts the initial vacuolar membrane surrounding the bacterium, it multiplies in epithelial cells, invading cells by exploiting actin polymerization. It manipulates the host cell death and signalling pathways. It has adapted a sophisticated mechanism to escape autophagy (see Figure 1.7). Shigella's outer membrane protein VirG, which is crucial for its actin-based motility [77, 78], has a binding site for the host protein Atg5, by which autophagic destruction of the pathogen is triggered. However, Shigella secrets IcsB through its TT3S, which masks the binding site of Atg5 on VirG [78]. Mutant Shigella bacteria lacking IcsB were enwrapped by multilamellar structures positive for LC3 more frequently, as observed by EM. In vitro interactions of VirG-IcsB and VirG-Atg5 were confirmed by pulldown assays. Both VirG and IcsB originate from Shigella flexneri's large virulence plasmid. VirG triggers autophagy, whereas IcsB did not reduce overall autophagy levels [78].


Shigella flexneri evades autophagy Shigella $\Delta / c s B$ : entrapment by autophagy


Figure 1.7: Mechanism of Shigella flexneri's escape from xenophagy
VirG on the outer membrane of Shigella contains a common binding site for Shigella's virulence effector IcsB and the host cell's protein Atg5. IcsB masks the binding site, protecting Shigella from degradation by autophagy. In $\Delta \mathrm{IcsB}$ strains, VirG is recognized by the autophagic machinery through interaction with Atg5 and entrapped by autophagosomes.

In addition to this escape mechanism, Shigella also induces autophagy via Shiga toxins, resulting in cell death in an autophagy-dependent manner [79]. Remnants of the disrupted vacuolar membrane are targeted to autophagy via ubiquitination and interaction with p62 and LC3 [80]. Recently, also the cytoskeleton has been involved in the host cell's response to Shigella. Cytosolic Shigella are trapped in septin cages [81] and Shigella are targeted to an actin and septin-dependent autophagic pathway, which requires p62 and NDP52 [64].

### 1.3.3 The autotransporter protein VirG

VirG, also connoted as IcsA, is an autotransporter protein with the typical domain structure of a type Va autotransporter. It features a N-terminal signal sequence (1-52), a passenger domain (53-758) and a transmembrane porin domain (759-1102). The secretion mechanism of type Va autotransporters is depicted in Figure 1.8. In the bacterial cytosole, VirG is stabilized by chaperones, e.g. DnaK [83]. VirG is translocated through the inner bacterial membrane by the Sec machinery. The signal sequence is cleaved in the periplasm,


Figure 1.8: Secretion mechanism of type Va autotransporters
Figure was modified from Junker et al. [82]. Copyright (2006) National Academy of Sciences, USA
where VirG is chaperoned by Skp [84]. The transmembrane porin structure is inserted into the membrane and VirG's passenger domain is secreted through the porin structure.

Native folding occurs at the outer bacterial membrane, with the autochaperone region comprising residues 591-758 serving as a template and platform for correct folding of the entire passenger domain [82, 85, 86], however partial folding in the periplasm has also been discussed[84]. The autochaperone region has been shown to be essential for folding by mutational analysis [87].

A fragment of VirG comprising the autochaperone region has been crystallized by Dr. K. Kühnel (PDB 3ML3, Figure 1.9). The VirG fragment folds into two coils of a right handed parallel $\beta$-helix, with the last two antiparallel $\beta$-sheets covering the hydrophobic core. $\beta$-helical fold is typical for autotransporters [82].

VirG localizes to the pole of Shigella, where it recruits factors important for Shigella's actin-based motility. VirG hijacks the Cdc42-controlled molecular machinery essential for actin assembly. First, IcsA binds to N-WASP and activates it. A ternary complex with Arp2/3 is formed, which stimulates actin assembly and polymerization. N-WASP and the Arp2/3 complex are crucial for Shigella's ability to move and replicate within the host cell [77].


Figure 1.9: Crystal structure of VirG (591-758)
Side and top view of rainbow-coloured VirG (591-758) from blue (Nterminus) to red (C-terminus)

### 1.3.4 The secretion protein IcsB-IpgA

IcsB was described first by Allaoui et al. [88] as a virulence factor located on the Shigella virulence plasmid in 1992. Initial studies on a IcsB defective strain indicated, that IcsB was not crucial for invasiveness of bacteria, but caused invading bacteria to be trapped by "protrusions surrounded by two membranes". This was probably the first observation of IcsB's role in protecting the bacterium from autophagy. IcsB-defective bacteria were therefore not able to spread across cells [88]. IcsB is secreted via Shigella's TT3S in vivo and in vitro. It is chaperoned by IpgA, the protein originating from the gene downstream of IcsB. The stop codon between the two of them is transient, so that they can be translated and secreted together as a translational fusion protein. IcsB's middle domain was found to be involved in the interaction [89].

### 1.3.5 Aims

VirG and IcsB are part of a mechanism exploiting a evolutionary niche by hijacking the host cell's defense mechanism. In the long term, structural insights into the protein structure and their interactions could contribute to the development of specific drugs against Shigellosis.

Hence, the aim of this project was to purify and structurally characterize Shigella flexneri's proteins VirG and IcsB-IpgA. This involved the development of a suitable purification strategy for VirG. The VirG passenger domain is a membrane-attached protein, which folds into its native state at the outer membrane of the bacterium. Hence, it would be challenging to find suitable conditions for native folding to occur. Furthermore, protein interactions should be characterized by suitable biochemical methods.

## 2 Materials and Methods

### 2.1 Materials

### 2.1.1 Enzymes

Enzymes were used according to the manufacturers instructions. Table 2.1 lists the enzymes used in this study.

## Table 2.1: Enzymes

| Enzyme | Manufacturer |
| :--- | :--- |
| Restriction enzymes | NEB |
| T4 DNA Ligase | NEB |
| Alkaline Phosphatse | NEB |
| Trypsin | Hampton Research |
| Subtilisin | Hampton Research |
| DNaseI | Applichem |
| Lysozyme | Roth |

### 2.1.2 Kits

Table 2.2 lists the kits used in this study.
Table 2.2: Kits

| Kit | Manufacturer |
| :--- | :--- |
| NucleoSpin Plasmid kit | Macherey \& Nagel |
| NucleoSpin Extract II kit | Macherey \& Nagel |
| NucleoBond Xtra | Macherey \& Nagel |

(...)

## Kits (continued)

| Kit | Manufacturer |
| :--- | :--- |
| Phusion High-Fidelity PCR Kit | NEB |
| Proti-Ace | Hampton Research |
| Proti-Ace II | Hampton Research |
| QuickChange Lightning Site-Directed Mu- Agilent Technologies (Strata- <br> tagenesis Kit |  |

### 2.1.3 Columns for Chromatography

Table 2.3 lists the columns used in this study.
Table 2.3: Columns

| Column | Manufacturer |
| :--- | :--- |
| HiTrap Q FF column $(5 \mathrm{~mL})$ | GE Healthcare |
| His-Trap FF column $(1 \mathrm{and} 5 \mathrm{~mL})$ | GE Healthcare |
| Strep-Trap column $(5 \mathrm{~mL})$ | GE Healthcare |
| GSTrap column $(5 \mathrm{~mL})$ | GE Healthcare |
| HiLoad $16 / 60$ Superdex 200 prep grade | GE Healthcare |
| HiLoad $16 / 60$ Superdex 75 prep grade | GE Healthcare |
| HiTrap Q FF column $(5 \mathrm{~mL})$ | GE Healthcare |
| Protino® GST/4B $(5 \mathrm{~mL})$ | Macherey and Nagel |
| Protino® Ni-NTA Column $(5 \mathrm{~mL})$ | Macherey and Nagel |
| Superdex $20010 / 300 \mathrm{GL}$ | GE Healthcare |

### 2.1.4 Antibodies

Table 2.4 lists the antibodies used in this study.

Table 2.4: Antibodies

| Antibody | Manufacturer |
| :--- | :--- |
| GST (monoclonal) | Clontech |
| Hexa-Histidine tag (DIA900) | Dianova |
| murine Strep-tag II | IBA GmbH |
| goat polyclonal mouse IgG (HRP labeled) | BioRad Laboratories GmbH |
| goat polyclonal rabbit IgG (HRP labeled) | BioRad Laboratories GmbH |
| SCOC coiled coil domain | generated for this Study by |
|  | SySy |
| FEZ1 | gift from John Chua |

### 2.1.5 Buffers, media and antibiotics

$1 \times$ PBS
$150 \mathrm{mM} \mathrm{NaCl}, 20 \mathrm{mM} \mathrm{NaH} \mathrm{NO}_{4} \mathrm{pH} 7.4$

## 1x TBS

50 mM Tris, 150 mM NaCl , pH 7.5
for TBS-T $0.1 \% ~(v / v)$ Tween 20 was added.

## $3 \times$ sample buffer for Schägger gel electrophoresis

2.5 mL 1 M Tris, 6 g SDS, 15 mg Serva Blue, 4.33 g Glycerol, $\mathrm{H}_{2} \mathrm{O}$ to 50 mL make 10 mL aliquots, add $200 \mu \mathrm{~L} \beta$-Mercaptoethanol

## $10 \times$ Anode buffer for Schägger gel electrophoresis

2 M Tris to pH 8.9 with HCl
10x Cathode Buffer Schägger gel electrophoresis
1 M Tris, 1 M Tricin
$10 \times$ SDS-PAGE electrophoresis buffer
30.3 g Tris, 142.6 g Glycine, 10 g SDS pH $\sim 8.4$
$10 \times$ TBE
$121 \mathrm{~g} / \mathrm{L}$ Tris, $61.8 \mathrm{~g} / \mathrm{L}$ boric acid, $7.5 \mathrm{~g} / \mathrm{L}$ EDTA

## $1000 \times$ Antibiotic stocks

Ampicillin $100 \mu \mathrm{~g} / \mathrm{ml}$ (w/v)
Kanamycin $30 \mu \mathrm{~g} / \mathrm{ml}$ (w/v)

## Blotto

5 \% (w/v) Milkpowder, 0.1 \% (v/v) Tween 20 in TBS

## Coomassie Blue staining solutions

A: 500 mg CoomassieR, $650 \mathrm{~mL} \mathrm{H} \mathrm{H}_{2} \mathrm{O}, 250 \mathrm{~mL}$ isopropanol, 100 mL acetic acid
B: 50 mg CoomassieR, $800 \mathrm{~mL} \mathrm{H} \mathrm{H}_{2} \mathrm{O}, 100 \mathrm{~mL}$ isopropanol, 100 mL acetic acid
C: 20 mg CoomassieR, $900 \mathrm{~mL} \mathrm{H}_{2} \mathrm{O}, 100 \mathrm{~mL}$ acetic acid
D: $900 \mathrm{~mL} \mathrm{H} \mathrm{H}_{2} \mathrm{O}, 100 \mathrm{~mL}$ acetic acid

## Gel buffer for Schägger gel electrophoresis

3 M Tris pH 8.45, 0.3 \% SDS

## Lower gel buffer for SDS gel electrophoresis

1.5 M Tris pH 8.8, 0.4 \% SDS

## Upper gel buffer for SDS fel electrophoresis

0.5 M Tris pH 6.8 with $\mathrm{HCl}, 0.4 \mathrm{~g}$ SDS

## Transfer buffer

25 mM Tris, 192 mM glycine, $0.04 \% \mathrm{w} / \mathrm{v}$ SDS, $20 \% \mathrm{v} / \mathrm{v}$ methanol

## Luria Bertani (LB) media and plates

$10 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v})$ tryptone, $5 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v})$ yeast extract, $10 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NaCl}$
Plates contained 18 g/L (w/v) Agar.

## SOC-media

$2 \%$ tryptone, $0.5 \%$ yeast extract, $10 \mathrm{mM} \mathrm{NaCl}, 2.5 \mathrm{mM} \mathrm{KCl}, 20 \mathrm{mM}$ glucose After autoclaving $10 \mathrm{mM} \mathrm{MgCl} 2,10 \mathrm{mM} \mathrm{Mg} \mathrm{MO}_{4}$ were added.

## M9 minimal media for ${ }^{15} \mathrm{~N}$-labelling

See Table 2.5, modified from Studier [90].

Table 2.5: Composition of 1 L minimal media for ${ }^{15} \mathrm{~N}$-labelling (modified from Studier [90])

| Volume (mL) | Component | composition |
| :---: | :---: | :---: |
| 200 | $5 \times \mathrm{M} 9$ | $\begin{aligned} & 37.66 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NaH}_{2} \mathrm{PO}_{4} \times 2 \mathrm{H}_{2} \mathrm{O} \\ & 15 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{KH}_{2} \mathrm{PO}_{4} \\ & 2.5 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NaCl} \end{aligned}$ |
| 2.5 | $\mathrm{NH}_{4} \mathrm{Cl}(0.2 \mathrm{~g} / \mathrm{mL})$ |  |
| 1 | $1 \mathrm{M} \mathrm{MgSO}_{4}$ |  |
| 100 | $4 \%$ glucose |  |
| 0.1 | thiamine vitamin |  |
| 0.1 | $1 \mathrm{M} \mathrm{CaCl}_{2}$ |  |
| 0.2 | 1000x trace metals mixture |  |
| 700 | $\mathrm{H}_{2} \mathrm{O}$ |  |

M9 minimal media for selenomethionine-labelling
See Table 2.6, modified from Studier [90].

Table 2.6: Composition of 1 L minimal media for selenomethionine-labelling (modified from Studier [90])

| Volume (mL) | Component | composition |
| :---: | :---: | :---: |
| 200 | $5 \times \mathrm{M} 9$ | $\begin{aligned} & 37.66 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NaH}_{2} \mathrm{PO}_{4} \times 2 \mathrm{H}_{2} \mathrm{O} \\ & 15 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{KH}_{2} \mathrm{PO}_{4} \\ & 5 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NH}_{4} \mathrm{Cl} \\ & 2.5 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NaCl} \end{aligned}$ |
| 1 | $1 \mathrm{M} \mathrm{MgSO}_{4}$ |  |
| 100 | $4 \%$ glucose |  |
| 0.1 | thiamine vitamin |  |
| 1 | $\mathrm{Fe}(\mathrm{II})_{2} \mathrm{SO}_{4}$ |  |
| 10 | Aminosäuremix | Lysin $10 \mathrm{~g} / \mathrm{L}$ <br> Phenylalanine $10 \mathrm{~g} / \mathrm{L}$ <br> Threonin $10 \mathrm{~g} / \mathrm{L}$ <br> Isoleucine $5 \mathrm{~g} / \mathrm{L}$ <br> Leucine $5 \mathrm{~g} / \mathrm{L}$ <br> Valine $5 \mathrm{~g} / \mathrm{L}$ |
| 700 | $\mathrm{H}_{2} \mathrm{O}$ |  |

## Terrific broth (TB) media

$12 \mathrm{~g} / \mathrm{L}$ tryptone, $24 \mathrm{~g} / \mathrm{L}$ yeast extract, $0.4 \%$ glycerol, $2.31 \mathrm{~g} / \mathrm{L} \mathrm{KH} \mathrm{KO}_{4}$, $12.54 \mathrm{~g} / \mathrm{L} \mathrm{K}_{2} \mathrm{HPO}_{4}$

## ZYM-5052 media (Autoinducible media)

See Table 2.7, Studier [90].

Table 2.7: Composition of 1 L ZYM-50502 media [90]

| Volume $(\mathrm{mL})$ (mL) | Component | composition |
| :---: | :---: | :---: |
| 950 | ZY | $10 \mathrm{~g} / \mathrm{L}$ N-Z-Amine AS (Sigma) $5 \mathrm{~g} / \mathrm{L}$ yeast extract-B (QBIOgene) |
| 20 | $50 \times 5052$ | $\begin{aligned} & 250 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \text { glycerol } \\ & 25 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \text { glucose } \\ & 100 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \alpha \text {-lactose } \mathrm{x}_{2} \mathrm{O} \\ & 730 \mathrm{~mL} \mathrm{H} \end{aligned}$ |
| 20 | 50xM | $\begin{aligned} & 222.5 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{Na}_{2} \mathrm{HPO}_{4} \times 2 \mathrm{H}_{2} \mathrm{O} \\ & 170 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{KH}_{2} \mathrm{PO}_{4} \\ & 134 \mathrm{~g} / \mathrm{L}(\mathrm{w} / \mathrm{v}) \mathrm{NH}_{4} \mathrm{Cl} \\ & 35.5 \mathrm{~g} / \mathrm{L} \mathrm{Na} 2 \mathrm{SO} 4 \\ & 800 \mathrm{~mL} \mathrm{H} \end{aligned}$ |
| 1 | $2 \mathrm{M} \mathrm{MgSO}_{4}$ |  |
| 0.2 | 1000x trace metals mixture | 50 mL FeCl 3 in $\sim 0.12 \mathrm{M} \mathrm{HCl}$ $2 \mathrm{~mL} 1 \mathrm{M} \mathrm{CaCl}_{2}$ $1 \mathrm{~mL} 1 \mathrm{M} \mathrm{MnCl}_{2} \times 4 \mathrm{H}_{2} \mathrm{O}$ $1 \mathrm{~mL} 1 \mathrm{M}_{\mathrm{ZnSO}}^{4}$ x $7 \mathrm{H}_{2} \mathrm{O}$ $1 \mathrm{~mL} 0.2 \mathrm{M} \mathrm{CoCl}_{2} \times 6 \mathrm{H}_{2} \mathrm{O}$ $2 \mathrm{~mL} 0.1 \mathrm{M} \mathrm{CuCl}_{2} \times 2 \mathrm{H}_{2} \mathrm{O}$ $1 \mathrm{~mL} 0.2 \mathrm{M} \mathrm{NiCl}_{2} \times 6 \mathrm{H}_{2} \mathrm{O}$ $2 \mathrm{~mL} 0.1 \mathrm{M} \mathrm{Na}_{2} \mathrm{MoO}_{4} \times 2 \mathrm{H}_{2} \mathrm{O}$ $2 \mathrm{~mL} 0.1 \mathrm{M} \mathrm{Na}_{2} \mathrm{SeO}_{3} \times 5 \mathrm{H}_{2} \mathrm{O}$ $2 \mathrm{~mL} 0.1 \mathrm{M} \mathrm{H}_{3} \mathrm{Bo}_{3}$ |

### 2.1.6 DNA constructs

Table 2.8 lists the DNA constructs used in this study.

Table 2.8: DNA constructs used in this study

| gene | vector | tag | restriction sites | resis- <br> tance |
| :---: | :---: | :---: | :---: | :---: |
| Arl1 (15-181) Q79L | pET-22b | $6 \times \mathrm{His}$ | NdeI XhoI | Amp C. Behrens |
| Arl1 (15-181) wt | pET-22b | $6 \times \mathrm{His}$ | NdeI XhoI | Amp C. Behrens |
| FEZ1 full length (John Chua) | pASK-IBA37 | $6 \times$ His, StrepII |  | Amp |
| FEZ1 (226-290) | pET-22b | $6 \times \mathrm{His}$ | NdeI XhoI | Amp C. Behrens |
| FEZ1 (226-295) | pET-22b | $6 \times \mathrm{His}$ | NdeI XhoI | Amp C. Behrens |
| FEZ1 (227-290) | pET-22b | $6 \times \mathrm{His}$ | NdeI XhoI | Amp C. Behrens |
| FEZ1 (227-295) | pET-22b | $6 \times$ His | NdeI XhoI | Amp C. Behrens |
| FEZ1 (225-295) | pET-22b | $6 \times \mathrm{His}$ | NdeI XhoI | Amp C. Behrens |
| IcsB (235-494) (MCSI) IpgA full length (MCSII) | pETDuet-1 | $6 \times \operatorname{His}$ (I) | BamHI NotI <br> (MCSI) NdeI <br> Xhoi (MCSII) | Amp C. Behrens |
| IcsB full length (MCSI) IpgA full length (MCSII) | pETDuet-1 | $6 \times \operatorname{His}(\mathrm{I})$ | BamHI NotI <br> (MCSI) NdeI <br> Xhoi (MCSII) | Amp C. Behrens |
| IcsB full length (MCSI) IpgA full length (MCSII) | pETDuet-1 | ```6 x His (I) StrepII C- terminal (MC- SII)``` | BamHI NotI <br> (MCSI) NdeI <br> Xhoi (MCSII) | Amp C. Behrens |

DNA constructs used in this study (continued)

| gene | vector | tag | restriction sites | resis- <br> tance |
| :---: | :---: | :---: | :---: | :---: |
| IcsB full length (MCSI) IpgA full length (MCSII) | pETDuet-1 | $6 \quad \mathrm{x}$ His (I)  <br> StrepII $\mathrm{N}-$ <br> terminal  <br> SII)  <br> (MC-  | $\begin{array}{lr} \text { BamHI } & \text { NotI } \\ \text { (MCSI) } & \text { NdeI } \\ \text { Xhoi (MCSII) } \end{array}$ | Amp C. Behrens |
| IcsB full length (MCSI) (K. Kühnel) | pETDuet-1 | $6 \times$ His (I) | BamHI NotI | Amp K. Kühnel |
| IcsB (216-494) (MCSI) IpgA full length (MCSII) | pETDuet-1 | $6 \times$ His (I) | BamHI NotI <br> (MCSI) NdeI <br> Xhoi (MCSII)  | Amp C. Behrens |
| IcsB (293-494) (MCSI) IpgA full length (MCSII) | pETDuet-1 | $6 \times$ His (I) | $\begin{array}{lr} \text { BamHI } & \text { NotI } \\ \text { (MCSI) } & \text { NdeI } \\ \text { Xhoi (MCSII) } \end{array}$ | Amp C. Behrens |
| IcsB (185-494) (MCSI) IpgA full length (MCSII) | pETDuet-1 | $6 \times$ His (I) | $\begin{array}{lr} \text { BamHI } & \text { NotI } \\ \text { (MCSI) } & \text { NdeI } \\ \text { Xhoi (MCSII) } \end{array}$ | Amp C. Behrens |
| SCOC (78-159) | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |
| SCOC (78-159) | pGEX-4T1 | GST | BamHI XhoI | Amp C. Behrens |
| SCOC (78-159) E93V/K97L | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |
| SCOC (78-159) L105M | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |
| SCOC (78-159) N125L/N125V | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |

DNA constructs used in this study (continued)

| gene | vector | tag | restriction sites | resistance |
| :---: | :---: | :---: | :---: | :---: |
| SCOC (78-159) R17E | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |
| SCOC (78-159) R99E | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |
| SCOC (78-159) R99E/R117E | pET-28a | Strep II | NcoI XhoI | Kan C. Behrens |
| SCOC (78-141) | pET-22b | $6 \times$ His | NdeI XhoI | Amp C. Behrens |
| SCOC (78-151) | pET-22b | $6 \times$ His | NdeI XhoI | Amp C. Behrens |
| SCOC (78-132) | pET-28a | $6 \times \mathrm{His}$ | NdeI XhoI | Kan C. Behrens |
| SCOC (112-159) | pET-28a | $6 \times \mathrm{His}$ | NdeI XhoI | Kan C. Behrens |
| SCOC full length | pGEX-4T1 | GST | BamHI XhoI | Amp C. Behrens |
| VirG (52-758) | pET-28a | $6 \times$ His | NdeI XhoI | Kan C. Behrens |
| VirG (353-758) | pET-28a | 6 x His with linker, Strep II C-terminal | NdeI XhoI | Kan C. Behrens |
| VirG (353-758) | pET-28a | $\begin{aligned} & \text { Strep II C- } \\ & \text { terminal } \end{aligned}$ | NdeI XhoI | Kan C. Behrens |
| VirG (353-758) | pET-28a | 6 x His with linker | NdeI XhoI | Kan C. Behrens |
|  | pET-22b | $6 \times \mathrm{His}$ |  | Amp Novagen |
|  | pET-28a | $6 \times$ His, T7 |  | Kan Novagen |
|  | pETDuet-1 | $6 \times$ His, S-Tag |  | Amp Novagen |

[^0]DNA constructs used in this study (continued)

| gene | vector | tag | restriction <br> sites | resis- <br> tance |
| :--- | :--- | :--- | :--- | :--- |
|  | pGEX-4T1 | GST |  | Amp K. Kühnel |

### 2.1.7 Oligonucleotides

Table 2.9 lists the oligonucleotides used in this study.

Table 2.9: Oligonucleotides

| Name | Sequence 5' to 3' |
| :--- | :--- |
| Arl1 Q181 NotI noStop rev | ATAGTTTAGCGGCCGCCTGGCGACTTTTCAGTGTTTC |
| Arl1 T15 BamHI fwd | CGGGATCCTATGACACGTGAAATGCGTATCCTGATTC |
| Arl1 T15 NdeI fwd | GGAATTCCATATGACACGTGAAATGCGTATCCTGATTCTGGGGC |
| FEZ1 ccd H226 NdeI fwd | GGAATTCCCCATATGCACATGTCTGGG |
| FEZ1 ccd L290 Strep Stop XhoI rev | CCGCTCGAGTTATTTTTCGAACTGCGGGTGGCTCCAGCTGCCGCGCGGCA |
|  | CCAGCTTTTCATCAGTTC |
| FEZ1 ccd L290 XhoI noStop rev | CCGCTCGAGGCTGCCGCGCGGCACCAGCTTTTTTCATCAGTTCTCGCTG |
| FEZ1 ccd L295 Strep Stop XhoI rev | CCGCTCGAGTTATTTTTCGAACTGCGGGTGGCTCCAGCTGCCGCGCGGCA |
|  | CCAGTTTCTCTTTCCGCCTCTT |
| FEZ1 ccd L295 XhoI noStop rev | CCGCTCGAGGCTGCCGCGCGGCACCAGTTTCTCTTTCCGCCTCTTTTT |
| FEZ1 ccd M227 NdeI fwd | GGAATTCCCCATATGTCTGGGTCTGAG |
| FEZ1 ccd R225 NdeI fwd | GGAATTCCCCATATGAGGCACATGTCT |
| IcsB A235 BamHI fwd | CGGGATCCCGCTAATCAAAAAAAGACCCCTATG |
| IcsB I494 NotI rev | ATAAGAATGCGGCCGCCTATATATTAGAATGAGAGTTATTCA |
| IcsB N216 BamHI fwd | CGGGATCCCAACTTATTAAATTCAAACAAGATCAAAATAACAACAAAAA |
| IcsB Q293 BamHI fwd | CGGGATCCCCAATTGGCAAATTATAAATTAATCAGTAAATCTGAAAA |
| IcsB S185 BamHI fwd | CGGGATCCCTCAGGTTACAGTGTCGATAC |
| SCOC ccd 112E NdeI fwd | GGAATTCCCCATATGACACTGGAAGATC |


| Name | Sequence 5' to 3' |
| :--- | :--- |
| SCOC ccd 132N XhoI rev | CCGCTCGAGTTAATTCTCCTCTTTTACG |
| SCOC ccd 159K XhoI rev | CCGCTCGAGTTATTTACGTTTGGATTGGT |
| SCOC ccd M78 NcoI fwd | GAATTCCATATGATGAATGCCGACATGGATG |
| SCOC ccd M78 NdeI fwd | GGAATTCCCCATATGATGAATGCCGAC |
| SCOC ccd M78 pGex4T1 fwd | CGGGGATCCATGATGAATGCCGACATGGATGCC |
| SCOC ccd N141 XhoI rev | CCGCTCGAGTTAATTTTCGATATACTGGC |
| SCOC ccd T151 XhoI rev | CCGCTCGAGTTAGGTTTGAAAGACGCT |
| SCOC E93V fwd | TGCCGAAAATCAGGTGGTACTGGAGGAAAAAACCC |
| SCOC E93V/K97L fwd | GCCGAAAATCAGGTGGTACTGGAGGAATTAACCCGTCTGATCAAC |
| SCOC E93V/K97L rev | GTTGATCAGACGGGTTAATTCCTCCAGTACCACCTGATTTTCGGC |
| SCOC E93V rev | GGGTTTTTTCCTCCAGTACCACCTGATTTTCGGCA |
| SCOC fl pGex4ti BamHI fwd | CGGGGATCCATGCGTCGCCGTGTGTTTTCT |
| SCOC fl pGex4ti stop XhoI rev | CCGCTCGAGTTATAATTTACGTTTGGATTTGGTATCGGTGG |
| SCOC Gateway ccd M78 BamHI fwd | CACCATGATGAATGCCGACATGGATGC |
| SCOC Gateway rev | TTTACGTTTGGATTTGGTATCGGTGGTTTGA |
| SCOC L105M fwd | ACCCGTCTGATCAACCAAGTTATGGAGCTGCAG |
| SCOC L105M rev | CTGCAGCTCCATAACTTGGTTGATCAGACGGGT |
| SCOC N125L fwd | GTGTCGATGCCGTAAAAGAGGAGCTACTGAAACTGAAAAGTGAGAATCA |

Oligonucleotides (continued)

| Name | Sequence 5' to 3' |
| :--- | :--- |
| SCOC N125L rev | TGATTCTCACTTTTCAGTTTCAGTAGCTCCTCTTTTACGGCATCGACAC |
| SCOC N132V fwd | GAATCTGAAACTGAAAAGTGAGGTTCAAGTGCTGGGCCAGTATATC |
| SCOC N132V rev | GATATACTGGCCCAGCACTTGAACCTCACTTTTCAGTTTCAGATTC |
| SCOC R117E fwd | ACTGGAAGATCTGTCTGCCGAGGTCGATGCCGTAAAAGAGG |
| SCOC R117E rev | CCTCTTTTACGGCATCGACCTCGGCAGACAGATCTTCCAGT |
| SCOC R99E fwd | GTGGAACTGGAGGAAAAACCGAGCTGATCAACCAAGTTCTGGAG |
| SCOC R99E rev | CTCCAGAACTTGGTTGATCAGCTCGGTTTTTTCCTCCAGTTCCAC |
| SCOC Strep rev 1 | CTCCAGCTGCCGCGCGGCACCAGTTTACGTTTGG |
| SCOC Strep XhoI rev 2 | CCGCTCGAGTTATTTTTCGAACTGCGGGTGGCTCCAGCTG |
| VirG R758 Strep XhoI rev | CCGCTCGAGTTATTTTTCGAACTGCGGGTGGCTCCACCGGCCGCGACTAC |
|  | TCATTTGAGTAGACTCTTGATTG |
| VirG R758 XhoI rev | CCGCTCGAGTTAGCGACTACTCATTTGAGTAGACTCTTGATTG |
| VirG S353 NdeI fwd | GGAATTCCATATGTCATCCATTCTGAAAATTATCAACAATGATTACACTG |
| VirG S353 TEV linker NdeI fwd | GGAATTCCATATGCGTAAACGTGAAAATTTATATTTTCAGGGCTCATCCA |
|  | TTCTGAAAATTATC |
| VirG synthGene A52 NdeI fwd | CTGGAATTCCATATGGCTACACCTCTGAGTG |
| VirG synthGene R758 XhoI rev | CCGCTCGAGTTAACGACTACTCATCTGTGTC |

### 2.2 Methods

### 2.2.1 Molecular cloning

### 2.2.1.1 PCR

Cloning was performed with standard methods. For PCR, Phusion HighFidelity PCR kit was used and the manufacturer's manual was followed as below (see Table 2.10). Template DNA concentration was $10 \mathrm{ng} / \mu \mathrm{L}$.

## Table 2.10: PCR reaction $50 \mu \mathrm{~L}$

| Component | volume $(\mu \mathrm{L})$ |
| :--- | :--- |
| water | 32.5 |
| 5 x HF | 10 |
| 10 mM dNTP | 1 |
| $10 \mathrm{\mu MP}$ fwd | 2.5 |
| $10 \mathrm{\mu M} \mathrm{P}$ rev | 2.5 |
| template | 1 |
| Phu | 0.5 |

PCRs with primer pairs of $\sim 59^{\circ} \mathrm{C}$ melting temperatures were performed with basic temperature cycling. Long primers or primer pairs with larger differences in melting temperatures required touchdown temperature cycling. Temperature cycling comprised following steps:

1. initial denaturation
2. denaturation
3. annealing
4. elongation
5. final extension
6. hold

For standard procedure, steps 2-4 were repeated for 30 cycles. Annealing temperature was chosen according to primers. In case of Touchdown temperature cycling, the annealing temperature changed with every $5^{\text {th }}$ step.

Table 2.11: PCR temperature cycling

| Touchdown |  |  |  | Standard |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Step | $T\left({ }^{\circ} \mathrm{C}\right)$ | Length <br> (s) | Repeat | Step | $T\left({ }^{\circ} \mathrm{C}\right)$ | Length <br> (s) | Repeat |
| 1 | 98 | 120 | - | 1 | 98 | 120 | - |
| 2 | 98 | 15 |  | 2 | 98 | 15 |  |
| 3 | 70 | 30 | 4 x | 3 | 57-62 | 30 | 30 x |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  | 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |
| 2 | 98 | 15 |  | 5 | 72 | 420 | - |
| 3 | 68 | 30 | 4 x | 6 | 16 | $\infty$ |  |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |  |  |  |  |
| 2 | 98 | 15 |  |  |  |  |  |
| 3 | 66 | 30 | 4 x |  |  |  |  |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |  |  |  |  |
| 2 | 98 | 15 |  |  |  |  |  |
| 3 | 64 | 30 | 4 x |  |  |  |  |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |  |  |  |  |
| 2 | 98 | 15 |  |  |  |  |  |
| 3 | 62 | 30 | 4 x |  |  |  |  |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |  |  |  |  |
| 2 | 98 | 15 |  |  |  |  |  |
| 3 | 60 | 30 | 4 x |  |  |  |  |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |  |  |  |  |
| 2 | 98 | 15 |  |  |  |  |  |
| 3 | 58 | 30 | 4 x |  |  |  |  |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |  |  |  |  |
| 5 | 72 | 420 | - |  |  |  |  |
| 6 | 16 | $\infty$ |  |  |  |  |  |

### 2.2.1.2 DNA agarose gel electrophoresis and gel extraction purification

PCR products and DNA plasmids were visualized by $1 \%$ and $0.8 \%$ agarose gel electrophoresis, respectively. Samples for electrophoresis were mixed with 6 x loading dye (Fermentas). $1 \times$ TBE was used as running buffer. Agarose gels were stained with GelGreen ${ }^{\mathrm{TM}}$ Nucleic Acid Gel Stain and sizes of DNA products were assessed with Fermentas DNA ladders (GeneRuler 1 kb or GeneRuler 100 bp Plus). Gel extraction was conducted with the NucleoSpin Extract II kit according to the manufacturer's instructions.

### 2.2.1.3 Restriction digest

Restriction digest reactions were carried out for one hour at $37^{\circ} \mathrm{C}$ with enzymes from NEB in $40 \mu \mathrm{~L}$ reactions (see Table 2.12).

Table 2.12: Restriction digest reaction setup

| digest | PCR | vector | control |
| :--- | :---: | :---: | :---: |
| Component | volume $(\mu \mathrm{L})$ |  |  |
| water | 3.6 | to $40 \mu \mathrm{~L}$ | 20.7 |
| PCR product | 30 | - | - |
| vector $(\sim 1 \mu \mathrm{~g} / \mu \mathrm{L})$ | - | $4 \mu \mathrm{~g}$ | - |
| plasmid | - | - | 5 |
| $10 \times$ buffer | 4 | 4 | 3 |
| enzyme 1 | 1 | 1 | 0.5 |
| enzyme 2 | 1 | 1 | 0.5 |
| BSA (if required) | 0.4 | 0.4 | 0.3 |

### 2.2.1.4 Ligations

Ligations were performed with 100 ng of vector combined with 5-10-fold excess of insert. A final reaction volume of $10 \mu \mathrm{~L}$ was set up with $1 \mu \mathrm{~L}$ of T4 DNA Ligase and $1 \mu \mathrm{~L}$ of 10 x buffer. Ligation was conducted at room temperature for 30 min , or, if unsuccessful, over night at $4^{\circ} \mathrm{C}$.

### 2.2.1.5 Transformation

Heat shock Transformation Chemocompetent E. coli (100 $\mu \mathrm{L}$ XL1-blue or BL21 (DE3)) cells were incubated with DNA for 20 min on ice. Cells were heat shocked at $42^{\circ} \mathrm{C}$ for 45 s , then $900 \mu \mathrm{~L}$ prewarmed LB or SOC medium was added. Bacteria recovered for 50 min at $37^{\circ} \mathrm{C}$, before they were spun down for 2 min at 5000 rpm in a table top centrifuge. Cells were plated out on LB agar plates containing appropriate antibiotics.

Electroporation Transformation For transformation of two plasmids, electrocompetent BL21 (DE3) were incubated on ice in 2 mm gap electroporation cuvettes for 20 min . $2 \mu \mathrm{~L}$ of $100 \mathrm{ng} / \mu \mathrm{L}$ of each plasmid DNA were added. Cells were shocked with 2.5 kV in a Biorad Gene Pulser II. $900 \mu \mathrm{~L}$ prewarmed SOC media was added and cells were recovered and plated out following the same protocol as above.

### 2.2.1.6 Plasmid purification

The NucleoSpin Plasmid Kit was utilized for small scale preparation of plasmid DNA. Plasmids were checked for successful cloning by control restriction digest (Section 2.2.1.3) or colony PCR.
For sequencing, mid scale plasmid purifications were conducted with the NucleoBond ${ }^{\circledR}$ Xtra Midi Kit according to the manufacturer's instructions. Concentration of DNA was determined spectroscopically using a Nanodrop spectrophotometer (ND-1000 from NanoDrop Technologies Inc.).

### 2.2.1.7 Mutagenesis

Side-directed mutagenesis of SCOC was performed with the QuickChange Lightning site-directed mutagenesis kit. See table Table 2.13 and Table 2.14 for reaction setup and temperature cycling.

Table 2.13: Mutagenesis PCR reaction ( $25 \mu \mathrm{~L}$ ) setup

| Component | volume $(\boldsymbol{\mu L})$ |
| :--- | :---: |
| water | 17.18 |
| 10x buffer | 2.5 |
| dNTP mix | 1 |

## Mutagenesis PCR reaction ( $25 \mu \mathrm{~L}$ ) setup (continued)

| Component | volume $(\boldsymbol{\mu L})$ |
| :--- | :---: |
| 100 ng P fwd | 1 |
| 100 ng P rev | 1 |
| template 50 ng | 1.32 |
| enzyme | 1 |

Table 2.14: Mutagenesis PCR Temperature cycling

| Step | Temperature $\left({ }^{\circ} \mathrm{C}\right)$ | Length (s) | Repeat |
| :---: | :---: | :---: | :---: |
| 1 | 98 | 120 |  |
| 2 | 98 | 15 |  |
| 3 | $57-62$ | 30 | 30 x |
| 4 | 72 | $30 \mathrm{~s} / \mathrm{kb}$ |  |
| 5 | 72 | 420 |  |
| 6 | 16 | $\infty$ |  |

After PCR, parental DNA was digested by incubation with additional $1 \mu \mathrm{~L}$ DpnI. Cells were transformed with DpnI-treated DNA according to the provided maunal.

### 2.2.2 Expression and Purification

### 2.2.2.1 Expression analysis

Expression conditions were tested in LB, TB and autoinducible media at different temperatures ( $18{ }^{\circ} \mathrm{C}, 25{ }^{\circ} \mathrm{C}, 30^{\circ} \mathrm{C}$ and $37{ }^{\circ} \mathrm{C}$ ). 200 mL cultures were inoculated with an over night culture and grown at $37{ }^{\circ} \mathrm{C}$ until OD $\sim 0.5$ at 600 nm . Expression in LB and TB was induced with 1 mM IPTG. After this, cultures were distributed to different temperatures. Samples for SDS-PAGE gel electrophoresis were taken after appropriate incubation times. $200 \mu \mathrm{~L}$ of culture were spun down at maximum speed for 1 min in a microcentrifuge, resuspended in $50 \mu \mathrm{~L} \mathrm{H} \mathrm{H}_{2} \mathrm{O}$ and augmented with SDS sample buffer. At the
last time point, 50 mL of the culture were harvested, resuspended in 5 mL buffer and lysed by sonication. After 10 min centrifugation in a table top microcentrifuge, 2 mL of the supernatant were incubated for 1 hour with appropriate beads. Samples for SDS-PAGE gel electrophoresis were taken of pellet, supernatant and beads.

### 2.2.2.2 Minimal expression for selenomethione-labelling

A colony from a freshly streaked plate was picked and grown overnight at $37^{\circ} \mathrm{C}$ in LB. Minimal media expression cultures for incorporation of selenomethionine were set up according to Table 2.6 on page 22 and prewarmed at $37^{\circ} \mathrm{C}$. For inoculation the overnight culture was harvested at low speed and gently resuspended in $\mathrm{H}_{2} \mathrm{O}$. Minimal media cultures were grown until OD 0.3-0.5 at 600 nm . Then, the cultures were augmented with amino acid mix and solid selenomethionine ( $50 \mathrm{mg} / \mathrm{L}$ ). After another 20 min incubation, expression was induced with 1 mM IPTG. Expression was carried out at $25^{\circ} \mathrm{C}$ over night.

### 2.2.2.3 Minimal expression for ${ }^{15} \mathrm{~N}$-labelling

A colony from a freshly streaked plate was picked and grown overnight at $37{ }^{\circ} \mathrm{C}$ in LB. Minimal media expression cultures for ${ }^{15} \mathrm{~N}$-labelling were set up according to Table 2.5 on page 21 and prewarmed at $37^{\circ} \mathrm{C}$. For inoculation the overnight culture was harvested at low speed and gently resuspended in $\mathrm{H}_{2} \mathrm{O}$. Minimal media cultures were grown until OD 0.3-0.5 at 600 nm . Expression was induced with 1 mM IPTG and carried out at $25^{\circ} \mathrm{C}$ over night.

### 2.2.2.4 Expression and purification of Strep-tagged SCOC (78-159) domain and mutants

A synthetic gene of human SCOC isoform 1 was ordered from Mr Gene (DNA sequence Section A.1). Strep-tagged SCOC ccd constructs were cloned with NcoI and XhoI restriction sites into vector pET-28a (Novagen) using the full length synthetic gene as template for PCR. The StrepII-Tag was added by a 2 -step PCR strategy with two overlapping reverse primers. Single and double mutants of SCOC's ccd M78-K159 Strep-SCOC-pET28a were created by using the QuickChange Lightning site-directed mutagenesis kit. M78-K159 Strep-SCOC-pET28a constructs were transformed into BL21(DE3) by heat-shock protocol.
9 L of LB culture supplemented with $30 \mathrm{mg} / \mathrm{L}$ kanamycin were grown until OD ~0.6 at 600 nm . Expression was induced with 1 mM IPTG and cells were
harvested after 3 h incubation at $37^{\circ} \mathrm{C}$. Bacteria were spun down with a JS4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into $500 \mathrm{mM} \mathrm{NaCl}, 50 \mathrm{mM}$ HEPES pH 7.5 or 500 mM $\mathrm{NaCl}, 30 \mathrm{mM}$ HEPES pH 7.5. Cell suspension was frozen at $-20^{\circ} \mathrm{C}$ or directly used for protein purification. After thawing (if required), a PI tablet, DNaseI, lysozyme, and $1 \mathrm{M} \mathrm{MgCl}_{2}$ at a final concentration of 1 mM were added. The mixture was left with gentle stirring for 20 min at room temperature. Cells were lysed with three repetitions in a microfluidizer M-110L (Microfluidics Corporation) according to the provided manual. Cell debris was pelleted by 45 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filled in a 50 mL Superloop (GE Healthcare) and applied to a 5 mL StrepTrap column (GE Healthcare) connected to the Äkta Prime FPLC system or Äkta Purifier FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 7 CV buffer at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein complexes were eluted at $1 \mathrm{~mL} / \mathrm{min}$ with 6 CV of buffer supplemented with 2.5 mM desthiobiotin. Elution fractions containing the protein were collected and pooled.

Pooled protein fractions were concentrated to $\sim 4 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 10000 MWCO; Sartorius) and spun for 5 min at maximum speed in a microcentrifuge at $4^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 75 16/60 column connected to the Äkta FPLC system, using $250 \mathrm{mM} \mathrm{NaCl}, 20 \mathrm{mM}$ HEPES pH 7.5 as running buffer at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. The size exclusion buffer contained additional 5 mM TCEP when selenomethionine-labelled protein was purified. Samples for SDSPAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

### 2.2.2.5 Expression and purification of His-tagged SCOC constructs

Expression and purification of SCOC (78-132) and SCOC (112-159)
Overlapping parts of SCOC's ced were cloned into pET-28a with NdeI and XhoI restriction sites using the synthetic SCOC gene as template for PCR. Due to time constraints, both constructs were expressed in minimal media with selenomethionine incorporation only.

9 L of M9 minimal media culture supplemented with $30 \mathrm{mg} / \mathrm{L}$ kanamycin were grown until OD $\sim 0.5$ at 600 nm . After addition of amino acid mix and
solid selenomethionine, expression was induced with 1 mM IPTG. Cells were harvested after over night incubation at $25^{\circ} \mathrm{C}$. Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into buffer A ( 50 mM HEPES $\mathrm{pH} 7.5,400 \mathrm{mM}$ $\mathrm{NaCl}, 15 \mathrm{mM}$ imidazole). A PI tablet, DNaseI, lysozyme, and $1 \mathrm{M} \mathrm{MgCl}{ }_{2}$ at a final concentration of 1 mM were added. The mixture was left with gentle stirring for 20 min at room temperature. Cells were lysed on ice by sonication with a Branson Sonifier 450 sonicator. Duty cycle was set to 50 and output control to the microtip limit, which resulted in an output of $20-30 \%$. Cycles of 30 s on/off were performed summing up to 2 min total sonication time. Cell debris was pelleted by 45 min centrifugation with a SS 34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filled in a 50 mL Superloop (GE Healthcare) and applied to a 5 mL HisTrap column (GE Healthcare) connected to the Äkta Prime FPLC system or Äkta Purifier FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 30 CV buffer A at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein was eluted with a gradient towards $50 \%$ buffer B ( 50 mM HEPES $\mathrm{pH} 7.5,400 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{M}$ imidazole) at $1 \mathrm{~mL} / \mathrm{min}$. Elution fractions containing the protein were collected and pooled.
Pooled protein fractions were concentrated to $\sim 4 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 3000 MWCO; Sartorius) and then spun for 5 min at maximum speed in a microcentrifuge at $4{ }^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 75 16/60 column connected to the Äkta FPLC system, using gf buffer ( $300 \mathrm{mM} \mathrm{NaCl}, 20 \mathrm{mM}$ HEPES pH $7.5,5 \mathrm{mM}$ TCEP) at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDS-PAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

## Expression and purification of SCOC (78-141) and SCOC (78-K151)

C-terminally truncated constructs of SCOC's ccd were cloned into pET-22b with NdeI and XhoI restriction sites using the synthetic SCOC gene as template for PCR. The constructs were expressed differently but purified via the same protocol.

For expression of SCOC ccd (78-141), 9 L of LB culture supplemented with $100 \mathrm{mg} / \mathrm{L}$ ampicillin were grown until OD $\sim 0.5$ at 600 nm . Expression was induced with 1 mM IPTG. Cells were harvested after 3 h incubation at $37^{\circ} \mathrm{C}$.

For expression of SCOC (78-151), 9 L of autoinducible culture supplemented with $100 \mathrm{mg} / \mathrm{L}$ ampicillin were grown until OD $\sim 0.7$ at 600 nm . Cultures were
shifted to $18{ }^{\circ} \mathrm{C}$ and left for expression over night.
Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into buffer A $(50 \mathrm{mM}$ HEPES pH 7.5, $400 \mathrm{mM} \mathrm{NaCl}, 15 \mathrm{mM}$ imidazole). A PI tablet, DNaseI, lysozyme, and $1 \mathrm{M} \mathrm{MgCl}_{2}$ at a final concentration of 1 mM were added. The mixture was left with gentle stirring for 20 min at room temperature. Cells were lysed with three repetitions in a microfluidizer M-110L (Microfluidics Corporation) according to the provided manual. The debris was pelleted by 45 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filled in a 50 mL Superloop (GE Healthcare) and applied to a 5 mL HisTrap column (GE Healthcare) connected to the Äkta Prime FPLC system or Äkta Purifier FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 30 CV buffer A at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein was eluted with a gradient towards $50 \%$ B ( 50 mM HEPES pH 7.5, 400 mM NaCl , 1 M imidazole) at $1 \mathrm{~mL} / \mathrm{min}$. Elution fractions containing the protein were collected and pooled.

Pooled fractions were dialyzed against gf buffer ( $250 \mathrm{mM} \mathrm{NaCl}, 20 \mathrm{mM}$ HEPES pH 7.5, $2 \mathrm{mM} \mathrm{MgCl}_{2}$ ) over night at $4{ }^{\circ} \mathrm{C} .200 \mu \mathrm{~L}$ Thrombin ( $1 \mathrm{U} / \mu \mathrm{L}$ ) was added to the dialysis tube for cleavage of the His-Tag. On the next day, Thrombin activity was inhibited by the addition of Pefabloc to a final concentration of 0.4 mM . The protein solution was loaded onto an 5 mL GSTrap column (GE Healthcar) at $1 \mathrm{~mL} / \mathrm{min}$. The flowthrough containing the cleaved protein was fractionated and collected. The flowthrough fractions were concentrated to $\sim 4 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 3000 MWCO; Sartorius) and then spun for 5 min at maximum speed in a microcentrifuge at $4^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 200 16/60 column connected to the Äkta FPLC system, using gf buffer ( $250 \mathrm{mM} \mathrm{NaCl}, 20 \mathrm{mM}$ HEPES $\mathrm{pH} 7.5,2 \mathrm{mM} \mathrm{MgCl})_{2}$ ) at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDS-PAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

### 2.2.2.6 Expression and purification of GST-SCOC fusion proteins

GST-tagged full length SCOC and GST-tagged SCOC (78-159) were cloned into pGEX-4T1 with BamHI and XhoI restriction sites using the synthetic SCOC gene as template for PCR.

For expression of both GST fusion proteins, 9 L of LB culture supplemented with $100 \mathrm{mg} / \mathrm{L}$ ampicillin were grown until OD $\sim 0.5$ at 600 nm . Expression was induced with 1 mM IPTG. Cells were harvested after 3 h incubation at $37^{\circ} \mathrm{C}$. Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into buffer A ( 50 mM HEPES $\mathrm{pH} 7.5,300 \mathrm{mM} \mathrm{NaCl}$ ). A PI tablet, DNaseI, lysozyme, and 1 M $\mathrm{MgCl}_{2}$ at a final concentration of 1 mM were added. The mixture was left with gentle stirring for 20 min at room temperature. Cells were lysed with three repetitions in a microfluidizer M-110L (Microfluidics Corporation) according to the provided manual. The debris was pelleted by 45 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filled in a 50 mL Superloop (GE Healthcare) and applied to a 5 mL Protino® GST/4B column (Macherey and Nagel) connected to the Äkta Prime FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 10 CV buffer A at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein was eluted with 12 CV buffer B ( 50 mM HEPES $\mathrm{pH} 7.5,300 \mathrm{mM} \mathrm{NaCl}, 10 \mathrm{mM}$ glutathione) at $1 \mathrm{~mL} / \mathrm{min}$. Elution fractions containing the protein were collected and pooled.
Pooled fractions were concentrated to $\sim 4 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 30000 MWCO; Sartorius) and then spun for 5 min at maximum speed in a microcentrifuge at $4{ }^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 200 16/60 column connected to the Äkta FPLC system, using gf buffer ( $250 \mathrm{mM} \mathrm{NaCl}, 20 \mathrm{mM}$ HEPES pH 7.5 ) at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDS-PAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

### 2.2.2.7 Expression and purification of Arl1 (15-181) Q79L

A synthetic gene of human Arl1 with a dominant active mutation Q79L was ordered from Mr Gene (DNA sequence in Section A.1). His-tagged Arl1 (15181) was cloned with NdeI and XhoI restriction sites into vector pET-22b using the full length synthetic gene as template for PCR.

9 L of autoinducible media supplemented with $100 \mathrm{mg} / \mathrm{L}$ ampicillin were grown until OD $\sim 0.7$ at 600 nm . Expression was conducted over night at $18^{\circ} \mathrm{C}$. Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into buffer A ( $50 \mathrm{mM} \mathrm{NaH} 2_{2} \mathrm{PO}_{4} \mathrm{pH} 7.5,300 \mathrm{mM} \mathrm{NaCl}, 10 \mathrm{mM}$ imidazole, $5 \mathrm{mM} \mathrm{MgCl} \mathrm{M}_{2}$ ).

Cell suspension was frozen at $-20^{\circ} \mathrm{C}$ or directly used for protein purification. After thawing (if required), a PI tablet, DNaseI and lysozyme were added. The mixture was left with gentle stirring for 20 min at room temperature. Cells were lysed on ice by sonication with a Branson Sonifier 450 sonicator. Duty cycle was set to 50 and output control to the microtip limit, which resulted in an output of $20-30 \%$. Cycles of 30 s on/off were performed summing up to 2 min total sonication time. Cell debris was pelleted by 60 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filled in a 150 mL superloop (GE Healthcare) and applied to a 5 mL HisTrap column (GE Healthcare) connected to the Äkta Prime FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 30 CV buffer A at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinitypurified protein was eluted with a gradient towards $50 \%$ buffer B ( 50 mM $\mathrm{NaH}_{2} \mathrm{PO}_{4} \mathrm{pH} 7.5,300 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{M}$ imidazole, 5 mM MgCl 2 ) at $1 \mathrm{~mL} / \mathrm{min}$.

Pooled protein fractions were concentrated to $\sim 4 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 10000 MWCO; Sartorius) and then spun for 5 min at maximum speed in a microcentrifuge at $4{ }^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 200 16/60 column connected to the Äkta FPLC system running with gf A buffer ( $50 \mathrm{mM} \mathrm{NaH} \mathrm{NO}_{2} \mathrm{PO}_{4} \mathrm{pH} 7.5$, $300 \mathrm{mM} \mathrm{NaCl}, 5 \mathrm{mM} \mathrm{MgCl} 2$ ) at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Pooled protein fractions were concentrated to $\sim 8 \mathrm{mg} / \mathrm{mL}$.

2 mL of the protein solution were mixed with excess EDTA ( $125 \mu \mathrm{~L}$ of a 0.2 M EDTA stock), $16 \mu \mathrm{~L}$ of shrimp alkaline phosphatase $(1 \mathrm{U} / \mu \mathrm{L})$ and diluted with 20 mM HEPES pH 7.5 to 2.5 mL . GDPNHP, a non-hydrolyzable GTP derivate, was added to a final concentration of 10 mM . The sample was incubated in the cold room over night for nucleotide exchange. On the next day, excess $\mathrm{MgCl}_{2}$ was added. GDPNHP-loaded Arl1 T15-Q181 Q79L was diluted to 5 mL with gf B buffer ( 30 mM Tris pH 8.0, $300 \mathrm{mM} \mathrm{NaCl}, 5 \mathrm{mM} \mathrm{MgCl}{ }_{2}$, 5 mM DTT) and purified again over Superdex 200 16/60 column as before. Samples for SDS-PAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of elution fractions containing protein. The concentrated protein was mixed with $20 \%$ glycerol, aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

### 2.2.2.8 Coexpression and copurification of SCOC-FEZ1 complexes

Human FEZ1 ccd constructs were cloned with NdeI and XhoI restriction sites into vector pET-22b (Novagen) using full length FEZ1 as template for PCR (gift by John Chua). Both FEZ1-pet22b and SCOC-pET-28a (78-159) were
co-transformed into BL21 by electroporation.
3 L of LB culture supplemented with $100 \mathrm{mg} / \mathrm{L}$ ampicillin and $30 \mathrm{mg} / \mathrm{L}$ kanamycin were grown until OD $\sim 0.6$ at 600 nm . Expression was induced with 1 mM IPTG and cells were harvested after 3 h incubation at $37^{\circ} \mathrm{C}$. Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into 250 mM NaCl , 50 mM HEPES pH 7.5 . Cell suspension was frozen at $-20^{\circ} \mathrm{C}$ or directly used for protein purification. After thawing (if required), a PI tablet, DNaseI, lysozyme, and $1 \mathrm{M} \mathrm{MgCl}_{2}$ at a final concentration of 1 mM were added. The mixture was left with gentle stirring for 20 min at room temperature. Cells were lysed with three repetitions in a microfluidizer M-110L (Microfluidics Corporation) according to the provided manual. Cell debris was pelleted by 45 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filled in a 50 mL Superloop (GE Healthcare) and then applied to a 5 mL StrepTrap column (GE Healthcare) connected to the Äkta Prime FPLC system or Äkta Purifier FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 7 CV buffer at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein complexes were eluted at $1 \mathrm{~mL} / \mathrm{min}$ with 6 CV of buffer supplemented with 2.5 mM desthiobiotin. Elution fractions containing the protein were collected and pooled.

For SEC-MALLS analysis, the protein complex was further purified by size exclusion chromatography. Pooled protein fractions were concentrated to $\sim 4 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 3000 MWCO; Sartorius) and spun for 5 min at maximum speed in a microcentrifuge at $4^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 75 16/60 column connected to the Äkta Prime FPLC system in the cold room, using $250 \mathrm{mM} \mathrm{NaCl}, 50 \mathrm{mM}$ HEPES pH 7.5 as running buffer at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDS-PAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated complex, either affinity- or gel-filtration purified, was prone to aggregration and precipiation, and was therefore freshly used for different applications.

### 2.2.2.9 Expression and denaturing purification of VirG (353-758)

Several methods and constructs were tried for expression and purification of VirG (353-758). Due to the formation of inclusion bodies, all purification protocols involved denaturation and refolding of the protein. VirG (353-758) with
different tags was cloned into pET-28a using the pWR100 virulence plasmid of Shigella flexneri (gift from Prof. A. Zychlinsky) as template for PCR.

## GdnHCl-denaturing purification of C-terminal Strep-tagged VirG (353-758) with stepwise refolding

9 L of LB culture supplemented with $30 \mathrm{mg} / \mathrm{L}$ kanamycin were grown until OD ~0.6 at 600 nm . Expression was induced with 1 mM IPTG and cells were harvested after incubation over night at $30^{\circ} \mathrm{C}$. Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into sonication buffer $20 \mathrm{mM} \mathrm{NaH} \mathrm{NO}_{4} \mathrm{PO}_{4} \mathrm{pH} 7$, $300 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{mM}$ EDTA, 2 mM benzamidine. Cell suspension was frozen at $-20^{\circ} \mathrm{C}$ or directly used for protein purification. After thawing (if required), a PI tablet, DNaseI, lysozyme and $1 \mathrm{M} \mathrm{MgCl}_{2}$ at a final concentration of 1 mM were added. The mixture was left stirring in the cold room for 20 min .

Cells were lysed on ice by sonication with a Branson Sonifier 450 sonicator. Duty cycle was set to 50 and output control to the microtip limit, which resulted in an output of $20-30 \%$. Cycles of 30 s on/off were performed summing up to 2 min total sonication time. Unsoluble fractions were harvested by centrifugation for 20 min in a SS 34 rotor at $14000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ in a Du Pont Sorvall centrifuge. The pellet was resuspended in 300 mL sonication buffer and $1 \%$ Triton-X-100 was added. After 5 minutes of stirring, the pellet was again harvested and resuspended as before. Inclusion bodies were solubilized with 6 M GdnHCl by thorough homogenization. At $4^{\circ} \mathrm{C}$, the solution was slowly and drop-wise diluted with sonication buffer with three times its own volume of sonication buffer to 2 M GdnHCl while gently stirred. Debris and precipitate were pelleted as before. The remaining supernatant was dialyzed over night against 4 L sonication buffer supplemented with 1.5 M GdnHCl at $4^{\circ} \mathrm{C}$. On the next day, the solution was dialyzed for 5 h against 1 M and then 0.5 M GdnHCl sonication buffer. Final dialysis occurred over night against 0 M GdNHCl . Between all the dialysis steps, precipitate was removed by centrifugation as before.

The final supernatant was filtered through a $0.45 \mu \mathrm{~m}$ filter, filled into a 150 mL Superloop (GE Healthcare) and applied to a 5 mL StrepTrap column (GE Healthcare) connected to the Äkta Prime FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 7 CV buffer at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein was eluted at $1 \mathrm{~mL} / \mathrm{min}$ with 6 CV of sonication buffer supplemented with 2.5 mM desthiobiotin. Elution fractions containing the protein were collected and pooled. Pooled protein fractions were concentrated to $\sim 5 \mathrm{~mL}$ with a concentrator (Vi-
vaspin 20, 30000 MWCO; Sartorius) and spun for 5 min at maximum speed in a microcentrifuge at $4^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 200 16/60 column connected to the Äkta FPLC system, using $300 \mathrm{mM} \mathrm{NaCl}, 30 \mathrm{mM} \mathrm{NaH} \mathrm{N}_{2} \mathrm{PO}_{4} \mathrm{pH} 7.5,1 \mathrm{mM}$ EDTA, 2 mM benzamidine and 2 mM DTT as running buffer at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDS-PAGE gel electrophoresis were taken of all pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

### 2.2.2.10 Expression and denaturing purification of VirG passenger domain (52-758)

VirG (52-758) was cloned into pET-28a from a synthetic gene optimized for E.coli expression. Due to the expression in inclusion bodies, the purification protocol involved denaturation and refolding of the protein. 4.5 L of LB culture supplemented with $30 \mathrm{mg} / \mathrm{L}$ kanamycin were grown until OD $\sim 0.5$ at 600 nm . Expression was induced with 1 mM IPTG and cells were harvested after incubation for 5 h at $37^{\circ} \mathrm{C}$. Bacteria were spun down with a JS-4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into 30 mM Tris $\mathrm{pH} 7.4,500 \mathrm{mM} \mathrm{NaCl}, 15 \mathrm{mM}$ imidazole, 5 mM benzamidine. Cell suspension was frozen at $-20^{\circ} \mathrm{C}$ or directly used for protein purification.
After thawing (if required), a PI tablet, DNaseI, lysozyme and $1 \mathrm{M} \mathrm{MgCl}_{2}$ at a final concentration of 1 mM were added. The mixture was left stirring in the cold room for 20 min . Cells were lysed on ice by sonication with a Branson Sonifier 450 sonicator. Duty cycle was set to 50 and output control to the microtip limit, which resulted in an output of $20-30 \%$. Cycles of 30 s on/off were performed summing up to 2 min total sonication time. Urea was added to a final concentration of 6 M urea. The sample was sonicated again with the same settings as above. Cell debris was pelleted by 60 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filtered through a $0.45 \mu \mathrm{~m}$ filter, filled into a 150 mL Superloop (GE Healthcare) and applied to a Protino® Ni-NTA Column 5 mL (Macherey and Nagel) connected to the Äkta Prime FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 30 CV buffer A ( 30 mM Tris $\mathrm{pH} 7.4,500 \mathrm{mM} \mathrm{NaCl}, 4 \mathrm{M}$ urea, 15 mM imidazole, 5 mM benzamidine) at $2.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein was eluted with a gradient towards $40 \%$ buffer B ( 30 mM Tris $\mathrm{pH} 7.4,500 \mathrm{mM}$
$\mathrm{NaCl}, 2 \mathrm{M}$ urea, 10 mM imidazole, 5 mM benzamidine) at $1 \mathrm{~mL} / \mathrm{min}$. Elution fractions containing the protein were pooled and collected.

VirGs passenger domain was further purified via anion exchange chromatography. Over night, pooled fractions were dialyzed against buffer AX A ( 100 mM $\mathrm{NaCl}, 30 \mathrm{mM}$ Tris pH 8.0, 1 M urea, 1 mM EDTA, 5 mM benzamidine). The protein solution was loaded at $0.5 \mathrm{~mL} / \mathrm{min}$ onto a 5 mL HiTrapQ FF column (GE Healthcare) via a 50 mL superloop. The column was washed with 5 CV buffer AX A. A gradient from $0-40 \%$ buffer AX B ( $1 \mathrm{M} \mathrm{NaCl}, 30 \mathrm{mM}$ Tris $\mathrm{pH} 8.0,1 \mathrm{M}$ urea, 1 mM EDTA, 5 mM benzamidine) at $1 \mathrm{~mL} / \mathrm{min}$ eluted the protein from the column. Finally, VirG A52-R758 was polished in a size exclusion purification step. Pooled protein fractions were dialyzed against gf buffer ( 30 mM Tris $\mathrm{pH} 8.0,400 \mathrm{mM} \mathrm{NaCl}, 500 \mathrm{mM}$ urea, 1 mM EDTA, 5 mM benzamidine) at $4{ }^{\circ} \mathrm{C}$, concentrated to $\sim 5 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 30000 MWCO; Sartorius) and then spun for 5 min at maximum speed in a microcentrifuge at $4{ }^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 200 16/60 column connected to the Äkta Prime FPLC system at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDS-PAGE gel electrophoresis were taken of all pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was supplemented with $20 \%$ glycerol, aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.

### 2.2.2.11 Expression and purification of IcsB-IpgA complexes

The virulence factor IcsB and its chaperone IpgA were cloned into the two multiple cloning sites (MCS) of pETDuet-1 with the Shigella virulence plasmid as template for PCR. IcsB was cloned with restriction sites BamHI and NotI into MCS I, IpgA was cloned with NdeI and XhoI sites into MCS II. C- or N-terminal StrepII-Tag was added to IpgA by PCR with the reverse primer. Complexes were affinity-purified via the His-Tag on IcsB and furthermore by size exclusion chromatography.

9 L of autoinducible media supplemented with $100 \mathrm{mg} / \mathrm{L}$ ampicillin were grown until OD $\sim 0.7$ at 600 nm . Cultures were incubated over night for expression at $18{ }^{\circ} \mathrm{C}$. Bacteria were spun down with a JS- 4.2 rotor in a Beckman J6-MI centrifuge at $4,000 \mathrm{rpm}, 4^{\circ} \mathrm{C}$ for 20 min . The pellet was resuspended into buffer $\mathrm{A}\left(50 \mathrm{mM} \mathrm{NaH} \mathrm{NO}_{4} \mathrm{pH} 7.5,300 \mathrm{mM} \mathrm{NaCl}, 30 \mathrm{mM}\right.$ imidazole). Cell suspension was frozen at $-20^{\circ} \mathrm{C}$ or directly used for protein purification. After thawing (if required), a PI tablet, DNaseI, lysozyme and $1 \mathrm{M} \mathrm{MgCl}{ }_{2}$ at a final concentration of 1 mM were added. The mixture was left stirring in the
cold room for 20 min . Cells were lysed on ice by sonication with a Branson Sonifier 450 sonicator. Duty cycle was set to 50 and output control to the microtip limit, which resulted in an output of $20-30 \%$. Cycles of 30 s on/off were performed summing up to 2 min total sonication time. Cell debris was pelleted by 60 min centrifugation with a SS34 rotor in a Du Pont Sorvall centrifuge at 14000 rpm and $4^{\circ} \mathrm{C}$. The supernatant was filtered through a $0.45 \mathrm{\mu m}$ filter, filled into a 150 mL Superloop (GE Healthcare) and applied to a 5 mL HisTrap column (GE Healthcare) connected to the Äkta Prime FPLC system. Supernatant was loaded onto the column at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$, then the column was washed with 30 CV buffer A at $1.5 \mathrm{~mL} / \mathrm{min}$. Affinity-purified protein was eluted with a gradient towards $50 \%$ buffer $\mathrm{B}\left(50 \mathrm{mM} \mathrm{NaH} \mathrm{PO}_{4}\right.$ $\mathrm{pH} 7.5,300 \mathrm{mM} \mathrm{NaCl}, 1 \mathrm{M}$ imidazole) at $1 \mathrm{~mL} / \mathrm{min}$. Elution fractions containing the protein were collected.
Pooled fractions were dialyzed against gf buffer ( $300 \mathrm{mM} \mathrm{NaCl}, 30 \mathrm{mM}$ HEPES $\mathrm{pH} 7.5,2 \mathrm{mM}$ DTT) at $4^{\circ} \mathrm{C}$, concentrated to $\sim 5 \mathrm{~mL}$ with a concentrator (Vivaspin 20, 30000 MWCO; Sartorius) and spun for 5 min at maximum speed in a microcentrifuge at $4{ }^{\circ} \mathrm{C}$. The sample was applied on a 5 mL sample loop and loaded on an equilibrated Superdex 200 16/60 column connected to the Äkta Prime FPLC system at a flow rate of $1 \mathrm{~mL} / \mathrm{min}$. Samples for SDSPAGE gel electrophoresis were taken of pellet, supernatant and flowthrough fractions and of all elution fractions containing protein. The concentrated protein was aliquoted, flash frozen in liquid nitrogen and stored at $-80^{\circ} \mathrm{C}$.
For the complexes with shortened IcsB constructs (IcsB (235-494), (216494), (293-494) and (185-494)), the same protocol was followed except that the gf buffer contained only $200 \mathrm{mM} \mathrm{NaCl}(30 \mathrm{mM}$ HEPES $\mathrm{pH} 7.5,200 \mathrm{mM}$ $\mathrm{NaCl}, 2 \mathrm{mM}$ DTT).

### 2.2.3 Biochemical methods

### 2.2.3.1 SDS-PAGE and Western blot

For routine applications, such as quality control of purification protocols, $S D S$ PAGE was used. Gels were made up of a resolving and a separating gel. The protocol for $8-15 \%$ SDS-PAGE gels was adapted from Laemmli [91]. For analysis of smaller proteins, gels were prepared by a protocol from Schägger \& von Jagow [92]. Composition of all buffers and solutions can be found in Section 2.1.5. Samples were mixed with 3 x sample buffer and heated to $95^{\circ} \mathrm{C}$ for 3-5 min. SDS-PAGE gels were run at a constant current of 180 V until the blue front was leaking through. For electrophoresis of Schägger gels, a current
of 90 V was applied until the protein front reached the separating gel. Then the current was adjusted to 120 V .

Gels were stained with Coomassie Brilliant Blue with a fast staining protocol. The gel was placed in a microwavable plastic container, well covered with solution A and heated for 1 min at maximum power in the microwave. Solution A was replaced by solution B and heated again. The same procedure was followed with solution C and D. Gels were left shaking in destaining solution D for 5 min .

For western blotting with the semi-dry method [93], the gel and a nitrocellulose membrane were washed in water and then transfer buffer. Four filter papers were also soaked in transfer buffer. The sandwich of two filter papers, gel, membrane and two filter papers was applied to 45 mA . Transfer time varied depending on the protein size. Next, the mebrane was washed with TBS-T and then blocked for 20 min with Blotto. Incubation with the first antibody diluted in Blotto occurred over night or for one hour. Again, the membrane was washed three times with TBS-T. The membrane was incubated with the second antibody for 45 min , thouroughly washed with TBS-T before detection with ECL solution (Perkin Elmer). For detection and analysis, a Imageready LAS-1000 CCD camera (Fujifilm) and AIDA software (Fujifilm) were used.

### 2.2.3.2 Limited proteolysis

Limited proteolysis was performed in search of stable fragments or domains of proteins. For this purpose, the Proti-Ace I + II (Hampton Research) Kits were utilized and the manufacturers instructions were followed. The kits contain twelve different proteases ( $\alpha$-Chymotrypsin, Trypsin, Elastase, Papain, Subtilisin, Endoproteinase Glu-C, Proteinase K, Endoproteinase Arg-C, Pepsin, Thermolysin, Bromelain, Actinase) that were diluted to a working concentration of $0.01 \mathrm{mg} / \mathrm{mL}$ in the provided buffer ( 10 mM HEPES $\mathrm{pH} 7.5,500 \mathrm{mM}$ NaCl ). Proteases were mixed with the same volume of protein solution (1$10 \mathrm{mg} / \mathrm{mL}$ ). Time course of the degradation process was followed by taking samples after different time points (e.g. 5, 10, 15, 10, 30, 45 and 60 min ). Reactions in the samples were stopped by the immediate addition of sample buffer. Samples were analyzed by SDS-PAGE.

### 2.2.3.3 N -terminal sequencing

Stable fragments found by limited proteolysis were sent to SeqLab (Sequence Laboratories Göttingen GmbH ). The first five amino acids of a fragment were
determined by Edman's degradation. For preparation of the fragment, the manufacturers instructions were followed. The protocol included western blotting of the fragment on a PVDF membrane. The PVDF membrane was activated for 20 s in methanol before washing it in transfer buffer. For transfer, CAPS buffer ( 10 mM CAPS pH 11, $10 \%$ methanol) was used. After blotting, the membrane was washed with water and methanol and then stained with Coomassie Blue R-250 ( $0.1 \%$ (w/v) Coomassie Blue R-250, $1 \%$ acetic acid, $40 \%$ methanol). Bands were visualized by destaining with $50 \%$ methanol. The membrane was washed with water and dried. Relevant protein bands were cut out with a scalpel and sent to SeqLab in an Eppendorf tube.

### 2.2.3.4 GST-Pulldown

Pulldown of immobilized GST-SCOC-ccd was applied to find novel interaction partners from HEK lysate. The pulldown procedure was modified from a Nature Methods protocol by Einarson based on Einarson [94]. Two reactions of $50 \mu \mathrm{~L}$ of glutathione SepharoseTM 4 Fast Flow beads (GE Healthcare), same amounts of cleared HEK lysate and $10 \mu \mathrm{~g}$ GST or GST-SCOC-ccd, respectively, were incubated at $4{ }^{\circ} \mathrm{C}$ in a head over end shaker. The two samples were spun down for 5 min at 5000 rpm in a microcentrifuge. Beads were washed 4 times with ice-cold PBS buffer and centrifuged again. Samples of supernatant, wash fractions and beads were analyzed by SDS-PAGE gel electrophoresis. The gel with bands of pulled protein was given to the mass spectrometry facility for further analysis.

### 2.2.3.5 Nucleotide-dependent Arl1-Pulldown

Table 2.15: Composition of Arl1-Pulldown reactions

| component |  | control | GTP | GTPrs | GDP |
| :--- | :---: | :---: | :---: | :---: | :---: |
| His-Arl1 Q79L | $(15-181)$ | $200 \mu \mathrm{~L}$ | $200 \mu \mathrm{~L}$ | $200 \mu \mathrm{~L}$ | $200 \mu \mathrm{~L}$ |
| $(2 \mathrm{mg} / \mathrm{mL})$ |  | - | $20 \mu \mathrm{~L}$ | $20 \mu \mathrm{~L}$ | $20 \mu \mathrm{~L}$ |
| NTP $(20 \mathrm{mM})$ |  | - |  |  |  |
| Strep-SCOC <br> $(12 \mathrm{mg} / \mathrm{mL})$ | $(78-159)$ | $30 \mu \mathrm{~L}$ | $30 \mu \mathrm{~L}$ | $30 \mu \mathrm{~L}$ | $30 \mu \mathrm{~L}$ |
| buffer |  | $770 \mu \mathrm{~L}$ | $750 \mu \mathrm{~L}$ | $750 \mu \mathrm{~L}$ | $750 \mu \mathrm{~L}$ |

To check whether SCOC's ccd is interacting with Arl1 in a nucleotidedependent manner, a pulldown experiment was performed. Four reactions were set up according to Table 2.15.

Arl1 was preincubated with an excess of the respective nucleotide on ice for 20 min . Then, SCOC (78-159) was added and the reactions were left on a rotary shaker at $4{ }^{\circ} \mathrm{C}$ over night. After the addition of $50 \mu \mathrm{~L}$ of $\mathrm{Ni}^{2+}$-sepharose beads to each tube, the mixtures were left for another two hours for binding on the rotary shaker. Beads were pelleted by 2 min centrifugation at 2000 rpm in a microcentrifuge. The flowthrough was collected and beads were washed twice with 2 mL ice-cold buffer. Protein complexes were eluted with buffer B. Samples of supernatant, flowthrough, wash and beads were analyzed by SDS-PAGE.

### 2.2.3.6 Isothermal titration calorimetry

Isothermal titration calorimetry can reveal insights into thermodynamic features of an interaction of a protein and an interaction partner. Binding affinities, stochiometry and enthalpy can be determined.

The ITC200 (Microcal) was used for measurements of SCOC and Arl1. This instrument holds a cell of $200 \mu \mathrm{~L}$ volume and a syringe of of $40 \mu \mathrm{~L}$. The concentration of the component in the cell should be $\sim 10$ times higher than in the cell. SCOC (78-159) in the syringe was applied at a concentration of $615 \mu \mathrm{M}$ and GDPNHP-loaded Arl1 $(15-181)$ at $50 \mu \mathrm{M}$. Both proteins were diluted from stock solutions of higher concentration with ITC buffer ( 20 mM HEPES pH 7.5, 150 mM NaCl ). Stock solutions were dialyzed in the same buffer over night before. Standard settings of the ITC200 were used. 25 total injections of $2 \mu \mathrm{~L}$ were performed with 120 s delay. Temperature was set to $20^{\circ} \mathrm{C}$, stirring speed to 300 rpm and reference power to $7 \mu \mathrm{cal} / \mathrm{s}$.

### 2.2.3.7 Circular Dichroism spectroscopy

Circular Dichroism spectroscopy (CD) was used to analyze secondary structure and stability of proteins.

CD protein samples were dialyzed to buffers containing NaF instead of NaCl . For SCOC ccd constructs, $20 \mathrm{mM} \mathrm{NaH} \mathrm{H}_{2} \mathrm{PO}_{4} \mathrm{pH} 7.5,250 \mathrm{mM} \mathrm{NaF}$, for VirG S353-R758 $30 \mathrm{mM} \mathrm{NaH} 2_{2} \mathrm{PO}_{4} \mathrm{pH} 7.4,300 \mathrm{mM} \mathrm{NaF}$ were used. Measurements of VirG's passenger domain were performed in the latter buffer supplemented with 0.5 M urea. For each spectrum, three repetitions and a buffer baseline were collected. Protein concentration was usually between $15-30 \mu \mathrm{M}$.

Measurements were done with a Chirascan Circular Dichrosim spectrometer (Applied Photophysics) using a Hellma quartz cuvette with a path length of 0.1 cm . Far UV CD spectra of SCOC were recorded between 200 and 260 nm with a step size of 0.5 nm , a band width of 1.5 nm and an averaging time of 5 s at either $20^{\circ} \mathrm{C}$ or $93^{\circ} \mathrm{C}$. Thermal melts were carried out from $20^{\circ} \mathrm{C}$ to $93{ }^{\circ} \mathrm{C}$ at 208 nm with a heating rate of $0.5^{\circ} \mathrm{C} / \mathrm{min}$. Bandwidth was 1.5 nm and the averaging time was 1.5 s . For analysis of VirG's secondary structure, bandwidth was set to 2 nm , thermal melts were carried out at 216 nm . Data were analyzed with the manufacturer's ProView Software. Melting curves were fitted to a sigmoid shape and melting points were determined as the maxima of the first derivative of the function $f(x)=A b+((A t-A b) /(1+\exp ((x 0-$ $x) / w)))+m$.

### 2.2.3.8 SEC-MALLS

The oligomerization state of SCOC's ccd and its mutants were analyzed by Size exclusion chromatography coupled to a Multi Angle Laser Light Scatterer (SEC-MALLS). All proteins loaded on the column were affinity and gel filtration purified before.

A Superdex 10/300 GL was connected to an Eclipse 2 system from Wyatt Technology with a DAWN EOS multi-angle light scattering setup and an Agilent 1100 series HPLC pump. The instruments were equilibrated with buffer ( 20 mM HEPES pH 7.5, $250 \mathrm{mM} \mathrm{NaCl}, 0.1 \mathrm{\mu M}$ filtered) until the baseline of the MALLS detector perpendicular to the laser (detector 11) was stable. For determination of the current protein concentration, a variable wavelength detector (Agilent) was connected to the MALLS instrument. The wavelength was set to 280 nm and the instrument was balanced (autozero function). $500 \mu \mathrm{~L}$ of $\sim 1.5 \mathrm{mg} / \mathrm{mL}$ protein sample were injected manually into a $500 \mu \mathrm{~L}$ sample loop. Data collection was started, then the sample loop valve was turned manually from "load" to "inject". Scattering data and absorption at 280 nm were recorded for 60 min at a flow rate of $0.5 \mathrm{~mL} / \mathrm{min}$. Scattering data were analyzed with the manufacturer's ASTRA software. Molecular weights were determined from three SEC-MALLS experiments.

### 2.2.3.9 Crystallization

## Screening

Initial screening for crystallization conditions were done in 96 -well format with purchased crystallization screens. Sitting drops with two different pro-
tein concentrations were pipetted into the two wells of MRC plates (Hampton Research) by the Cartesian Mycrosys robot (Cartesian Dispensing Systems). Routinely, a method setting 200 nL drops of 100 nL protein solution and 100 nL crystallization buffer was used. After complete dispensing of the robot, plates were rapidly covered with transparent sealing tape to prevent drying of the crystal drops. Plates were stored at $20^{\circ} \mathrm{C}$ for SCOC screening plates and at $4^{\circ} \mathrm{C}$ for VirG and IcsB proteins in a Formulatrix robot for automated imaging. Available crystallization screens included $\left(\mathrm{NH}_{4}\right)_{2} \mathrm{SO}_{4}$, Anions, Cations, ClassicLite, Classics I+II, ComPas, MbClass I+II, JCSG+, PACT, PEGI+II, pHclearI+II, ProComplex (all Qiagen), SaltRx and Index (Hampton Research).

## Refinement of crystallization conditions

First hits were refined with different strategies.
With the Tecan robot, strategies for refinement with 96-well format Grid Screens and Random Screens were done. The Tecan robot dispensed newly customized screens from stock solutions into master blocks with one 1 mL reservoirs. Stock solutions were either purchased (Hampton Research or Qiagen) or self made from ultrapure chemicals. 96 -well MRC plates were filled with the new crystallization conditions. With this method, rapid refinement of pH and precipitant concentration is possible, but with random screens also the necessivity of the presence of several components can be addressed.

Larger crystals for data collection at the synchrotron were usually grown in 24-well format. In 24 -well grid screens, pH and precipitant concentration of a known crystallization condition were varied along smaller increments. Hanging drops were set up in self greased 24-well Linbro plates (Jena Bioscience) with Bayer medium viscosity silicon grease (Jena Bioscience) or in pre-greased Crystalgen SuperClearT Plates (Jena Bioscience). 500-1000 $\mu \mathrm{L}$ reservoirs were set up from self-made screening buffers from ultrapure chemicals or stock solutions purchased from Hampton Research. Up to 4 crystal drops made up of $1 \mu \mathrm{~L}$ protein and $1 \mu \mathrm{~L}$ reservoir solution were pipetted on a siliconized cover slide ( 22 mm diameter). Slides were turned upside down and fitted tightly onto the grease above a reservoir.

Strike seeding was used for optimization of crystal growth and diffraction quality. A crystal or a crystalline structure like a cluster was smashed with an accupuncture needle in mother liquor. A newly set drop was streaked through with the accupuncture needle to provide nucleation sites for crystal growth.

## In situ proteolysis

Crystals for the structure determination of SCOC's ccd were obtained by in situ proteolysis. Crystal drops were supplemented with small amounts of protease to cleave flexible parts of the protein in order to improve diffraction quality.

For in situ proteolysis crystallization, $3 \mathrm{mg} / \mathrm{ml}$ of selenomethionine-labelled L105M SCOC (78-159) were mixed with subtilisin in a 1:2000 (w/w) ratio and kept on ice until setting of the crystallization plates. Crystal drops were streak seeded and set at 3 and $1.5 \mathrm{mg} / \mathrm{mL}$. Crystals were grown in hanging drops using Linbro plates at $20^{\circ} \mathrm{C}$ by mixing $1 \mu \mathrm{~L}$ protein with $1 \mu \mathrm{~L}$ of the precipitant containing 20 mM sodium acetate $\mathrm{pH} 4.7,1 \mathrm{M} 1,6$-hexanediol and 10 mM CoCl 2 . Crystals were soaked in mother liquor supplemented with $20 \%$ PEG 400 and flash cooled in liquid nitrogen.

### 2.2.3.10 Flash cooling of protein crystals

X-ray diffraction data of protein crystals are collected at 100 K in order to protect the crystal from radiation damage. Hence, crystals are flash cooled in liquid nitrogen before data collection. The formation of ice in a protein crystal leads to loss of diffraction quality. Soaking of crystals in cryoprotectants prevents ice formation. Cryoprotectants used in this study are e.g. glycerol, ethylene glycol, sugars (xylitol and sucrose) and PEG 400. Cryoprotectant mixes were composed in a way that the cryoprotectant replaced water from the initial crystallization condition, so that buffer and precipitant concentration remained constant during soaking. Crystals fished from their drops were first soaked in a fresh drop of mother liquor, then in a drop mixed 1:1 of mother liquor and cryoprotectant and finally in a cryoprotectant drop. Crystals were fished out of the cryoprotectant and rapidly flash cooled.

### 2.2.4 Computational methods

### 2.2.4.1 Structure determination of SCOC ccd

X-ray diffraction data were collected at 100 K at beamline X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). Data were processed and scaled with the XDS software package [95]. The package consists of three programs, XDS, XSCALE and XDSCONV. XDS performs eight subroutines. XYCORR, INIT and COLSPOT are used for determination and correction of spots versus the background of the dataset. Spots are indexed by IDXREF and integrated by INTEGRATE. During the final CORRECT step, unit cell
dimensions are refined and the space group determined). A XDS input file specific for the Pilatus detector at beamline X10SA can be found in the Appendix Section A.4.3. Values that need to be provided include detector specifications as well as unit cell dimensions and a space group-if unknown, CORRECT identifies for a space group. Furthermore, resolution cutoff and other values can be customized according to the respective dataset. XSCALE is used for scaling and merging of data. XDSCONV converts to output formats specific for the following programs, e.g. SHELX, CNS or CCP4, CCP4_F or CCP4_I format. Processed data was converted to .mtz file format.

With the experimental data, intensities of the reflections are provided. The goal for successful structure determination is the calculation of an electron density map which can be obtained by Fourier synthesis methods. A function of the electron density is given as:

$$
\begin{equation*}
\rho(x, y, z)=\frac{1}{V} \sum_{-h}^{h} \sum_{-k}^{k} \sum_{-l}^{l}\left|F_{h k l}\right| \exp \left[-2 \pi i\left(h x+k y+l z-\alpha_{h k l}\right)\right] \tag{2.1}
\end{equation*}
$$

Structure factors $F_{h k l}$ are experimentally obtained via the measured intensities of the reflection spots. Phases $\alpha_{h k l}$ cannot be measured directly but must be derived. The phase problem can be solved via direct methods (suitable for small proteins with excellent diffraction data above $1.2 \AA$, molecular replacement or experimental phasing. Molecular replacement requires the availability of a structurally similar model. Ideally at least $30 \%$ sequence identity of the target and model is required. In the case of SCOC, no structure with sufficient sequence identity is deposited in the PDB, hence experimental phasing by single anomalous diffraction (SAD) was chosen as method structure determination. In a SAD experiment, differences between Friedel pairs are measured at a specific wavelength where anomalous diffraction occurs. This requires the presence of an anomalous scatterer, in this case selenium, which was incorporated as selenomethionine. From these differences, the positions of the anomalous atom positions can be determined by Patterson methods or direct methods. Phenix [96]), which was utilized in this study, contains the program AutoSol for finding anomalous atom positions. AutoSol uses hybrid substructure search (HYSS), which is a combination of both Patterson and direct methods. After determination of the Se positions, PHASER and RESOLVE, two other subprograms of Phenix, were used for refining and density modification of the initial map. Initial model building was performed with AutoBuild. Successive manual model building was done with Coot8 [97].

During refinement, which was performed with Phenix, the atomistic model was compared to the observed diffraction data, while taking into account the geometrical restraints. Rotamer outliers of side chains and other geometric constraints were identified and corrected with Coot. Figures were prepared with PyMOL [98].

### 2.2.4.2 Sequence alignment of SCOC

For the analysis of SCOC ccd conservation, a BLAST search was performed with SCOC isoform 1. Several sequences from $30 \%$ identity upwards were picked and aligned with T-Coffee. Furthermore, human isoform 1, 2 and 3, and a close mammalian homologue (rat SCOC) were included. Analysis of the degree of conservation was done with AMAS [99]. Figures were prepared with PyMOL [98].

## 3 SCOC and its interaction partners

### 3.1 Characterization \& structure determination of the SCOC coiled coil domain

### 3.1.1 Generation of SCOC constructs for crystallization

Structure determination of SCOC ccd was a major goal of this study. In general, proteins for crystallization can be engineered at two levels: at the $D N A$ level by modifying the recombinant DNA sequence, or at the protein level, adding modifications to the protein by (bio)chemical methods such as limited proteolysis. This chapter deals with strategies utilized to engineer the protein on the DNA level, while protein modifications and optimization of crystallization conditions will be explained in the following chapters. The design and cloning of truncated versions of SCOC's ccd was one main pillar to solve the SCOC ccd structure. Figure 3.1 gives an overview of the constructs used for crystallization.
SCOC is a small protein with a well structured, highly conserved ccd (see Section 3.1.6). I performed initial bioinformatic analysis to characterize the SCOC ccd. When analyzing SCOC isoform 1 with the coiled coil prediction program COILS [100], a C-terminal coiled coil domain was confirmed, starting around residue 80 and ending latest with residue 144 (see Section A.4.1 for complete COILS prediction results). Further analysis with IUpred [101, 102] strengthened the prediction: A ordered region of unknown function from amino acid 89 to 149 was located (see Figure 3.2). IUpred also detected another ordered region at the N-terminus (residues 1-54). Between the two regions, SCOC isoform 1 was predicted to contain a unstructured stretch. The extend of assumed flexibility differed between long and close distance disorder tendency. In addition, also the very C-terminus from residue 150 to 159 is predicted to be unstructured.

Flexible or disordered parts of a protein lead to a variety of energetically

| SCOC (78-159) | 78 |  | 159 |
| :---: | :---: | :---: | :---: |
|  |  |  |  |
|  | StrepTag |  |  |
| SCOC L96M (78-159) | 78 L96M |  | 159 |
|  |  |  |  |
|  | 78 L105M |  | 159 |
| SCOC L105M (78-159) |  |  |  |
| SCOC (78-151) | 78 |  | 151 |
|  |  |  |  |
|  | HisTag |  |  |
| SCOC (78-141) | 78 |  | 141 |
|  |  |  |  |
| SCOC (78-132) | 78 | 132 |  |
|  |  |  |  |
|  | 112 |  | 159 |
| SCOC (112-159) |  |  |  |

Figure 3.1: Overview of SCOC constructs used for crystallization


Figure 3.2: Disorder prediction for SCOC Isoform 1 by IUpred [101, 102]
Domains of unknown functions domains are labelled green. The dark blue line shows the disorder tendency for long disorder ( $\sim 30$ residues) and light blue for short disorder at a threshold of 0.5 .
equally favored conformational states, that the protein can adopt. Heterogeneity of conformational states in a protein sample can cause problems with crystallization. As a result, the protein might not crystallize at all or formed crystals diffract poorly. The homogeneity of a protein's conformational state is a crucial determinant for successful protein crystallization. Therefore, I aimed to crystallize two C-terminally truncated ccd constructs, SCOC (78-151) and SCOC (78-141). Both of them were designed on the basis of IUpred predicitions, to avoid problems arising from the more flexible C-terminus.

Although SCOC ccd is a small protein, the elongated form of the a long ccd and potential conformational flexibility hamper crystallization. Therefore I also created two constructs comprising overlapping halves of the coiled coil domain SCOC (78-132) and SCOC (112-159) in order to facilitate crystallization. Structure determination of the two overlapping halves of the coiled coil domain would allow assembly of the complete coiled coil domain.

When solving a protein crystal structure by X-ray crystallography, every crystallographer comes across the phase problem (see Section 2.2.4.1 for more details). In order to obtain an electron density map, structure factor amplitudes $F_{h k l}$ and the phase angles $a_{h k l}$ are needed. Structure factors are directly obtained by the diffraction experiment, as they are proportional to the square root of the measured intensities of reflections spots. Phases, however, cannot be directly determined from a simple diffraction experiments but must be supplied via specific experimental methods, like single- or multi wavelength anomalous diffraction, or by molecular replacement, where a similar known structure with a minimum of $30 \%$ sequence can be used as a search model for determination of the new protein structure.

I subjected the sequence of $\operatorname{SCOC}(78-159)$ to analysis through HHpred server [103-105]. HHpred looks for homologues of the search model using hidden Markov models, searching through sequence alignment databases such as Pfam or SMART instead of sequence databases like UniProt. Protein Data Bank (PDB) numbers of homologues with known structure are returned in the results, making HHpred a powerful tool when looking for models to solve structures by molecular replacement. The closest protein with solved structure found by HHpred shared only 19 \% identity with SCOC's ccd (see Section A.4.2 for a text file of HHpred results). This was not sufficient for molecular replacement. Hence, it became obvious that the phases for structure solvation had to obtained through experimental methods. SCOC (78-159) contains four methionines which can be labelled with Se by minimal expression with selenomethionine, making single and multi-wavelength anomalous diffraction (SAD and $M A D)$ a good option for obtaining the phases. However, three of the four me-
thionines are located within the first ten amino acids of the construct. Thus, they might be flexible residues, giving only little or no anomalous signal. Two mutants were created with additional methionine sites, SCOC L96M (78-159) and L105M (78-159), to facilitate structure determination by SAD or MAD.

TarO, a bioinformatic tool for the prediction of likeliness of crystallization [106], classified SCOC (78-159) as "recalcitrant" with a rather low crystallization index of $1.76 \mathrm{e}+6$. Nevertheless, due to its highly ordered structure and its small size, the ccd seemed to be an ideal target for crystallization at first glance.

### 3.1.2 Expression and Purification of SCOC constructs

### 3.1.2.1 Expression and Purification of SCOC (78-159)

Full-length SCOC isoform 1 with any other tag than GST proved to express only in low amounts and to be very unstable, prone to aggregration and degradation. Therefore, I aimed for expressing and purification of the ccd shared by all SCOC isoforms.

I successfully cloned SCOC (78-159) into pET-28a, thereby cleaving the plasmid's His-Tag and adding a StrepTag II by a two-step PCR protocol. By this approach I obtained a Strep-tagged protein in a plasmid with kanamycine resistance, which was suitable for coexpression and proper analysis with Histagged Arl1/Fez1 expressed from ampicillin-resistant pET-22b plasmids.

Expression behavior was analyzed in LB, TB and autoinducible media at different temperatures. SCOC (78-159) was expressed as soluble protein in large amounts in LB medium at $37^{\circ} \mathrm{C}$. After expression for 3 hours, cells were harvested and lysed. SCOC (78-159) was purified in two steps via affinity chromatography and size exclusion chromatography (see Figure 3.3). As StrepTagII-affinity purification is very specific, the protein was already pure after the first purification step (see Figure 3.3 C). A polishing step with size exclusion chromatography was performed to ensure the absence of protein aggregrates for crystallization.

SCOC (78-159) concentrated to high concentrations ( $30 \mathrm{mg} / \mathrm{mL}$ ) without precipitation. For crystallization, it was used at concentrations of 1 $10 \mathrm{mg} / \mathrm{mL}$. In general, SCOC (78-159) purification proved to be very robust, producing high yields of very pure protein.

SCOC (78-159) single mutants (L96M, L105M, R99E, R117E) and double mutants (R99E/R117E, E93V/K97L, N125V/N132L) were expressed and purified via the same protocol. Expression behavior, stability and purity after


Figure 3.3: Purification of SCOC (78-159)
(A) Elution profile of affinity chromatography via StrepTrap column (B) elution profile of size exclusion chromatography via HiLoad 16/60 S75 column (C) SDS-PAGE of affinity chromatography (D) SDS-PAGE of size exclusion chromatography
purification steps remained the same.

### 3.1.2.2 Expression and Purification of SCOC (78-132) and SCOC (112-159)



Figure 3.4: Purification of SCOC (78-132)
(A) Elution profile of affinity chromatography via HisTrap column (B) elution profile of size exclusion chromatography via HiLoad 16/60 S200 column (C) Schägger gel of affinity chromatography (D) concentrated fractions from size exclusion chromatography

Two overlapping fragments of SCOC ccd were cloned into pET-28a. The fragments (78-132) and (112-159) were expressed in minimal media for selenomethionine incorporation. After overnight expression at $25^{\circ} \mathrm{C}$, cells were harvested and lysed by sonication. SCOC fragments were purified in two steps via HisTrap chromatography and a polishing step with size exclusion chromatography. Elution profiles and SDS-PAGE analysis of both purification steps are depicted in Figure 3.4 for SCOC (78-132) and in Figure 3.5 for


Figure 3.5: Purification of SCOC (112-159)
(A) Elution profile of affinity chromatography via HisTrap column (B) Schägger gel of affinity chromatography (C) elution profile of size exclusion chromatography via HiLoad 16/60 S200 column (D) Schägger gel from size exclusion chromatography

SCOC (112-159). Both proteins were concentrated and used for crystallization screening.

### 3.1.2.3 Expression and Purification of SCOC (78-141) and SCOC (78-151)



Figure 3.6: Purification of SCOC (78-141)
(A) Elution profile of affinity chromatography via HisTrap column
(B) Schägger gel of fractions from affinity chromatography (C) elution profile of size exclusion chromatography via HiLoad 16/60 S200 column (D) anti-His western blot of size exclusion chromatography

C-terminally truncated constructs were cloned into pET-22b. SCOC (78141) was expressed in LB at $37^{\circ} \mathrm{C}$, $\operatorname{SCOC}(78-151)$ was expressed in au-


Figure 3.7: Purification of SCOC (78-151)
(A) Elution profile of affinity chromatography via HisTrap column (B) Schägger gel of affinity chromatography (C) elution profile of size exclusion chromatography via HiLoad 16/60 S200 column (D) Schägger gel of size exclusion chromatography
toinducible medium at $18{ }^{\circ} \mathrm{C}$. After lysis of the cells, proteins were purified via HisTrap chromatography, yielding contamined proteins in large amounts. The HisTag was cleaved by Thrombin in an overnight incubation and removed by a second step of HisTrap chromatography. Protein aggregates were removed in a polishing step via size exclusion chromatography. Peaks observed in SCOC (78-141) elution profiles are less significant as the protein did not contain aromatic residues for UV absorption. Elution profiles and Schägger gel analysis can be found in Figure 3.6 for SCOC (78-141) and Figure 3.7 for SCOC (78-151). Pure proteins were concentrated to $\sim 15 \mathrm{mg} / \mathrm{mL}$ for crystallography.

### 3.1.2.4 Expression and Purification of GST-tagged SCOC constructs

GST-tagged full length SCOC isoform 1 and GST-tagged SCOC (78-159) were cloned into pGEX-4T1. Both fusion proteins were expressed in LB at $37^{\circ} \mathrm{C}$. After lysis of the cells, proteins were purified via Protino® GST/4B column chromatography. GST-Tag was cleaved by Thrombin in an overnight incubation and removed by a second step of Protino® GST/4B chromatography. Protein aggregates were removed in a polishing step via size exclusion chromatography. Elution profiles and Schägger gel analysis can be found in Figure 3.8 for GST-SCOC full length and Figure 3.9 for GST-SCOC (78-159). Full length GST-SCOC yielded less protein amounts with contaminations of 40 and 70 kDa , presumably chaperones.

### 3.1.3 Biochemical and biophysical characterization of SCOC coiled coil domain

SCOC (78-159) was characterized by biochemical and biophysical methods.

### 3.1.3.1 Limited proteolysis of SCOC coiled coil domain

Well structured, compact domains lacking flexible regions and/or residues are more likely to crystallize. Limited proteolysis was performed in search of stable fragments of SCOC ccd.

The protein was digested by twelve different proteases from the Proti-Ace Kits $1 \& 2$ (Hampton Research). Progress of proteolysis was assessed by taking samples after different time points. For comparison, also undigested protein sample (time $=0 \mathrm{~min}$ ) was loaded on gels. Analysis by Schägger gels showed, that SCOC (78-159) is stable (see Figure 3.10). Most of the proteases left the


Figure 3.8: Purification of GST-SCOC full length
(A) Elution profile of affinity chromatography via GST column (B) SDSPAGE of affinity chromatography (C) elution profile of size exclusion chromatography via HiLoad 16/60 S200 column (D) SDS-PAGE of size exclusion chromatography


Figure 3.9: Purification of GST-SCOC (78-159)
(A) Elution profile of affinity chromatography via GST column (B) SDSPAGE of affinity chromatography (C) elution profile of size exclusion chromatography via HiLoad 16/60 S200 column (D) SDS-PAGE of size exclusion chromatography
protein almost intact, showing that the chosen fragment of the ccd is fairly structured with a compact fold. Three proteases, Trypsin, Proteinase K and Subtilisin, produced different proteolytic fragments. Trypsin cleaved only a few residues, yielding a fragment that only a little smaller than the full-length construct. Proteinase-K and Subtilisin trimmed the protein more aggressively, creating at least two smaller fragments at $\sim 5$ and $\sim 10 \mathrm{kDa}$.

Proteolysis by Subtilisin and Trypsin was analyzed more thoroughly to obtain the fragments which would be sent for N -terminal sequencing. The experiment was repeated at a larger scale with both of the proteases. Samples were taken at time points after $5,10,20,30$ and 45 minutes. The proteolysis fragments were reproduced (see Figure 3.11). The fragment at $\sim 10 \mathrm{kDa}$ (band 1 in Figure 3.11) appeared with both proteases. Subtilisin also yielded a slightly


Figure 3.10: Limited proteolysis of SCOC (78-159)
SCOC (78-159) was digested by twelve proteases at RT. Samples at different time points were analyzed on Schägger gels.
smaller size fragment (band 2 in Figure 3.11) and a $\sim 5 \mathrm{kDa}$ fragment (band 3 in Figure 3.11). The three bands were blotted on a PVDF membrane and sent for N -terminal sequencing to Seqlab.
The four N-terminal amino acids were sequenced. Results are shown in Table 3.1. Sequence matches of fragments and target sequence are indicated with bold letters.

Comparison with the sequence of the full-length construct revealed that fragments 1 and 2 remained with intact N-terminus. This means, that Subtilisin created two C-terminally truncated fragments slightly smaller than the fulllength protein. As the digest was performed with C-terminally Strep-tagged protein, I assumed that Subtilisin cleaved the StrepTag and a few additional residues from the C-terminusof SCOC, since the calculated size of SCOC (78159) without StrepTag is 9.4 kDa . This result is in agreement with the prediction made by IUpred (see Figure 3.2), that the last few residues of SCOC are disordered. However, the exact C-terminal end of the fragment cannot be concluded from the height of the band in the gel.


Figure 3.11: Limited proteolysis of SCOC (78-159) by Trypsin and Subtilisin
Bands indicated with red numbers were sent for N -terminal sequencing.

Table 3.1: N -terminal sequencing results

| fragment | approx. <br> molecular <br> weight <br> (kDa) | sequence |
| :--- | :--- | :--- |
| 1 | 10 | AMMN |
| 2 | $<10$ | MMN |
| 3 | 5 | (D/E)TKS |
| full-length | 11 | MMNADMDAVDAENQVELEEKTRLINQVLELQHTLEDLSARV <br> (StrepTag) |
|  | DAVKEENLKLKSENQVLGQYIENLMSASSVFQTTDTKSKRK <br> LVPRGSWSHPQFEK |  |

Fragment number 3 was identified as the C-terminal part of the fragment, namely the StrepTag with linker plus SCOC's seven C-terminal residues although the calculated molecular weight of only 2.5 kDa does not correspond to the migrating length of the fragment in the gel. This construct was not of interest for crystallization. Yet I concluded that the C-Terminus of SCOC is flexible, and assumed that residues from amino acid D153 onwards are likely to be disordered.

### 3.1.3.2 Pull-down experiments for the identification of novel SCOC binding partners

A GST-Pulldown experiments were conducted to identify novel interaction partners of SCOC ccd. GST-SCOC (78-159) was immobilized on beads and incubated lysate from HEK cells or lysate from starved, autophagy activated HEK cells. Also, GST protein alone was incubated with HEK cells as control experiment. Samples were analyzed by SDS-PAGE (see Figure 3.12).


Figure 3.12: GST-Pulldown of GST-SCOC (78-159)
GST-SCOC was incubated with lysate from HEK cells/starved HEK cells. Bands indicated by red numbers were given to mass spectrometry for analysis.

Several proteins were pulled by GST-SCOC (78-159), but there was no difference observable between pulldown with HEK or starved HEK cells. False positives were excluded by comparison with the bands of a pulled-down with GST alone, leaving six bands for further analysis. The indicated bands were digested with Trypsin and the peptides were analyzed by mass spectrometry. Identified peptides were screened with a human protein library. Mostly peptides of GST, Keratin and some chaperones were detected (see Section A. 5 for mass spectrometry results). Only band number five contained relevant peptides: five peptides unique for SCOC were obtained with signicificant protein score (Table 3.2).

Table 3.2: SCOC peptides detected by mass spectrometry in band 5

| Peptide | Sequence |
| :--- | :--- |
| 1 | VDAVKEENLK |
| 2 | ASGWDGMGFFSR |
| 3 | LINQVLELQHTLEDLSAR |
| 4 | SENQVLGQYIENLMSASSVFQTTDTK |
| 5 | LKSENQVLGQYIENLMSASSVFQTTDTK |
| full-length isoform 1 | MRRRVFSSQDWRASGWDGMGFFSRRTFCGRSGRSCRGQLVQVSR |
| (StrepTag) | PEVSAGSLLLPAPQAEDHSSRILYPRPKSLLPKMMNADMDAVDA |
|  | ENQVELEEKTRLINQVLELQHTLEDLSARVDAVKEENLKLKSE |
|  | NQVLGQYIENLMSASSVFQTTDTKSKRK |

Peptide 2 was not only unique for SCOC, but specific for isoform 1 . This result indicated, that SCOC is interacting with itself via the ccd in HEK cells.

### 3.1.3.3 Analysis of secondary structure and stability of SCOC coiled coil domain by CD spectroscopy

Secondary structure of SCOC was investigated by CD spectroscopy. CD spectra were measured from 200 to 250 nm at $20^{\circ} \mathrm{C}$. The spectrum showed two minima around 208 and 223 nm , typical for proteins with $\alpha$-helical structure (Figure 3.13 A). This confirmed the folding of SCOC in $\alpha$-helices. Stability of SCOC (78-159) was assessed by thermal unfolding from RT to $95^{\circ} \mathrm{C}$ measured at 209 nm by CD (Figure 3.13 B ). The melting point of $48^{\circ} \mathrm{C}$ was defined by fitting the unfolding curve to a sigmoidal function. After heating
the sample to $95^{\circ} \mathrm{C}$, it was cooled to RT. Another spectrum was collected of the same sample, showing that SCOC refolds sfter thermal denaturation.


Figure 3.13: CD measurements of SCOC (78-159)
(A) CD spectra (B) Melting curve

### 3.1.3.4 Characterization of oligomerization state of SCOC coiled coil domain by SEC-MALLS measurements

Oligomerization state of SCOC was investigated by SEC-MALLS. MALLS, in contrast to analytical gel filtration, is yields a molecular weight of a protein independent of shape and can therefore be used for the determination of molecular weights of non-globular proteins. The protein samples were ran on a Superdex $10 / 300$ GL before analysis with the MALLS detector. Molecular concentrations were determined with a multi-wavelength spectrophotometer. Molecular weights were determined from three runs (see Figure 3.14).
The calculated molecular weight of Strep-tagged SCOC is 10.5 kDa . The measured molecular weight of wild-type SCOC is $26.3 \pm 0.3 \mathrm{kDa}$, which is consistent with a dimer.

### 3.1.4 Crystallization of SCOC coiled coil domain

The structure determination of SCOC ccd was a major milestone for this study. To achieve this goal, I pursued several strategies for cloning and crystallization of SCOC ccd constructs, which were introduced in Section 3.1.1. Hits from screening of these constructs with 200 nL sitting drops at $20^{\circ} \mathrm{C}$ are shown in Figure 3.15, the respective crystallization conditions are listed in Table 3.3.


Figure 3.14: SEC-MALLS experiments of SCOC (78-159)

Table 3.3: Exemplary crystallization conditions of SCOC ccd constructs from 96-well plate screening

| condition | construct | buffer composition |
| :---: | :---: | :---: |
| A | SCOC (78-159) | $0.085 \mathrm{M} \mathrm{NaH}_{2} \mathrm{PO}_{4}$ <br> $0.085 \mathrm{M} \mathrm{KH}_{2} \mathrm{PO}_{4}$ <br> 0.085 M MES pH 6.5 <br> 1.7 M NaCl <br> $15 \%$ (v/v) glycerol |
| B | SCOC (78-159) L105M | $0.01 \mathrm{M} \mathrm{CoCl}_{2}$ <br> 0.1 M NaAc pH 4.6 <br> 1.0 M 1,6-hexanediol |
| C | SCOC (78-151) | 0.1 M BIS-TRIS pH 5.5 $17 \%$ w/v PEG 10,000 |
| D | SCOC (78-141) | $\begin{aligned} & 0.4 \mathrm{M} \mathrm{Li}_{2} \mathrm{SO}_{4} \\ & 12 \%(\mathrm{w} / \mathrm{v}) \text { PEG } 8000 \\ & 20 \%(\mathrm{v} / \mathrm{v}) \text { glycerol } \end{aligned}$ |
| E | SCOC (78-132) | 0.1 M TRIS pH 8.5 25 \% (w/v) PEG 8000 |
| F | SCOC (112-159) | 0.1 M BICINE pH 9.0 2.0 M NaCl |



Figure 3.15: Exemplary crystallization hits of SCOC ccd constructs from 96-well plate screening
(A) SCOC (78-159) (B) SCOC L105M (78-159) (C) SCOC (78-151)
(D) SCOC (78-141) (E) SCOC (78-132) (F) SCOC (112-159). Crystallization conditions are listed in Table 3.3.

### 3.1.4.1 Crystallization screening of SCOC (78-159)

The first construct subjected to several crystallization screens was SCOC ccd (78-159). It yielded crystals in more than 100 initial conditions (see Figure 3.15 and Table 3.3). A table of the crystallization conditions from 96 -well screens can be found in Section A.2. Thorough analysis of the table revealed that the construct showed a tendency to crystallize with low-molecular weight PEGS or sodium salts as precipitants. The pH for most initial hits was limited to acidic to neutral conditions - a lot of hits contained NaAc (Sodium acetate) around pH 4.6 or MES and HEPES buffer between $\mathrm{pH} 6.0-7.5$. SCOC crystals exhibited different shapes- among them cubic (Figure 3.15), star-like (Figure 3.16) and also bipyramidal shapes (Figure 3.17). Many crystal shapes featured snowflake or flower-like forms, hinting towards multiple crystals growing from one nucleation site. SCOC (78-159) crystallized best from low protein concentrations, mostly between $1-7 \mathrm{mg} / \mathrm{mL}$. Above $10 \mathrm{mg} / \mathrm{mL}$, the protein rather precipitated than crystallized.


Figure 3.16: Effect of streak seeding
(A) Star-shaped, multiple crystals in a sitting drop in a 96 -well plate screen. (B) Single, cubic crystal in a sitting drop set up with streak seeding in a 24 -well plate grid screen. Both crystals were grown in 0.1 M MES $\mathrm{pH} 6.5,20 \mathrm{mM} \mathrm{MgCl} 2$ and PEG 33550 as precipitant (A: $19 \%$ (w/v), B: $25 \%$ (w/v) PEG 3350).

### 3.1.4.2 Refinement of the crystallization conditions of SCOC (78-159) crystals

First crystallization conditions were optimized with grid screens in 24-well format. Usually, pH was varied along rows in increments of one pH unit for first optimization. Precipitant concentration was varied along columns.


Figure 3.17: Crystals in hanging drops grown in 24-well format
(A) Crystals from a grid screen varying pH (MES 5.5-MES 6.5) against NaAc concentration (B) Crystals from a grid screen varying pH (MES 5.5 - HEPES 7.5) against PEG 3350 concentration

Figure 3.17) shows crystals obtained by two grid screens (see Table 3.4 for crystallization conditions). In general, 24 well plates yielded larger crystals suitable for flash cooling and data collection. The range of protein concentration tested remained the same for 24 -well plates. In order to obtain single, slow growing crystals instead of multiple, fast growing crystals, I also tested crystallization at $4{ }^{\circ} \mathrm{C}$. However, this did not yield any crystals. I further tried to control the vapor diffusion rate to obtain slower growing crystals. In 24well sitting drop plates, $5 \mu \mathrm{~L}$ ( $2.5 \mu \mathrm{~L}$ protein plus $2.5 \mu \mathrm{~L}$ crystallization buffer) drops were covered with silicon oil. Only phase separation but no crystals were observed.

Table 3.4: Crystallization conditions in 24 well plate screens

| condition | construct | buffer composition |
| :---: | :--- | :--- |
| A | SCOC (78-159) | 0.1 M MES pH 6.5 |
|  |  | 1.4 M NaAc |
| B | SCOC $(78-159)$ | 0.1 M MES pH 6.5 |
|  |  | $19 \%(\mathrm{w} / \mathrm{v}) \mathrm{PEG} 3350$ |
|  |  | 0.01 M MgCl |

When refining the crystallization conditions in 24 well plates, I applied streak seeding, providing nucleation sites with the small crushed crystal fragments added by the streak in order to avoid multiple crystals. Figure 3.16 demonstrates the effect of this method: Panel A shows star-shaped crystals grown in a 96 -well plate. Panel B shows a crystal with almost the same buffer condition, grown from a streak seeded drop in a 24 -well plate.

Crystals from 24 -well and 96 -well plates were soaked stepwise in a variety of cryoprotectants, and flash cooled. Diffraction quality was tested at 100 K at the synchrotron (Beamline X10SA, Paul Scherrer Institute, Swiss Light Source Villigen, Switzerland) and eventually data were collected. Crystals from PEG conditions diffracted only up to $6 \AA$. Other samples from salt conditions diffracted to better resolution ( $4 \AA$ ), but the lattice was of insufficient quality with multiple, smeary spots and high mosaicity. The best crystal from initial screening was taken out of a drop from the Cryo screen condition D6 (see Figure 3.15). It diffracted up to $3.6 \AA$, but with split and smeary spots.

Next, Random and Grid Screens were designed and dispensed with the Tecan robot, taking the Cryo screen condition D6 yielding the best crystals so far as basis. Several Grid Screens were set up, varying NaCl concentration in small increments against the pH of MES buffer between 5.2-6.9 or HEPES buffer between 6.8-8.0. As the Cryo condition contained several components, including two different phosphate salts and glycerol, a Random screen was designed to evaluate their effects on crystallization. Crystals obtained from these screens are shown in Figure 3.18, the respective buffer compositions are shown in Table 3.5.

Table 3.5: Exemplary crystallization conditions of Random and Grid screens

| condition | construct | buffer composition |
| :---: | :--- | :--- |
| A | SeMet SCOC (78-159) | $0.085 \mathrm{M} \mathrm{MES} \mathrm{pH} \mathrm{6.77}$ |
|  |  | $0.085 \mathrm{M} \mathrm{NaH}_{2} \mathrm{PO}_{4}$ |
|  |  | $0.085 \mathrm{M} \mathrm{KH}_{2} \mathrm{PO}_{4}$ |
|  |  | 1.43 M NaCl |
|  |  | $15 \%(\mathrm{v} / \mathrm{v})$ glycerol |
| B | SCOC $(78-159) \mathrm{w} / \mathrm{o} \mathrm{Tag}$ | 0.085 M MES pH 6.45 |
|  |  | $0.0122 \mathrm{M} \mathrm{NaH}_{2} \mathrm{PO}_{4}$ |
|  |  | $0.147 \mathrm{M} \mathrm{KH}_{2} \mathrm{PO}_{4}$ |
|  |  | 1.77 M NaCl |
| C | SCOC $(78-151)$ | 0.1 M MES pH 5.552 .79 M NaCl |
| D | SCOC $(78-141)$ | 0.1 M HEPES pH 7.31 |
|  |  | 2.68 M NaCl |

The designed screens yielded many crystals, most of them multiple or single


Figure 3.18: Crystals obtained from refinement with grid and random screens
(A) selenomethionine-labelled SCOC (78-159) crystals from a random Screen (B) SCOC (78-159) crystals from a random screen, crystallized without StrepTag (C) SCOC (78-159) crystals from a grid screen (D) SCOC (78-159) crystals from a grid screen
crystals in elongated cuboid shapes. In addition, the screens were utilized to test the crystallization behaviour of SCOC (78-159) variants without the StrepTag (cleaved with Thrombin with a protocol according to Section 2.2.2.5) (see Figure 3.18 B) or selenomethionine-labelled SCOC (see Figure 3.18 A) (see Section A. 2 for a table summarizing crystallization conditions from random and grid screens). Large and single crystals were soaked in cryoprotectant (only if necessary, as many conditions already contained glycerol as cryoprotectant), and their diffraction was tested. However, neither diffraction resolution nor lattice quality was significantly improved.

Hence, although SCOC (78-159) crystallized easily from a large variety of conditions, the diffraction quality even after extensive screening was not sufficient to solve the structure.

### 3.1.4.3 Screening of other SCOC ccd constructs

In parallel, I cloned and purified C-terminally truncated constructs SCOC (78-141) and SCOC (78-151). Crystallization screens were set up at $20^{\circ} \mathrm{C}$ with 200 nL sitting drops. SCOC (78-151) at 15 and $7.5 \mathrm{mg} / \mathrm{mL}$ protein concentration yielded mostly crystal clusters (Figure 3.15 C). SCOC (78-141) at 12 and $6 \mathrm{mg} / \mathrm{mL}$ was easily crystallized, forming needles or needle clusters in a few conditions (Figure 3.15 D ) (see Table 3.3 for crystallization conditions). The crystal needles were very fragile and required careful handling during soaking and flash cooling. The ccd fragment crystals diffracted to only 5-6 Å resolution.

Another attempt to achieve better diffracting crystals was made by cloning and purifying two overlapping halves of SCOC ccd, SCOC (78-132) and SCOC (112-159). 96-well plates sitting drops were dispensed at $20^{\circ} \mathrm{C}$ at 40 and $20 \mathrm{mg} / \mathrm{mL}$ (SCOC 78-132) and 17 and $8.5 \mathrm{mg} / \mathrm{mL}$ (SCOC 112159). Both constructs yielded only spherulites, gel or cluster-like structures in 96 -well screening (Figure 3.15 E and F).

Summing up, the purpose-built constructs - some of them missing presumably unstructured parts of the ccd, others designed to pack better in the crystal-did not result in better diffracting crystals compared to SCOC (78159).

### 3.1.4.4 Crystallization of selenomethionine-labelled SCOC crystals

Selenomethionine labelled crystals (SeMet SCOC (78-159) in Figure 3.18 A) grew predominantly in conditions similar to the native protein. The crystals showed similar diffraction quality as native crystals, however, the anomalous signal dropped rapidly between 5 and $6 \AA$, making structure determination from single or multi- wavelength anomalous diffraction (SAD or MAD) very challenging. Hence, two mutant constructs, SCOC L96M (78-159) and SCOC L105M (78-159), were cloned, purified and subjected to crystallization screens. Initial screening of SCOC L96M (78-159) did not yield promising conditions. SCOC L105M (78-159) showed similar crystallization behavior as wt selenomethionine crystals and was subjected to in situ proteolysis (see below).

### 3.1.4.5 Crystals grown with in situ proteolysis

After conducting limited proteolysis experiments (see Section 3.1.3) of SCOC (78-159), the overall stability but also the presence of flexible parts was demonstrated. Trypsin and Subtilisin were two proteases which were able to cleave

SCOC's ccd. It proved very challenging to isolate fragments of the ccd obtained by limited proteolysis. Hence, I aimed to mimic limited proteolysis in the crystal drop by conducting in situ proteolysis. Subtilisin and Trypsin were added to the protein stock in small amounts (1:1000 w/w Trypsin and $1: 2000 \mathrm{w} / \mathrm{w}$ Subtilisin) just before crystallization. Screening of SCOC (78-159) was performed as described before. Again, 96 -well screening yielded a lot of crystals, some of them shown in Figure 3.19, see Table 3.6 for buffer composition (see Section A. 2 for a table of crystallization conditions obtained by in situ proteolysis). Obtained crystals differed in crystal shape and quality of diffraction. In high $\mathrm{NH}_{4} \mathrm{NO}_{3}$ concentration (Figure 3.19 C ), round-shaped crystal clusters as well as cuboid crystals grew. Also, multiple crystals grew from the condition that had yielded crystals diffracting up to $3.6 \AA$ before (Figure 3.19 B). Comparison with the conditions found by conventional screening indicated a few novel crystallization conditions, one of them yielding crystal rods shown in Figure 3.19 A. Native crystals of this condition were flash cooled with a broad range of cryoprotectants and tested for diffraction. The use of $15-30 \%$ PEG 400 as cryoprotectant improved diffraction quality tremendously, showing distinct, well-defined diffraction spots up to a resolution of $3.0 \AA$. Crystals of similar rod shape were obtained by 24 -well grid screening of selenomethioninelabelled SCOC L105M (78-159) at 3 and $1.5 \mathrm{mg} / \mathrm{mL}$, varying 1,6-hexanediol concentration against pH of NaAc buffer (see Figure 3.19 D). Flash cooling with 20 \% PEG 400 resulted in high-quality diffraction patterns of SCOC L105M (78-159) crystals grown in $0.01 \mathrm{CoCL}_{2} \times 6 \mathrm{H}_{2} \mathrm{O}, 0.1 \mathrm{M} \mathrm{NaAc} \mathrm{pH} 4.63$, 0.7 M 1,6 hexanediol with streak seeding. The crystals yielded datasets $2.8 \AA$ resolution, which was sufficient for structure determination.

### 3.1.5 Structure determination

X-ray diffraction data were collected at 100 K at beamline X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). Data for structure determination were collected from a selenomethionine SCOC L105M (78-159) crystal grown in $0.01 \mathrm{CoCL}_{2}, 0.1 \mathrm{M} \mathrm{NaAc} \mathrm{pH} 4.63,0.7 \mathrm{M} 1,6$ hexanediol, cryosoaked in mother liquor supplemented with 20 \% PEG 400. First, a crystal of the same purification batch was used for a measurement of a fluorescence spectrum and a scan to define the exact Se K absorption edge. Inflection, Peak, and remote 1 and remote 2 energies were determined with AUTOCHOOCH [107]. After mounting ofvthe crystal for data collection, four test shots were taken for indexing of the crystal. Unit cell and collection strategies were determined with go.com (local software written by Dr. M. Wang).


Figure 3.19: Crystals grown by in situ proteolysis
(A) Crystal rods in a drop from ClassicLite screen (Qiagen) (B) Multiple crystal from in a drop from Cryo screen (Qiagen) (C) Spherulites and cuboid crystals in a drop from SaltRX screen (Hampton Research)
(D) Crystal rods in a streak-seeded drop from 24-well grid screening

A SAD dataset of $180^{\circ}$ was collected at Se peak wavelength (details of data collection are noted in Table 3.7.)

Data were processed with input values specific for the Pilatus detector and FRIEDEL'S LAW = FALSE with XDS [95] (see Section A.4.3 for XDS.INP file). The orthorhombic space group $20\left(\mathrm{C} 222_{1}\right)$ was confirmed by the expected absences of reflections along $(0,0,2 \mathrm{n})$ (see Section A.4.4 for a list of systematic absences as expected by CORRECT.LP). Dimensions of the unit cell, data and refinement statictics are listed in Table 3.8. With XDSCONV, scaled data was converted to unmerged CCP4F format.

Phenix was used for phasing, density modification, initial model building and refinement [96]. For structure determination, the unmerged diffraction data in CCP4F format was supplied as .mtz-file, together with the sequence as .fasta-file into Phenix. Moreover, wavelength was set to $0.979 \AA$, and $f^{\prime}(-6.9)$ and $f^{\prime \prime}(4.802)$ were put in as determined by the fluorescence scan. Model autobuilding was activated with thoroughness set to "thorough". Xtriage package

Table 3.6: Exemplary crystallization conditions of in situ proteolysis

| condition | construct | composition |
| :---: | :---: | :---: |
| A | SeMet SCOC (78-159) 1:2000 SU | $0.01 \mathrm{CoCL}_{2} \times 6 \mathrm{H}_{2} \mathrm{O}$ <br> 0.1 M NaAc pH 4.6 <br> 0.5 M 1,6 hexanediol |
| B | SCOC (78-159) 1:2000 SU | 0.085 M MES pH 6.45 <br> $0.085 \mathrm{M} \mathrm{NaH}_{2} \mathrm{PO}_{4}$ <br> $0.085 \mathrm{M} \mathrm{KH}_{2} \mathrm{PO}_{4}$ <br> 1.7 M NaCl <br> 15 \%(v/v) Glycerol |
| C | SCOC (78-151) 1:1000 TR | $\begin{aligned} & 0.1 \mathrm{M} \mathrm{NaAC} \mathrm{pH}^{\mathrm{Na}} .6 \\ & 6 \mathrm{M} \mathrm{NH}_{4} \mathrm{NO}_{3} \end{aligned}$ |
| D | SCOC L105M (78-141) 1:2000 SU | $0.01 \mathrm{CoCL}_{2} \times 6 \mathrm{H}_{2} \mathrm{O}$ <br> 0.1 M NaAc pH 4.63 <br> 0.7 M 1,6 hexanediol |

Table 3.7: Data collection

| Detector distance | 520 mm |
| :--- | :--- |
| $\varphi / \Delta \varphi$ | $0 / 0.5^{\circ}$ |
| Exposure time | 0.4 s |
| Beam intensity | 0.35 |
| $\lambda$ | 0.979 |
| No of frames | 360 |
| Space group | $\mathrm{C} 222_{1}$ |

Table 3.8: Diffraction data and refinement statistics

|  | SCOC L105M (78-159) |
| :--- | :--- |
| Data collection <br> Space group | C222 |
| Cell dimensions |  |
| $a, b, c(\AA)$ | $70.7,114.5,93.1$ |
| $\alpha, \beta, \gamma$ | $90,90,90$ |
| Resolution (highest res. shell) $(\AA)$ | $48.87-2.70(2.87-2.70)$ |
| Rmeas | $6.9(44.9)$ |
| no. of observed/unique reflections | $61581 / 20013(9535 / 3184)$ |
| I/ $\sigma(\mathrm{I})$ | $13.3(2.7)$ |
| Completeness $(\%)$ | $99.1(97.9)$ |
| Wilson B factor $\left(\AA^{2}\right)$ | 27.00 |
| Molecules/AU | 3 |
| Refinement |  |
| Resolution $(\AA)$ | 2.7 |
| Rwork/Rfree | $23.1 / 26.9$ |
| No of atoms |  |
| Residues included in model (number of pro- | A: $86-146(477)$ |
| tein atoms $)$ | $\mathrm{B}: 88-147(462)$ |
| Water | $\mathrm{C}: 86-146(440)$ |
| B-factors $\left(\AA^{2}\right)$ | 43 |
| Overall |  |
| Protein | 22.7 |
| Water | 23.7 |
| r.m.s.d. | 21.6 |
| Bond lengths | 0.08 |
| Bond angles | 1.015 |
| PDB ID |  |
|  |  |

by Phenix determined cutoff of the anomalous signal at $4.4 \AA$; whereas the high resolution limit for the dataset was $2.7 \AA($ see Figure 3.20). Phenix found ten Se sites, three of them with occupancies above 0.8 (see Section A.4.5 for a list of Se sites). The obtained experimental electron density map phasing model yielded an overall score of 39.01. The positions of three Se sites localized to correct positions in the electron density maps. The initial model contained three molecules A, B and C in the asymmetric unit, for two of them already large parts of the amino acid sequence were built in. Manual model building was done with Coot [97]. From the initial model, molecule B was rebuilt manually, as well as large parts of molecule C. Rotamer outliers of side chains and geometric constraints were checked and corrected with Coot. 29 Cycles of refinement with Phenix against the initial electron density map resulted in a final structure refined to $R_{\text {work }} / R_{\text {free }}$ of $23.1 / 26.9 \%$. Validation of the structure was done with Phenix. A polygon plot showing the refinement statictics of the solved final structure in comparison to structures in the PDB with similar resolution cutoff, is presented in Figure 3.21. All values lie within the permitted limits of other structures submitted to the PDB. The Ramachandran plot for assessing the correct geometry of the peptide backbone of the refined structure is shown in Figure 3.22. The residues are all located in the allowed regions.

### 3.1.6 Structure of SCOC's coiled coil domain

X-ray structure of SCOC L105M (78-159) revealed that SCOC is a parallel left-handed coiled coil dimer. The structure comprises eight heptad repeats and has a length of about $80 \AA$. Intriguingly, I observed two distinct dimers in the crystal structure (see Figure 3.23). The asymmetric unit contains three SCOC molecules A, B and C. Molecules A and B form dimer AB. The second dimer CC' contains an internal two-fold symmetry, since the dimer is composed of molecule C and a symmetry related copy of C. In the crystal structure, the C-terminus of the CC'-dimer is embedded between the N -termini of symmetry related copies of AB-dimers.

Dimer CC' is a regular coiled coil with tight intertwined helices. Chains A and $B$ are not as tightly packed because molecule $A$ is bent with a bulge around residues A116 (Figure 3.24 A ). Overlay of the two dimers (Figure 3.24 B ) showed that molecules B and C adopt a very similar conformation and superimpose with a r.m.s.d. of $1.0 \AA$ for the $\mathrm{C}_{\alpha}$ atoms. In contrast, the differences between A and either B or C are more pronounced with r.m.s.d. values of $2.9 \AA$ and $2.3 \AA$, respectively. The coiled coil pitch of dimer AB (residues $97-143$ ) is $129 \AA$ and $151 \AA$ for dimer $C^{\prime}$ ' as calculated with the program


Figure 3.20: Phenix Xtriage analysis
(A) Anomalous signal. Recommended resolution cutoff for heavy-atom search: $4.44 \AA$ (purple line). Optimistic resolution cutoff: $3.993 \AA$ (red line). (B) Signal to noise I/ $\sigma$ for SAD data set.


Figure 3.21: Polygon plot by Phenix
Selected statistics across 716 PDB entries of similar resolution are compared to the current structure, with range indicated by red numbers.


Figure 3.22: Ramachandran plot of all non Pro/Gly residues of SCOC L105M (78-159)


Figure 3.23: Structure of SCOC coiled coil
Two asymmetric units with six molecules A (red), A' (palered), B (blue), B' (paleblue), C (green) and C' (palegreen) are displayed.

TWISTER [108]. Both values are similar to the coiled coil pitch of $135 \AA$ for the regular left-handed parallel coiled coil GCN4 leucine zipper dimer (pdb entry: 2ZTA). The SCOC coiled coil domain (residues $78-146$ ) has a pI of 4.3 and the overall surface charge of the molecule is negative (Figure 3.25). There are only a few conserved positively charged patches present, which includes residues R99 and R117. Conservation of SCOC was analyzed across various species with T-Coffee [109] and displayed on the molecule's surface (Figure 3.26, see Section A.4.6 for alignment). In general, the surface and core of SCOC are highly conserved, but residues at both ends and near the bulge of molecule A are more variable across species (see Figure 3.26 and Figure 3.27).

Coiled coils are characterized by the heptad repeat 'abcdefg' featuring hydrophic core residues on positions a and d (see chapter 3). Heptad assignment of SCOC sequence is shown in the alignment (Figure 3.27) and in the helical wheel representation (Figure 3.28). Remarkably, half of the a heptad positions at the core of the ccd are occupied by asparagine residues and lysine K97. Non-canonical polar pairings at a-positions are found at the N-terminal end of the coiled coil (N90 and K97) and close to the bulge of molecule A (N125 and N132). Additionally, there is one charged d-residue (E93), whereas the other d-positions are occupied by leucines and V121 (Figure 3.28).

The charged and polar residues at the coiled coil interface are stabilized through hydrogen bonds and salt bridges (Figure 3.29). N125 forms a net of hydrogen bonds with E124 and K129 (Fig 1 F). In dimer AB, there is also a water molecule stabilizing N125. Polar interactions of N132 with E131 are very similar in both dimers. E93, however, forms both intra- and intermolecular salt bridges with K97 in dimer AB and, whereas it forms a intramolecular hydrogen bond with N90 in dimer CC'. Importantly, all polar and charged core residues are highly conserved among human isoforms and other species (Figure 3.27 and Figure 3.26). I expected that these residues result in weakened core interactions, creating a destabilized dimer, which would explain the observed conformational flexibility of SCOC. In order to test the influence of these polar core residues on the stability of the protein two double core mutants E93V/K97L and N125L/N132V were created. Additionally, a second set of mutants was prepared to probe SCOC-FEZ1 complex formation. SCOC is known to interact with the coiled coil domain of FEZ1 [37], (see Section 3.2.1, Figure 3.26 for further details). The FEZ1 coiled-coil domain (residues 227290 ) is negatively charged with a pI of 4.7 . I therefore speculated that SCOC residues R99 and R117, which are conserved and surface exposed might be important for SCOC-FEZ1 complex formation and prepared the R99E and R117E SCOC mutants.


B


Figure 3.24: Two distinct SCOC dimers in the crystal structure (A) Cartoon representation of the two SCOC dimers AB and CC'. Molecule A is colored red, B blue, C green and C' grey. (B) Stereo view of dimers overlay. Same coloring as in (A).


Figure 3.25: Surface charge of SCOC
Left panel shows a ribbon representation of dimer AB. Residues R99 and R117 are drawn as stick models. Electrostatic surface potential is shown for dimer AB in two orientations. Blue shows positive charge and red corresponds to negative charges. The first figure of the electrostatic surface potential is shown in the same orientation as the ribbon representation.

### 3.1.7 Biophysical characterization of SCOC's mutants

I assumed that the substitution of polar residues with hydrophobic amino acids in the coiled core would result in enhanced stability. CD was used to analyze secondary structure and the stabilities of SCOC mutants. All SCOC mutants exhibit $\alpha$-helical secondary structure at $20^{\circ} \mathrm{C}$ as the wt protein (see Figure 3.30 A ). Thermal unfolding curves were measured between $20^{\circ} \mathrm{C}$ and $93{ }^{\circ} \mathrm{C}$ at a wavelength of 208 nm . Wild-type SCOC (78-159) unfolds at $48^{\circ} \mathrm{C}$ (see Section 3.1.3). Both arginine surface mutations had no significant effect on stability of the proteins (see Figure 3.31 and Table 3.9 for a summary of the biophysical characterization of SCOC mutants). In contrast, both double core mutants are much more stable than the wild-type protein. The melting temperature of E93V/K97L is increased by almost $30{ }^{\circ} \mathrm{C}$. Strikingly, the N125L/N132V mutant is extremely stable. The protein remains fully folded at even $93{ }^{\circ} \mathrm{C}$ (see Figure 3.30 B ).

Non-polar core position of coiled coils influence the oligomerization state [59]. The dramatic differences in stability of both core double mutants indicated a change of oligomerization state. First, I analyzed the size of mutant SCOC oligomers by analytical gel filtration (Figure 3.32). Elution profiles showed


Figure 3.26: SCOC conservation degree on the surface
Left panel shows a ribbon representation of dimer AB. Residues R99 and R117 are drawn as stick models. The two right panels show the surface conservation of SCOC. Dark green correspond to strong conservation and lighter green shades represent less conserved regions. The first conservation figure is shown in the same orientation as the ribbon representation. Sequence alignments were done with T-Coffee and analysis of the degree of conservation was done with AMAS [99].


## Figure 3.27: Sequence alignment of human SCOC isoforms and homologues

Ailgnment was done with T-Coffee. Coiled coil heptad positions were assigned with TWISTER. Non-canonical polar amino acids at core positions a and d are colored red.


Figure 3.28: Helical wheel diagram of the SCOC dimer
Polar core residues are marked red.
Table 3.9: Summary of biophysical characterization of SCOC mutants

| SCOCO | Tm, ${ }^{\circ} \mathrm{C}$ | $\mathrm{Mw}, \mathrm{kDa}$ (error) | n (error) |
| :--- | :---: | :---: | :---: |
| wt | 48.0 | $26.29(0.3)$ | $2.40(0.1)$ |
| E93V/K97L | 75.0 | $34.80(0.1)$ | $3.18(0.1)$ |
| N125L/N132V | - | $42.07(0.1)$ | $3.85(0.1)$ |
| R99E | 42.0 | $27.00(0.6)$ | $2.47(0.1)$ |
| R117E | 51.0 | $23.31(2.1)$ | $2.13(0.2)$ |

similar elution volumes of $\sim 15 \mathrm{~mL}$, except for the N125L/N132V mutant that eluted around 14 mL . This indicated a higher oligomerization state. However, the non-globular shape of elongated coiled coils allows no accurate determination of molecular weight by analytical gel filtration. Therefore, I used SECMALLS to measure the molecular weights of the mutant proteins. Molecular weights were averaged from three SEC-MALLS measurements for each mutant (Figure 3.33) and are summarized in Table 3.9. The sequence based molecular weight of Strep-tagged SCOC is 10.5 kDa . The stoichiometry (n) is the ratio of the measured molecular weight and the MW of a single Streptagged SCOC molecule ( 10538 Da ). Measured molecular weight of wild-type SCOC is $26.3 \pm 0.3 \mathrm{kDa}$ (see Section 3.1.3). The molecular weight determined for N125L/N132V is $42.1 \pm 0.1 \mathrm{kDa}$, which corresponds to a tetramer. The






N132

Figure 3.29: Stabilizing interactions of non-canonical core positions
Detailed molecular interactions of the polar core positions of dimer AB (left panel) and dimer CC' (right panel). Core residue E93, K97, N125 and N132, which were used for mutagenesis studies are stabilized through a network hydrogen bonds and salt bridges as shown. Figures were prepared with PyMol.


Figure 3.30: CD spectra of SCOC mutants
(A) CD spectra of SCOC mutants at $20^{\circ} \mathrm{C}$ from 200 to 260 nm . (B) CD spectra of SCOC mutants at $93^{\circ} \mathrm{C}$ from 200 to 260 nm .


Figure 3.31: Thermal unfolding CD curves
Melting curves were recorded at 208 nm from 20 to $93{ }^{\circ} \mathrm{C}$ at a protein concentration of approx. $15 \mu \mathrm{M}$.

E93V/K97L double mutant forms a trimer ( $34.8 \pm 0.1 \mathrm{kDa}$ ). Both R99E and R117E surface mutants are dimers as the wt protein.


Figure 3.32: Analytical gel filtration elution profiles of SCOC mutants
Proteins at $2 \mathrm{mg} / \mathrm{mL}$ were separated via Superdex 10/300 GL chromatography.


Figure 3.33: Elution profiles and corresponding molecular weights determined by SEC-MALLS are shown for all SCOC mutants

### 3.2 Interaction of SCOC's coiled coil domain with Arl1 and FEZ1

### 3.2.1 Insights into SCOC-FEZ1 complex formation

### 3.2.1.1 Approaches to find a minimal FEZ1 binding domain



Figure 3.34: FEZ1 domain

Human FEZ1 (392 residues) has properties of a natively unfolded protein. It contains three glutamate rich regions and a conserved coiled coil domain in the C-terminal half of the protein [45, 110], see Figure 3.34. Coiled coils of both proteins are involved in the interaction of SCOC and FEZ1 [35].

As a protein with large intrinsically disordered parts, FEZ1 is a difficult target for crystallography. At first, I aimed to purify a complex of full-length FEZ1 with SCOC. However, coexpression in E.coli BL21 led to insoluble proteins, probably due to formation of inclusion bodies. I therefore prepared several FEZ1 constructs comprising parts of the coiled coil domain (see Table 3.10). According to COILS predictions, the ccd of FEZ1 starts around residue 230 and ends at residues 290-300. Noticable, this part of FEZ1 contains a lot of negatively charged residues and SCOC ccd also has a negative net charge. Hence, I cloned FEZ1 fragments with HisTag to add positive charge, so that SCOC and FEZ1 ccd would not repell each other in solution. FEZ1 ccd constructs were cloned with NdeI and XhoI restriction sites into vector pET22b (Novagen) using full length FEZ1 as template for PCR.

I expressed Strep-tagged SCOC (78-159) in combination with each of the FEZ1 constructs in E.coli BL21. Test expression was performed with Streptactin beads. The expression experiments revealed, that all of the His-tagged FEZ1 fragments were enriched together with Strep-tagged SCOC (78-159) in varying amounts. The minimal FEZ1 region interacting with SCOC (781-59) comprises residues 227-290 (Figure 3.35 A). Coexpression of FEZ1 (226-290) with SCOC (78-159) yielded a complex with equivalent amounts of both pro-

Table 3.10: FEZ1 fragments comprising the C-terminal ccd

| N- <br> terminal <br> aa | C- <br> terminal <br> aa | length | net <br> charge | net <br> charge <br> with | pI with <br> His Tag |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M227 | L290 | 64 | -5 | $-4 /+2$ | 5.94 |
| M227 | L295 | 69 | -2 | -1 | 6.65 |
| H226 | L290 | 65 | $-5 /-4$ | $-4 /-3$ | 6.03 |
| H226 | L295 | 70 | $-2 /-1$ | $-1 / 0$ | 6.71 |
| R225 | L290 | 66 | $-4 /-3$ | $-3 /-2$ | 6.22 |
| R225 | L295 | 71 | $-1 / 0$ | $0 /+1$ | 7.12 |
| SCOC |  | 98 | -5 |  | 4.98 |
| $(78-159)$ |  |  |  |  |  |



Figure 3.35: Test coexpression of Strep-SCOC (78-159) with His-FEZ1 ccd constructs
(A) Coexpression of Strep-SCOC (78-159) and His-FEZ1 (227-290) in LB medium at $37^{\circ} \mathrm{C}$ (B) Coexpression of Strep-COC (78-159) and His-FEZ1 (226-290) in LB medium at $37^{\circ} \mathrm{C}$
teins (Figure 3.35 B ). Therefore, this complex was chosen for further investigation of the interaction.

### 3.2.1.2 Coexpression and copurification of SCOC-FEZ1 ccd complexes



Figure 3.36: Copurification of wt Strep-SCOC (78-159) with His-FEZ1 (226-290)
(A) Schägger gel of affinity chromatography with StrepTrap column
(B) Schägger gel of size exclusion chromatography

Both FEZ1 (226-290) pET-22b and SCOC (78-159) pET-28a were co-transformed into BL21 by electroporation. The complex was expressed in LB medium at $37^{\circ} \mathrm{C}$. Cells were harvested and lysed. Affinity purification was conducted via StrepTrap chromatography. The protein complex eluted from the column in the same fractions $5-11$ as SCOC (78-159) alone as shown in Figure 3.3 and Figure 3.36 B (see Section A.3.1 for elution profiles). The FEZ1 SCOC complex was further purified via size exclusion for SEC-MALLS (see Figure 3.36 A, C). The complex eluted from Superdex 75 16/60 column in a single peak. For further analysis, the complex was concentrated and used without freezing or further incubation, as it showed a tendency to precipitate and aggregate when protein samples were stored at $4^{\circ} \mathrm{C}$ or $-80^{\circ} \mathrm{C}$.
I assumed that oligomerization state and basic residues of SCOC would influence the interaction with FEZ1. Hence, SCOC double core mutants E93V/K97L and N125L/N132V, and arginine mutants R99E and R117E were also coexpressed and affinity purified with FEZ1 (226-290) via the same protocol as above (see Section A.3.2 for gels of affinity purification). Figure 3.37

4.6

Figure 3.37: Coexpression of Strep-SCOC (78-159) constructs with His-FEZ1 (227-290)
Schägger gel with samples eluting from a StrepTrap column
shows copurification samples of all SCOC mutants with FEZ1 ccd. The tetrameric N125L/N132V and trimeric E93V/K97L mutants did not bind FEZ1 ccd showing that SCOC dimerization is crucial for SCOC-FEZ1 ccd complex formation. R117 is required for FEZ1 ccd interaction, since binding of R117E to FEZ1 ccd was almost completely abolished. The second arginine R99 is not important for complex formation, as R99E still interacted with FEZ1 ccd.

### 3.2.1.3 Characterization of SCOC-FEZ1 complexes

The formation of SCOC-FEZ1 ccd complex was analyzed by analytical gel filtration (Figure 3.38). The elution profile of the complex shows a considerable shift to shorter retention time compared to SCOC ccd alone. This indicates the formation of a stable complex with much larger molecular weight. Comparison to retention time of FEZ1 (227-190) was not possible, as the fragment was not expressed as soluble protein from E.coli, and could therefore not be purified.

The molecular weight of wt SCOC-FEZ1 ccd complex was analyzed with SEC-MALLS. The measurements yielded a molecular weight of $120.2 \pm 4 \mathrm{kDa}$ for the SCOC-FEZ1 ccd complex and showed that the complex is homogeneous (Figure 3.39). FEZ1 is a dimer in solution [44, 45, 111]. Assuming that both proteins are dimers and that they interact with a $1: 1$ stoichiometry, there would be six copies of each protein in the SCOC-FEZ1 complex.


Figure 3.38: Analytical gel filtration of SCOC (78-159)—FEZ1 (227-290) complex
Elution profiles of SCOC (78-159)-FEZ1 (227-290 complex and SCOC (78-159) and the respective SDS-PAGE gels of the elution fractions


Figure 3.39: SEC-MALLS measurements of wt SCOC (78159)—FEZ1 (227-290) complex

Elution profiles and molecular weights from three measurements are shown for the complex.

### 3.2.2 Interaction of SCOC with Arl1

### 3.2.2.1 Expression, purification and nucleotide exchange of Arl1

SCOC interacts with the small, Golgi-resident GTPase Arl1 in a nucleotide dependent manner [36]. For investigation of the interaction, I cloned dominant active Q79L Arl1 (15-181) into pET-22b. The protein was expressed overnight from autoinducible media. Cells were harvested and lysed. All buffers contained $\mathrm{MgCl}_{2}$ for stable nucleotide binding of Arl1. In a first purification step, Arl1 was affinity purified via HisTrap chromatography (Figure 3.40 A, B). Minor contaminations were then removed by size exclusion chromatography (Figure $3.40 \mathrm{C}, \mathrm{D}$ ).

SCOC is known to bind Arl1 in its GTP-bound state. Therefore, Arl1 had to be loaded with GTP or a non-hydrolyzable GTP derivative by nucleotide exchange. Several protocols are known for nucleotide exchange of GTPases [112]. For dominant active Arl1, a protocol with buffers supplemented with GTP was reported by Panic et al. [39]. Wu et al. [42] utilize wt Arl1 and convert it to GTP-bound state by adding EDTA, an alkaline phosphatase and excess of the non-hydrolyzable GDPNP. After His-Arl1 Q79L, which was purified in presence of GTP $\gamma \mathrm{s}$, failed to interact with SCOC, I utilized a modified protocol providing excess GDPNP. I performed nucleotide exchange of Arl1 with a protocol utilizing SAP for hydrolyzing nucleotides. Small amounts of Arl1 were incubated with excess EDTA for chelating of $\mathrm{Mg}_{2}^{+}$, SAP and an excess of the non-hydrolyzable GTP derivate GDPNP. After incubation over night at $4{ }^{\circ} \mathrm{C}$, the reaction was stopped with excess $\mathrm{MgCl}_{2}$. Protein samples were then subjected to another gel filtration purification step for the removal of excess nucleotide (Figure 3.40 E, F). Arl1 eluted from the column in two peaks. The first peak represented Arl1 which oligomerized via cysteine bridges, as the DTT concentration in the size exclusion buffer was not sufficient. The purification step of the fractions of the first peak was repeated with increased DTT concentration.

The nature of nucleotide-bound state was analyzed by reversed-phase chromatography runs of the protein and reference nucleotides. The measurements were conducted by Dr. Corinna Pohl (Department for Biophysical Chemistry, MPI-BPC). Analyses was done via a LiChrosorb column HiBar using a phosphate Acetonitril buffer (for a short description of the method, see Smith \& Rittinger [112]). As references, equal amounts of GDP, GDPNP and GTP were used. Also, EF-Tu, a GDP-binding protein, was loaded on the column for comparison (Figure 3.41). GDPNP and the Arl1 sample eluted


Figure 3.40: Purification of Q79L Arl1 (15-181)
(A) Elution profile of affinity chromatography (B) SDS-PAGE gel of affinity chromatography (C) Elution profile of first size exclusion step (D) SDS-PAGE gel of first size exclusion step (E) Elution profile of second size exclusion step (D) SDS-PAGE gel of second size exclusion step


Figure 3.41: Analysis of bound nucleotide
Arl1, EF-Tu and reference nucleotides were separated via reversed-phase chromatography. Figure was produced by C. Pohl.
at same retention times, confirming that the nucleotide bound to Arl1 was GDPNP.

### 3.2.2.2 Arl1-Pulldown experiments



Figure 3.42: His-Arl1 pulldown with SCOC (78-159)
Arl1 was preincubated with an excess of GTP, GTP $\gamma$ s, GDP and GDPNP respectively. SCOC (78-159) and $\mathrm{Ni}^{2+}$-sepharose beads were added for overnight incubation.

SCOC ccd interacts with Arl1 preferably in it's GTP-bound state, as shown
by yeast to hybrid screen and pulldown experiments [36]. I performed pulldown experiments with immobilized His-Arl1 (15-181) loaded with different nucleotides and SCOC (78-159) for confirmation of this interaction (Figure 3.42). Recombinantly expressed and purified proteins were incubated with $\mathrm{Ni}^{2+}$-sepharose beads and an excess of the respective nucleotide. Flowthrough and wash fractions, and proteins bound to the beads were analyzed by SDSPAGE.

GDP-bound Arl1 did not bind to SCOC. GTP and GTPץs loaded Arl1 pulled SCOC's ccd in small amounts, GDPNP-Arl1 enriched SCOC in larger amounts on elution and beads fractions.

### 3.2.2.3 Analytical gel filtration



Figure 3.43: Analytical gel filtration
Elution profiles of SCOC (78-159), GDPNP-Arl1 (15-181) and 1:1 mixture of Arl1 and SCOC with GDPNP and the respective SDS-PAGE gels of the elution fractions

For further investigation of the interaction, the proteins were analyzed with
analytical gel filtration via Superdex 10/300 GL chromatography. A shift of retention volumes to larger molecular weight would indicate complex formation. SCOC (78-159), GDPNP-bound Arl1 and a 1:1 mixture of the proteins were separated on the size exclusion column (Figure 3.43). The protein mixture was preincubated together with an excess of GDPNP overnight at $4^{\circ} \mathrm{C}$. SDS-PAGE shows that SCOC ccd elutes at $\sim 15 \mathrm{~mL}$, Arl1 elutes in two peaks at $\sim 16$ and 19 mL . The protein mixture sample shows three peaks in the elution profile. At $\sim 14 \mathrm{~mL}$, SCOC elutes from the column, a shoulder at $\sim 19 \mathrm{~mL}$ indicates Arl1 elution. The large peak at $\sim 20 \mathrm{~mL}$ corresponds to excess GDPNP.

This experiment showed, that the complex of GDPNP-Arl1 SCOC was not stable in a gel filtration experiment, as no peak shift in the elution profile was observed. This might indicate that the interaction of SCOC and Arl1 has a low affinity.

### 3.2.2.4 ITC

ITC experiments were conducted to prove whether SCOC and Arl1 interact with low affinity. In an ITC setup, the two interaction partners are slowly and stepwise mixed by titrating one protein in the syringe into the other protein in the cell. This occurs in an adjabiatic jacket, so that small differences in temperature arising from the endo- or exothermic mixing process can be recorded. SCOC ( $615 \mu \mathrm{M}$ ) was titrated into Arl1 ( $50 \mu \mathrm{M}$ ). As a control, SCOC was also titrated into ITC buffer, and ITC buffer was titrated into Arl1, to exclude errors resulting from dilution heat (Figure 3.44 A ). Titration curves showed, that SCOC and Arl1 interact in an exothermic manner. Also, a small dilution energy of SCOC was observed, and larger endothermic reaction for dilution of Arl1. However, analysis of the raw ITC data (Figure 3.44 B) for determination of affinity and stochiometry could not be achieved. An accurate measurement of enthalpy of the reaction was not possible, as the curve was missing an initial plateau at the beginning of the titration curve.

Hence, it can be concluded that Arl1 and SCOC do interact in a GTPdependent manner. Nevertheless, the detailed characterization of this interaction requires further experiments, including thorough analysis of Arl1's nucleotide state and optimization of ITC conditions.


Figure 3.44: ITC titration of SCOC ( $615 \mu \mathrm{M}$ ) into $\operatorname{Arl}(50 \mu \mathrm{M})$
(A) Raw data of SCOC titration into Arl1 (green line), SCOC into buffer (red line), and buffer into Arl1 (black line). (B) ITC analysis of raw data

### 3.3 Discussion

### 3.3.1 Characterization and structure of SCOC ccd

Here, I presented the crystal structure of SCOC ccd. The model comprises residues $86-147$ and shows that SCOC is a left-handed coiled coil dimer. Heptad assignment of the coiled coil reveals several non-canonical, polar residues in the hydrophobic core, which are crucial for stability and oligomerization state of the coiled coil. Moreover, the in vitro interaction of SCOC to a minimal binding region of FEZ1 is also dependent on its oligomerization state as shown by copurification of both proteins.

Several SCOC constructs were used in this study in order to determine the crystal structure of SCOC ccd. Number of hits from screening and their best diffraction resolution limits are summed up in Table 3.11. A Strep-tagged SCOC ccd construct (78-159) covering the whole ccd yielded crystallization hits in more than 100 initial screening conditions. Although first crystals of this construct were easily obtained, it proved to be difficult to improve their diffraction quality beyond $3.2|\mathrm{~A}|$ with low mosaicity. Limited proteolysis and structure prediction indicated flexible residues at the C-terminus of the ccd. Nevertheless, constructs with truncated C-termini did not result in better diffracting crystals. Optimized conditions yielded crystals diffracting to higher resolution, but problems with high mosaicity remained. Finally, in situ proteolysis of SCOC L105M (78-159) resulted in crystal rods diffracting to $2.8 \AA$.

From a SAD dataset collected from a single selenomethionine labeled SCOC L105M (78-159) crystal, I determined the structure of the SCOC coiled coil domain. Remarkably, the asymmetric unit contains 3 molecules, which form two distinct dimers with conformational differences. This plasticity is due to the polar and charged residues at the a/d-heptad positions. Imperfect coiled coils with polar residues in the hydrophobic coiled coil core have been observed before. For example, the autophagy protein Beclin1 also features an imperfect ccd with polar residues R and E in the hydrophobic core [113]. Mutation of these residues to canonical amino acids also led to increased stability. However, the crystal structure of Beclin1 features only one conformation of the coiled coil. The nature of the amino acids at the a/d-positions determines the oligomerization state of a coiled coil protein [55]. The influence of different amino acids at a/d heptad positions on the oligomerization state of a coiled coil protein was studied with the GCN4 leucine zipper in a landmark publication [59]. The GCN4 leucine zipper contains a single polar core residue (Asn16)

Table 3.11: Summary of SCOC ccd crystallization

| construct | screening hits | resolution $(\AA)$ |
| :--- | :---: | :---: |
| SCOC (78-159) | $>100$ | 3.6 |
| 24-well grid |  | 3.2 |
| 96-well grid and random |  | 3.6 |
| w/o Tag | $\sim 80$ | 3.0 |
| SCOC (78-159) L105M |  |  |
| in situ proteolysis | $\sim 40$ | $\mathbf{2 . 8}$ |
| SCOC (78-151) | $\sim 30$ | 5 |
| SCOC (78-141) | spherulites | 6 |
| SCOC (78-132) | spherulites | - |
| SCOC (112-159) |  | - |

at an a-position and the authors concluded that Asn16 imposed specificity for dimerization of the GCN4 leucine zipper at the expense of its stability. My results are in agreement with these data. The well conserved, non-canonical a/d heptad residues in SCOC were replaced with either leucines or valines. Double core mutations E93V/K97L and N125L/N132V led to a change from dimer to either trimer or tetramer formation and the thermostabilities of these core mutants were dramatically increased. I did not create single mutation variants of the core positions, therefore I cannot conclude whether the mutation of a single core residue would have been sufficient for change of the oligomerization state, as observed for GCN4. As expected, single mutations of conserved arginine sites on c and g positions at the surface of the protein (R99 and R117), which might be involved in ionic interactions, did not influence stability and oligomerization state.

### 3.3.2 Interaction with FEZ1 and Arl1

The SCOC-FEZ1 complex plays a regulatory role for induction and progression of starvation induced autophagy [35]. Complex formation is mediated through the coiled coil domains of SCOC and FEZ1 [35, 37, 44]. Here I demonstrated that SCOC ccd and FEZ1 ccd form a stable homogeneous complex with a molecular weight of 120 kDa , which would correspond to six copies of each
molecule assuming a 1:1 stoichiometry. A complex of full-length GFP-FEZ1 with FLAG-SCOC was analyzed with blue native gels by McKnight et al [35]. A molecular weight of 300 kDa was detected, corresponding to a $2: 2$ complex. Hence, the stochiometry of a complex formed under in vivo conditions cannot be conclusively evaluated. I tested whether oligomerization state of SCOC influenced complex formation in vitro by copurification experiments. Indeed, complex formation was abolished for both double core mutants N125L/N132V and E93V/K97L, forming a tetramer and a trimer, respectively. As these residues are buried in the hydrophobic core, it is very unlikely that they are directly involved in intermolecular contacts to FEZ1. Dimeric oligomerization state is thus crucial for the interaction in vitro. Also, the single arginine mutation R117E showed decreased binding to FEZ1 ccd. I conclude that R117 is essential for SCOC-FEZ1 interaction in vitro, probably mediating ionic interactions. Co-immunoprecipitation experiments with full-length FEZ1 and EmGFP-SCOC constructs were performed by Dr. J. Chua (Department of Neruobiology) in order to gain insights into the complex formation in vivo. For this purpose, full length V5-FEZ1 and EmGFP SCOC wt and mutant constructs were cotransfected in HEK cells. Co-immunoprecipitation was carried out with anti-GFP antibodies. The tetrameric core mutant N125L/N132V did not bind FEZ1 (Figure 3.45). However, in contrast to the copurification studies both R117E and the trimeric SCOC mutant bound full-length FEZ1 in the co-immunoprecipitation experiments. R117E is involved in interactions of both coiled coil domains, but the abolishing effect of a single mutation in vitro is in vivo rescued by other factors stabilizing the interaction. Based on these results I cannot exclude that the N-terminal region of FEZ1 might also be involved in SCOC binding, which was in fact reported earlier for NEK1 (Nima-related kinase 1). The coiled coil region of NEK1 comprising residues 497-555 interacts with both the coiled-coil region of FEZ1 and the N-terminal region of FEZ1 [114].

Interestingly, SCOC wt co-immunoprecipitated with three distinct FEZ1 bands co-immunoprecipitated with SCOC wt (Figure 3.45), corresponding to three differently phosphorylated FEZ1 variants. Four phosphorylation sites are known, S58, S301, S314 and S316 [48]. Binding of FEZ1 to Kinesin-1 and Munc18 is regulated by phosphorylation of the major phosphorylation site S58 [48]. SCOC bound preferably to the lowest FEZ1 band, indicating a preference for FEZ1 in its multi-phosphorylated state. How phosphorylation of FEZ1 might interplay with the recruitment of the SCOC-FEZ1 complex to the phagophore remains to be elucidated.

McKnight et al. [35] showed, that SCOC and FEZ1 together interact with


Figure 3.45: Co-immunoprecipitation of full length FEZ1 tagged N -terminally with a V5 epitope and various EmGFP-SCOC (78-159) variants from transfected 293 cell lysates using an anti-GFP antibody

ULK1 and UVRAG (see Section 1.2.1) to regulate induction and progression of macroautophagy. The crosstalk of Beclin1- and ULK1-complexes is mediated by phosphorylation: ULK1 phosphorylates AMBRA1, a member of a Beclin1 complex, which promotes autophagy[115]. Moreover, it was shown recently, that ULK1 phospohorylates also Beclin1 itself, thereby activating the Vps 34 complex fur autophagy[116]. ULK1- and Beclin1-complexes and their interactions are discussed inWirth et al. [117]. The interplay between these two essential autophagy complexes is not completely understood. Several functions of SCOC were proposed by McKnight et al. [35]:

1. upon aa starvation, SCOC binds to FEZ1-ULK1, which releases ULK1 complex
2. upon aa starvation, UVRAG dissociates from FEZ-SCOC, thereafter forming an UVRAG-Beclin1-PtdIns3K complex
3. SCOC might also play a role as membrane-proximal scaffolding protein, maybe in interplay with Arl1 at the Golgi.


Figure 3.46: SCOC complexes in autophagy and beyond
Functional implications of distinct SCOC dimers remain unclear

Complexes which contain SCOC are depicted in Figure 3.46. With our current knowledge, it remains unclear whether the distinct SCOC dimers observed in the crystal structure also exhibit distinct physiological functions. SCOC might change its conformation upon binding to one or the other interaction partner. Also (de)phosphorylation of FEZ1 or ULK1 might change the conformational state, maybe triggering dissociation of the complex. One can also speculate that SCOC functions as a FEZ1 effector, locking the intrinsically disordered protein in a conformation in which it is less affine for binding ULK1 and UVRAG. How FEZ1 and SCOC are recruited to the ULK1 complex or the phagophore is still unkown.

In this work, I also analyzed the interaction of SCOC with Arl1. The physiological function of this interaction is less understood than those of FEZ1-SCOC complexes. SCOC colocalizes with Arl1 at the Golgi [36], but upon aa starvation, it is recruited to the phagophore, partially colocalizing with Atg9 and LC3 [35]. I was able to confirm interaction of SCOC with Arl1 by pulldown experiments, which showed that SCOC binds to Arl1 preferably in its GTP-
bound state. Initial ITC measurements confirmed an exothermic interaction between Arl1 and SCOC, but more experiments are needed to gain insights into the stability, structure and function of this complex.

Further structural characterization of the SCOC-FEZ1 complex, combined with functional analysis of the larger assemblies with ULK1 or UVRAG, will help us to gain new insights into how this small protein fulfills its functions in complexes with diverse interaction partners.

### 3.4 Outlook

Currently it is unclear, whether the two distinct dimers observed in the crystal structure are functionally relevant and whether they are also present in solution. SCOC structure in solution can be further analyzed by NMR spectroscopy. A two dimensional HSQC spectrum of ${ }^{15} \mathrm{~N}$-labelled SCOC could display the presence of residues that exist in more than one conformation. That would be a strong hint for the physiological importance of the two dimers. The crystallization and structure determination of the FEZ1-SCOC ccd complex would reveal, which of the dimeric SCOC conformations interacts with FEZ1. The complex can be purified in large amounts and is homogenous as shown by SEC-MALLS. It might therefore be suitable for crystallization. Phasing of data would be possible by molecular replacement using the SCOC structure as a search model. My data show that FEZ1 ccd is sufficient but not exclusively responsible for interaction with SCOC. In our lab, a purification protocol of full-length FEZ1 was established by Dr. J. Chua.

A stable full length complex of recombinantly purified proteins can be subjected to biochemical and biophysical analysis. For example, by using SECMALLS information the stoichiometry of functional complex can be obtained. Proteolytic digest could lead to the identification of other FEZ1 regions interacting with SCOC. Alternatively, also detailed knowledge of the molecular structure of FEZ1 would be helpful to understand the interplay of both ccds. Human FEZ1, a mainly natively unfolded protein, has a presumably low success rate for crystallization. However, recent alignment studies revealed that there are also FEZ1 homologues in yeast. I subjected several FEZ1 homologues from yeast to analysis by the crystallography prediction software TarO (see Table 3.12).
Several yeast homologues yielded "high score" or "amenable" for crystallization likeliness, among others a homologue from Lachancea thermotolerans, a thermophilic yeast. Screening of one of these constructs might yield crystals

Table 3.12: Chrystallization probability of yeast FEZ1 homologues

| Sequence ID | Organism | crystallization <br> propability | length |
| :--- | :--- | :---: | :---: |
| C5DHV8 | Lachancea thermotolerans | high-scoring | 240 |
| Q6FVD2 | Candida glabrata | high-scoring | 251 |
| C8Z3Y6 | Saccharomyces cerevisiae | amenable | 280 |
| B5VDW9 | Saccharomyces cerevisiae | amenable | 280 |
| Q6CTM1 | Kluyveromyces lactis | amenable | 261 |

suitable for structure determination. Importantly, all of the yeast species have a SCOC homologue.

The interaction of SCOC with Arl1 should be thoroughly analyzed by ITC. Initial ITC experiments confirmed the interaction, but due to the missing plateau at the beginning of the titration curve, specific values for affinity and stochiometry could not be derived. The protein concentration of Arl1 needs to be adjusted for further experiments. There might still be a fraction of Arl1 not loaded with GDPNP but GDP. Either, nucleotide exchange has to be optimized, or Arl1 has to be more concentrated. Besides ITC studies, the protein complex could also be structurally characterized. Based on my results, it seems that the interaction has a low affinity. A gel-filtration stable Arl1-SCOC complex was not obtained so far. This circumstance, paired with the likeliness of SCOC to crystallize on its own, might make structural investigation by X-ray crystallography difficult. Again, two dimensional NMR experiments could provide further insights. Titration experiments with stepwise addition of Arl1 to a ${ }^{1} 5 \mathrm{~N}$-labelled SCOC sample could reveal amide peaks of amino acids involved in the interaction.

For a complete picture of SCOC's interaction with FEZ1, and their common interplay with complexes involved in autophagy, further experiments will be needed. We assume, that upon aa starvation, SCOC does not localize to the Golgi anymore, but is recruited together with FEZ1 to the phagophore. How is this recruitment regulated? What role does phosphorylation of FEZ1 and ULK1 play? Does the interplay of FEZ1-SCOC with different autophagy key players involve conformational changes of SCOC? Further research combining structural biology methods with biochemistry and cell biology will be needed for detailed understanding of SCOC's function.

## 4 Shigella flexneri and Autophagy

### 4.1 Characterization of VirG

### 4.1.1 Expression and purification of VirG (353-758)

The overexpression in E.coli and purification of VirG was extremely challenging. No fragment used in this study could be expressed as a soluble protein from E.coli. All purification protocols involved denaturation and refolding to the native structure of the protein. Finding conditions for successful refolding of VirG in vitro has been the main challenge of this project. VirG (353-758) originated from a limited proteolysis experiment of VirG (52-758) conducted by Dr. K. Kühnel. The tryptic digest yielded VirG (353-758) as stable fragment.

The fragment was cloned from Shigella flexneri's virulence plasmid with a C-terminal StrepTag into pET-28a. Expression of VirG (353-758) was tested under various conditions with different media and expression strains. Still no expression conditions yielding soluble protein were found.

VirG was expressed at $37^{\circ} \mathrm{C}$ in LB for 3 h . Cells were harvested and lysed, and after the first centrifugation step the supernatant was discarded. The pellet was resuspended and washed with Triton-X. Then, inclusion bodies were solubilized with 6 M GdnHCl . After dropwise dilution to 2 M GdnHcl , further refolding was performed by stepwise dialysis summing up to $\sim 36 \mathrm{~h}$ dialysis time. Between dialysis steps, large amounts of precipitate were removed. After final dialysis affinity StrepTrap chromatography was conducted. The protein eluted together with a $\sim 26 \mathrm{kDa}$ degradation product (Figure 4.1 A). Next, size exclusion chromatography was performed, by which the degradation product was partially removed (Figure 4.1 B). Addition of EDTA and benzamidine as protease inhibitors only confined the problem. Due to degradation and precipitation, yields of the purification protocol varied and were unreproducable.


Figure 4.1: Purification of VirG (353-758)
(A) Elution profile of affinity chromatography (B) SDS-PAGE gel of affinity chromatography (C) Elution profile of size exclusion chromatography
(D) SDS-PAGE gel of size exclusion chromatography


Figure 4.2: Purification of VirG (52-758)
(A) Elution profile of affinity chromatography (B) SDS-PAGE gel of affinity chromatography (C) Elution profile of anion exchange chromatography (D) SDS-PAGE gel of anion exchange chromatography (E) Elution profile of size exclusion chromatography (D) SDS-PAGE gel of size exclusion chromatography

### 4.1.2 Expression and purification of VirG (52-758)

VirG's passenger domain was cloned from a synthetic gene optimized for E.coli expression with a N-terminal His-Tag in pET-28a. Expression conditions were tested extensively. I tested different media (LB, TB, autoinducible and minimal media), a variety of E.coli expression strains (BL21, Rosetta, Lemo (NEB) and SoluBL21 (amsbio)), and a range of temperatures from $16{ }^{\circ} \mathrm{C}-37^{\circ} \mathrm{C}$ and also C- or N-terminal affinity tags. Nevertheless, the protein remained in the membrane fraction. Therefore, VirG (52-758) was expressed in LB at $37^{\circ} \mathrm{C}$, presumably in inclusion bodies. After harvesting and lysing the cells, the sample was denatured with 6 M urea. Affinity chromatography (Figure $4.2 \mathrm{~A} \& \mathrm{~B}$ ) was carried out with a gradient from 4 to 2 M urea. VirG (52-758) eluted from the Protino® Ni-NTA Column 5 mL in large amounts, but also with some contamination (Figure 4.2 B). Refolding was further performed via dialysis to 1 M urea. Contaminants were removed with the second purification step through anion exchange chromatography (Figure $4.2 \mathrm{C} \& \mathrm{D}$ ). The protein precipitated partially while concentrating for size exclusion chromatography. Also, removal of urea below 1 M resulted in precipitation. Size exclusion chromatography was carried out with 1 M urea. Despite addition of 2 mM DTT, VirG (52-758) eluted in two peaks from the gel filtration column, both containing the passenger domain (Figure $4.2 \mathrm{E} \& \mathrm{~F}$ ). Degradation of the passenger domain was inhibited by the addition of benzamidine and ETDA as protease inhibitors. The purification yielded between $1.2-1.8 \mathrm{mg}$ protein at a concentration of 10 - $15 \mathrm{mg} / \mathrm{mL}$.

### 4.1.3 Analysis of refolding and secondary structure by CD spectroscopy

Refolding and secondary structure of VirG fragments was assessed by CD spectroscopy. The crystal structure of the C-terminal autochaperone region showed a $\beta$-barrel, which is typical for autotransporter proteins [85].

The CD spectrum of VirG (353-758) was recorded from 190 to 250 nm with a bandwidth of 2 nm . It shows a minimum at 216 nm , confirming a $\beta$-strand rich secondary structure (Figure 4.3).

The CD spectrum for VirG (52-758) was measured from 200 to 250 nm in an NaF buffer supplied with 1 M urea. Due to the urea concentration, the signal becomes noisy towards lower wavelength (Figure 4.4). Nevertheless, the spectrum also clearly shows a minimum at 216 nm , indicating successful refolding for the passenger domain.


Figure 4.3: CD spectrum of VirG (353-758) at $20^{\circ} \mathrm{C}$


Figure 4.4: CD spectrum of VirG (52-758) in 1 M urea at $20^{\circ} \mathrm{C}$

### 4.1.4 Crystallization of VirG

96 -well plate screens were set up with $\operatorname{VirG}(353-758)$ at $4{ }^{\circ} \mathrm{C}$ with protein concentrations of 7.5 and $15 \mathrm{mg} / \mathrm{mL}$. The screens yielded no crystals, but some promising conditions with spherulites or microcrystalline structures (Figure 4.5). Crystallization conditions can be found in Table 4.1. Spherulites grew from clear drops (Figure 4.5 D ) or precipitate (Figure 4.5 B ) with crystallization conditions containing PEG 4000 or 8000 and $\mathrm{Li}_{2} \mathrm{SO}_{4}$. The spherulites were stained to confirm the protein content (Figure 4.5 A ). Microcrystalline structures were observed for one condition with $\mathrm{Li}_{2} \mathrm{SO}_{4}$ as precipitant (Figure 4.5 C ).

Due to the low yield from purification, refinement in 24 -well plate format was not possible. Also, the spherulites proved to be difficult to reproduce and


Figure 4.5: 96-well plate screening of VirG (353-758)
(A) Stained spherulites (B) Spherulites growing from protein precipitate
(C) microcrystals and small spherulites (D) spherulites

Table 4.1: Crystallization conditions of VirG (353-758) from 96well plate screens

| condition | buffer composition |
| :---: | :--- |
| A | $0.2 \mathrm{M} \mathrm{Li}_{2} \mathrm{SO}_{4}$ |
|  | 0.1 M Tris pH 8.5 |
|  | $15 \% \mathrm{w} / \mathrm{v}$ PEG 4000 |
| B | 0.1 M HEPES pH 7.5 |
|  | $1.5 \mathrm{M} \mathrm{Li}_{2} \mathrm{SO}_{4} \times \mathrm{H}_{2} \mathrm{O}$ |
| C | 0.1 M HEPES pH 7.5 |
|  | $0.75 \mathrm{M} \mathrm{Li}_{2} \mathrm{SO}_{4} \times \mathrm{H}_{2} \mathrm{O}$ |
| D | $0.2 \mathrm{M} \mathrm{ZnAc}_{2} \times 2 \mathrm{H}_{2} \mathrm{O}$ |
|  | 0.1 M Na cacodylate $\times 3 \mathrm{H}_{2} \mathrm{O} \mathrm{pH} 6.5$ |
|  | $9 \% \mathrm{w} / \mathrm{v} \mathrm{PEG} 8000$ |

could not be improved.


Figure 4.6: 96-well screening of VirG (52-758)
(A) Spherulites (B) Spherulites or microcrystals (C) Salt crystals (D) Microcrystals and spherulites

Drops were also set with VirG (52-758) at 4 and $20^{\circ} \mathrm{C}$ with protein concentrations of 11 and $15 \mathrm{mg} / \mathrm{mL}$. The protein buffer contained 1.0 M urea, so that final concentration of urea in the $1: 1$ sitting drops was 0.5 M urea. The fragment also yielded several conditions with almost crystalline structures (Figure 4.6), buffer compositions can be found in Table 4.2. Spherulites in different size and microcrystals were observed (Figure $4.6 \mathrm{~A}, \mathrm{~B}$ and D). The crystals in Figure 4.6 C turned out to be salt crystals, as they were not stained with protein dye.

Table 4.2: Crystallization conditions of VirG (52-758) from 96well screens

| condition | buffer composition |
| :---: | :---: |
| A | $\begin{aligned} & 0.2 \mathrm{M} \mathrm{NH}_{42} \mathrm{SO}_{4} \\ & 15 \% \mathrm{PEG} 8000 \end{aligned}$ |
| B | 0.01 Tris pH 7.5 <br> $18.3 \%$ w/v PEG MME |
| C | $0.7 \mathrm{M}\left(\mathrm{NH}_{4}\right)_{2} \mathrm{SO}_{4}$ |
| D | $\begin{aligned} & 0.5 \mathrm{M} \mathrm{Li}_{2} \mathrm{SO}_{4} \\ & 7,5 \% \mathrm{PEG} 8000 \\ & 1 \mathrm{M}(\mathrm{Na} / \mathrm{K})_{3} \mathrm{PO}_{4} \end{aligned}$ |

### 4.2 Characterization of IcsB-IpgA

### 4.2.1 Expression and purification of IcsB-IpgA

IcsB is translocated via the TTSS together with it's chaperone IpgA. In vivo, the stop codon between the two genes on the virulence plasmid of Shigella is transient and can be read-through, creating a translational fusion protein [89]. Therefore, IcsB was cloned together with IpGA into the two cloning sites of pETDuet-1 for coexpression. For limited proteolysis experiments, I prepared two plasmids comprising N- or C-terminally Strep-tagged IpgA. IcsB was Histagged via the vector.

Expression tests showed that IcsB-IpgA was expressed best in autoinducible media with overnight incubation at $18{ }^{\circ} \mathrm{C}$. Cells were harvested and lysed. Affinity purification was carried out via HisTrap chromatography. It yielded a complex IcsB-IpgA with minor contaminations (Figure 4.7 A ). The complex, which was prone to precipitation above $4^{\circ} \mathrm{C}$, was slowly concentrated and then subjected to size exclusion chromatography. IcsB-IpgA eluted together in a single peak from HiLoad 16/60 Superdex 200 column (Figure 4.7 B).

Furthermore, I also created four plasmids with shortened IcsB fragments IcsB (126-494), IcsB (185-494), IcsB (235-494) and IcsB (293-494) in MCSI and IpgA in MCSII. The stable fragments originated from a limited proteolysis experiment conducted by Dr. K. Kühnel. Shortened constructs of IcsB were expressed together with IpgA under same conditions. I followed the same


Figure 4.7: Purification of IcsB-IpgA
(A) Elution profile of affinity chromatography (B) SDS-PAGE gel of affinity chromatography (C) Elution profile of size exclusion chromatography (D) SDS-PAGE gel of size exclusion chromatography
purification protocols. Purification revealed that shorter IcsB fragments bound IpgA to less extend, indicating that the N-Terminal region of IcsB is involved in IcsB-IpgA interaction.

### 4.2.2 Limited proteolysis of IcsB-IpgA



Figure 4.8: Limited proteolysis of IcsB-IpgA by Trypsin and Chymotrypsin
(A) SDS-PAGE analysis of indicated time points (B) Anti-Strep western blot showing Strep-IpgA bands

Limited proteolysis was performed in search of stable fragments of IcsB and IpgA, or smaller, more stable complexes IcsB-IpgA. For proteolytic digest, a complex of His-tagged IcsB with N-terminal Strep-tagged IpgA was utilized. The protein complex was subjected to digest by Trypsin and Chymotrypsin at $1: 500$ and $1: 2000 \mathrm{w} / \mathrm{w}$ ratios. Progress of proteolysis was assessed by taking samples after different time points. For comparison, also undigested protein sample ( time $=0 \mathrm{~min}$ ) was loaded on gels. Analysis by SDS-PAGE gels showed, that IcsB is rapidly digested by both proteases (Figure 4.8). Also smaller fragments created by the proteases are no more resistant than the fulllength protein. In contrast, no proteolytic products of IpgA were observed. Western blot against the StrepTag of IpgA confirmed the integraty of the protein (Figure 4.8 B). Hence, I concluded, that IpgA is well structured and stable, whereas IcsB is more flexible and might comprise disordered regions.

### 4.2.3 Crystallization of IcsB-IpgA

Extensive crystallization screening was performed with IcsB-IpgA complexes. 1:1 drops were set in 96 -well plates at $4{ }^{\circ} \mathrm{C}$ with various protein concentrations between $10-50 \mathrm{mg} / \mathrm{mL}$. I conducted screening with all routinely available screens for the full-length complex, and to less extent also with the shortened IcsB fragments IcsB (126-494), IcsB (185-494), IcsB (235-494) and IcsB (293494). So far, the screens did not return a hit.

### 4.2.4 Analysis of IcsB-IpgA by heteronuclear NMR spectroscopy

Considering the results from limited proteolysis of $\mathrm{IcsB}-\mathrm{IpgA}$ and the lack of the crystallization hits, I speculated that IcsB is a protein with natively unfolded, flexible regions. The lack of secondary structure can in general be addressed by CD spectroscopy. However, the formation of the very stable IcsB-IpgA complex was likely to prevent any conclusions from a CD spectrum, as it would it contain overlayed signals from both proteins. Hence, I aimed to analyze the structural features of IcsB-IpgA by NMR spectroscopy in collaboration with Dr. S. Bibow and Prof. M. Zweckstetter.
For this purpose, I expressed and purified ${ }^{15} \mathrm{~N}$ labelled IpgA, and ${ }^{15} \mathrm{~N}$ labelled IcsB-IpgA. A heteronuclear single quantum coherence (HSQC) experiment of the complex was performed. In a resulting (optimal) spectrum, every proton attached to a nitrogen atom would give a signal, hence displaying all protons in peptide bonds as well as protons from side chains containing nitrogen. The HSQC spectrum of IcsB-IpgA shows some well-dispersed peaks, but also an overlap of several peaks in the middle of the spectrum (Figure 4.9. This indicates that large parts of the protein complex are flexible.
In addition, also transverse relaxation optimized spectroscopy experiments with both the complex and IpgA alone were conducted (Figure 4.10). The IpgA spectrum shows mostly well-dispersed peaks. Comparison of the spectrum of IpgA with the spectrum of IcsB-IpgA indicates that the overlapping peaks arising from 30-40 flexible residues must emerge from IcsB. Data collection was generally hampered by the fact that the complex precipitated at $20^{\circ} \mathrm{C}$, lowering the signal of data collection within 12 h acquisition time.
I concluded that IcsB contains flexible regions of unknown size and might not be a suitable target for crystallography.


Figure 4.9: Two-dimensional HSQC spectrum of IcsB-IpgA
Spectrum was collected by Dr. S. Bibow at $5{ }^{\circ} \mathrm{C}$ with 16 scans, 300 increments in the indirect ${ }^{15} \mathrm{~N}$ dimension and an acquisition time of 3 h . Figure was produced by Dr. S. Bibow.


Figure 4.10: Two-dimensional TROSY spectra of IcsB-IpgA and $\operatorname{lpg} A$
(A) IcsB-IpgA TROSY spectrum was collected by Dr. S. Bibow at $20^{\circ} \mathrm{C}$ with 128 scans, 256 increments and an acquisition time of 12 h . (B) IpgA TROSY spectrum was collected by Dr. S. Bibow at $15^{\circ} \mathrm{C}$ with 32 scans, 105 increments and an acquisition time of 2.5 h . Figure was produced by Dr. S. Bibow.

### 4.3 Discussion and Outlook

I aimed to structurally characterize two of Shigella flexneri virulence factors, VirG and IcsB, which are both part of Shigella's sophisticated mechanism to escape xenophagy (see Section 1.3.2). None of the VirG proteins used in this study was expressed as soluble protein. The C-terminal autochaperone region (591-758), which was purified and crystallized by Dr. K. Kühnel, is so far the only solubly expressed fragment of VirG [85]. I was able to succesfully purify two constructs of VirG.

VirG (353-758) was succesfully refolded via a stepwise protocol including several dialysis steps from $2-0 \mathrm{M} \mathrm{GdnHCl}$. Refolding was confirmed by CD spectroscopy. Although this progress was a milestone for the project, the purification protocol is still problematic. The entire purification spans five days, after which characterization by CD spectroscopy and other experiments with the fresh protein can only be started. I tried to confine degradation of the protein by the addition of protease inhibitors, and performed the entire purification at $4{ }^{\circ} \mathrm{C}$ in order to keep self-proteolysis to a minimum. However, the problem remained and resulted in very little and unreproducable protein yields. Moreover, the protocol also included the preparation of 12 L dialysis buffer, containing ultra-pure GdnHCl , which made the purification quite expensive. Hence, I tried to optimize the purification by using urea instead of GdnHCl , and aiming to reduce dialsysis steps. I also tested purification of His-tagged VirG (353-758), which would allow refolding on the affinity column. However, all attempts to purify the construct via any other method than described above, failed. Nevertheless, I was able to set up a few crystallization screens which yielded spherulites. The refinement of these conditions was tedious due to the unreproducability of both purification and crystallization results. Hence, although first steps towards a succesful crystallization of VirG (353-758) were made, I continued optimization with VirG (52-758), which featured a simplified and less demanding purification protocol.

VirG (52-758) was refolded while eluting from the affinity column and dialyzed to 1 M final urea concentration. Under these conditions, the protein was fairly stable at $4{ }^{\circ} \mathrm{C}$. Crystallizations screens yielded a few promising conditions, mostly comprising PEG 8000 or $\mathrm{Li}_{2} \mathrm{SO}_{4}$ as precipitant. First refinement attempts did not yield improved crystallization hits. More experiments are needed to optimize the crystallization of VirG (52-758).

IcsB-IpgA and it's shortened fragments were subjected to extensive crystallization screening without any hit. Initial characterization of IcsB-IpgA and IpgA by two-dimensional NMR spectroscopy revealed, that IcsB contains flex-
ible residues. I concluded that IcsB comprises natively unfolded regions and might thus not be a suitable target for crystallography.
Further insights into the interaction of VirG and IcsB might be difficult to obtain at the current stage of the project. First attempts of in vitro complex formation by analytical gel filtration with buffer containing 1 M urea showed no interaction of both proteins. Several reasons are possible. Maybe, IcsB is already considerably unfolded in 1 M urea, hence it cannot interact with VirG. Another reason might be, that VirG passenger domain did not refold to its native fold, but adopted a misfolded structure. Also, the interaction of both proteins might feature low affinity, which could be adressed by ITC. ITC measurements however will be very demanding due to the large protein amounts needed. In addition, VirG (52-758) precipitates below 0.5 M urea, and IcsB-IpgA precipitates above $4^{\circ} \mathrm{C}$, further constraining possible experimental conditions.
IcsB has been shown to bind to cholesterol in the host cell's membrane [118]. Upon deletion of IcsB's cholesterol binding domain, Shigella's evasion of autophagy is severed. VirG's passenger domain is responsible for Shigella's actinbased motility (see Section 1.3.3, Egile et al. [77], May \& Morona [87], Suzuki et al. [119]) and also membrane-attached. Hence, interaction of both proteins might also require proximity of the outer bacterial membrane or the host cell's membrane.
The involvement of septins into the entrapment of Shigella, and interference with the host cell's inflammatory response by polyubiquitination of NEMO further complicate the picture on how Shigella is interacting with the host cell (see Section 1.3.2, Mostowy et al. [81], Ashida et al. [120]). Additional factors might modulate IcsB-VirG interaction. Structural insights into VirG's passenger domain will help us to understand the interaction between the host cell and the microbe, and might in the long term help to find vaccines or antibiotics against bacillary dysentery.

## Appendix

## A. 1 DNA sequences of synthetic genes


#### Abstract

A.1.1 SCOC isoform 1 atgcgtcgccgtgtgttttctagccaggattggcgtgcttcaggatgggacggtatgggctttt ttagtcgtcgtaccttctgtggtcgttcaggtcgttcttgtcgtggacagctggttcaagtttc tcgcccggaagtttctgctggttctctgctgctgcctgctccacaagccgaagatcatagcagt cgtattctgtatcctcgcccaaaatccctgctgccgaaaatgatgaatgccgacatggatgccg ttgatgccgaaaatcaggtggaactggaggaaaaaacccgtctgatcaaccaagttctggagct gcagcatacactggaagatctgtctgcccgtgtcgatgccgtaaaagaggagaatctgaaactg aaaagtgagaatcaagtgctgggccagtatatcgaaaatctgatgagcgcctctagcgtctttc aaaccaccgataccaaatccaaacgtaaataa


## A.1.2 Arl1 full length Q79L

atgggtggctttttttcgagcatcttctcctccctgtttggtacacgtgaaatgcgtatcctga ttctggggctggatggtgctggcaaaaccacaatcctgtatcgtctgcaggttggtgaagttgt tacgacaatcccgacaatcggctttaatgttgaaaccgtgacctataaaaacctgaaattccag gtgtgggacctgggaggtctgacatcaattcgcccgtattggcgctgctattattctaacaccg acgccgtgatttatgttgttgactcctgtgaccgtgaccgtattggcatcagcaaatccgaact ggtggcaatgctggaagaagaggaactgcgcaaagcaattctggtggtattcgctaataaacaa gacatggagcaggctatgacaagctctgagatggccaactcactgggtctgccggctctgaaag accgtaaatggcaaatctttaaaacgtccgccacgaaaggcacgggtctggacgaagcaatgga gtggctggtagaaacactgaaaagtcgccagtaa

## A.1.3 VirG passenger domain (52-758)

## A.1.3.1 part 1

tgctacacctctgagtggaacccaagaactgcattttagcgaggacaactatgagaaactgctg accccggttgatggtctgtctcctctgggagctggtgaagatggtatggatgcttggtatatca cctccagcaatccgagtcatgcttctcgtacaaaactgcgcattaatagcgacatcatgattag
cgccggtcatggtggagccggtgacaacaacgatggtaacagctgtggtggtaacggtggagat tctatcacaggcagcgatctgtcgattatcaatcaagggatgatcctgggcggtagtggtggat ctggggctgatcacaatggagatggtggcgaagccgtgacaggggacaacctgtttatcattaa cggggaaatcatttcaggtggccacgggggtgactcttattcagactctgatggcggaaatggg ggggatgctgtaaccggtgtgaatctgcctatcatcaataaaggaaccattagcggtggcaatg gcggtaacaattatggcgagggtgacggggggaatggcggggatgctatcacagggagtagcct gagcgtgattaacaaaggcacctttgccgggggaaatggtggtgccgcctatggttatggctat gacggctatggcgggaatgccattactggtgacaatctgtccgtgattaacaatggggcgattc tgggcggaaatggaggacattggggtgacgctatcaacggtagcaatatgactatcgccaatag cgggtacattatcagcggtaaagaggacgacggtacacaaaatgttgccggaaatgctatccac attacgggtgggaacaattctctgatcctgcacgaaggttctgttattaccggagatgtccagg tgaacaattccagcattctgaaaatcattaacaacgactatacgggtacaacaccgactattga aggcgatctgtgtgctggtgattgtacaaccgttagcctgtcaggcaacaaattcaccgtgagc ggagatgtttcttttggggagaactcatcactgaacctggccggcattagtagcctggaagcaa gcggcaatatgagctttggcaataacgtgaaagtggaagcgattattaacaactgggcacagaa agactataaactgctgtccgccgataaaggcattaccggctttagcgtgagcaatatcagtatt atcaatccgctgctgaccactggtgctatcgattatacgaaatcctatatctctgaccagaata aactgatctatggtctgtcctggaacgataccgatggggattcccatggcgagtttaacctgaa agagaacgccgaactgaccgtcagtacaattctggccgataatctgagccatcacaacatcaac tcgtgggatggcaaatctctgacgaaaagcggtgagggtacactgattctg

## A.1.3.2 part 2

agcctgacaaaatccggtgaaggaacgctgattctggccgagaaaaacacctatagcggcttta ccaatatcaatgccggcatcctgaaaatgggtacggttgaggcaatgactcgtacagcaggcgt tatcgtgaataaaggtgccacgctgaactttagcggtatgaaccagaccgtgaacacactgctg aatagtggtacagtgctgatcaacaacatcaacgctccgtttctgcctgatcctgtgattgtta cgggcaacatgaccctggaaaaaaatggacacgtgattctgaataatagtagtagcaacgtggg acagacctatgtacaaaaaggcaactggcatggcaaagggggtattctgagcctgggagctgtt ctgggtaatgacaactccaaaaccgatcgtctggagattgctggacatgcttccggtatcactt atgtggccgtgaccaatgaaggcggtagtggggacaaaaccctggagggagtacagattatcag taccgatagcagcgacaaaaacgctttcatccagaaaggccgtattgtagcaggttcgtatgat tatcgtctgaaacagggcacagtgagtggactgaacaccaacaaatggtatctgaccagccaaa tggacaaccaggagtctaaacaaatgagcaaccaagagtcgacacagatgagtagtcgt

## A. 2 Crystallization conditions of SCOC ccd constructs

(see next page)

Crystallisation conditions of SCOC (78-159) with StrepTag, native

| No_screem_well | Salt 1 | Salt 2 | Buffer | Precipitant 1 | Precipitant 2 | crystal characterisation |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 43_Classics_D4 |  |  | 0.1 M Sodium cacodylate pH 6.5 | 1.4 M Sodium acetate |  | big crystals |
| 43_Classics_H4 | 0.2 M Magnesium chloride |  | 0.1 M TRIS.HCl pH 8.5 | $30 \%$ (w/v) PEG 4000 |  | big crystals |
| 44_PEGs_E5 |  | 0.2 M Magnesium chloride |  | 20 \%(w/v) PEG 3350 |  | big crystals |
| 44_PEGs_F5 |  | 0.2 M Sodium nitrate |  | $20 \%$ (w/v) PEG 3350 |  | big crystals |
| 45_pHClear_A8 |  |  | 0.1 M Citric acid 5.0 | 2.0 M Sodium chloride |  | big crystals |
| 52_Anions_A11 |  |  | 0.1 M MES pH 6.5 | 0.6 M Sodium fluoride |  | big crystals |
| 84_pHClearll_B6 |  | 1.0 M Lithium chloride | 0.1 M BICINE 9.0 | 20 \%(w/v) PEG 6000 |  | big crystals |
| 43_Classics_H5 | 0.2 M Lithium sulfate |  | 0.1 M TRIS.HCl pH 8.5 | $30 \%$ (w/v) PEG 4000 |  | crystals |
| 44_PEGs_F8 |  | 0.2 M Magnesium formate |  | 20 \%(w/v) PEG 3350 |  | crystals |
| 44_PEGs_G1 |  | 0.2 M Magnesium acetate |  | $20 \%$ (w/v) PEG 3350 |  | crystals |
| 44_PEGs_G9 |  | 0.2 M Sodium sulfate |  | 20 \%(w/v) PEG 3350 |  | crystals |
| 44_PEGs_H8 |  | 0.2 M di-Ammonium phosphate |  | $20 \%$ (w/v) PEG 3350 |  | crystals |
| 45_pHClear_B3 |  |  | 0.1 M MES 6.0 | 3.0 M Sodium chloride |  | crystals |
| 45_pHClear_B4 |  |  | 0.1 M HEPES 7.0 | 3.0 M Sodium chloride |  | crystals |
| 45_pHClear_D7 |  |  | 0.1 M Citric acid 4.0 | $30 \%$ (w/v) PEG 6000 |  | crystals |
| 45_pHClear_G1 |  |  | 0.1 M Citric acid 4.0 | $10 \%(\mathrm{v} / \mathrm{v})$ MPD |  | crystals |
| 52_Anions_E12 |  |  | 0.1 M MES pH 6.5 | 0.5 M Sodium succinate |  | crystals |
| 52_Anions_F6 |  |  | 0.1 M HEPES pH 7.5 | 0.5 M Sodium succinate |  | crystals |
| 52_Anions_H1 |  |  | 0.1 M HEPES pH 7.5 | 0.75 M Sodium sulfate |  | crystals |
| 52_Anions_H4 |  |  | 0.1 M HEPES pH 7.5 | 0.6 M K/Na tartrate |  | crystals |
| 53_Cations_B1 |  |  | 0.1 M HEPES pH 7.5 | 3.5 M Ammonium chloride |  | crystals |
| 53_Cations_H8 |  |  | 0.1 M TRIS. HCl pH 8.5 | 2.0 M Potassium acetate |  | crystals |
| 84_pHClearll_A12 |  | 1.0 M Lithium chloride | 0.1 M BICINE 9.0 | $10 \%$ (w/v) PEG 6000 |  | crystals |
| 84_pHClearll_C1 |  |  | 0.1 M Citric acid 7.5 | $5 \%(\mathrm{v} / \mathrm{v})$ Isopropanol |  | crystals |
| 84_pHClearll_E5 |  |  | 7.5 | $0.8 \mathrm{M} \mathrm{Na} / \mathrm{K}$ phosphate |  | crystals |
| 84_pHClearll_E11 |  |  | 7.5 | $1.0 \mathrm{M} \mathrm{Na} / \mathrm{K}$ phosphate |  | crystals |
| 44_PEGs_F3 |  | 0.2 M Lithium nitrate |  | $20 \%$ (W/v) PEG 3350 |  | large cluster |
| 52_Anions_H10 |  |  | 0.1 M TRIS.HCI pH 8.5 | 0.6 M K/Na tartrate |  | large cluster |
| 53_Cations_C8 |  |  | 0.1 M MES pH 6.5 | 2.25 M Ammonium acetate |  | large cluster |
| 53_Cations_D8 |  |  | 0.1 M TRIS.HCl pH 8.5 | 2.25 M Ammonium acetate |  | large cluster |
| 43_Classics_H1 | 0.2 M Ammonium sulfate |  | 0.1 M Sodium acetate pH 4.6 | 25 \%(w/v) PEG 4000 |  | microcrystals |


| 44_PEGs_F4 |  | 0.2 M Magnesium nitrate |  | 20 \%(w/v) PEG 3350 |  | microcrystals |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 45_pHClear_C2 |  |  | 0.1 M Citric acid 5.0 | 5 \%(w/v) PEG 6000 |  | microcrystals |
| 45_pHClear_C7 |  |  | 0.1 M Citric acid 4.0 | $10 \%$ (w/v) PEG 6000 |  | microcrystals |
| 45_pHClear_D1 |  |  | 0.1 M Citric acid 4.0 | $20 \%$ (w/v) PEG 6000 |  | microcrystals |
| 52_Anions_F5 |  |  | 0.1 M HEPES pH 7.5 | 1.0 M Sodium succinate |  | microcrystals |
| 52_Anions_G5 |  |  | 0.1 M Sodium acetate pH 4.6 | 2.4 M Sodium thiocyanate |  | microcrystals |
| 52_Anions_G10 |  |  | 0.1 M MES pH 6.5 | 0.6 M K/Na tartrate |  | microcrystals |
| 53_Cations_E2 |  |  | 0.1 M Sodium acetate pH 4.6 | 1.1 M Calcium chloride |  | microcrystals |
| 53_Cations_F9 |  |  | 0.1 M TRIS. HCl pH 8.5 | 3.2 M Sodium chloride |  | microcrystals |
| 84_pHClearll_B5 |  | 1.0 M Lithium chloride | 0.1 M TRIS 8.0 | $20 \%$ (w/v) PEG 6000 |  | microcrystals |
| 84_pHClearll_G7 |  |  | 5.0 | 1.0 M Sodium malonate |  | microcrystals |
| 43_Classics_F8 | 0.2 M Magnesium acetate |  | 0.1 M Sodium cacodylate pH 6.5 | $20 \%$ (w/v) PEG 8000 |  | multiple crystals |
| 43_Classics_H6 | 0.2 M Sodium acetate |  | 0.1 M TRIS. HCl pH 8.5 | $30 \%$ (w/v) PEG 4000 |  | multiple crystals |
| 44_PEGs_C7 |  |  | 0.1 M MES pH 6.5 | 25 \%(w/v) PEG 3000 |  | multiple crystals |
| 44_PEGs_C8 |  |  | 0.1 M MES pH 6.5 | 25 \%(w/v) PEG 4000 |  | multiple crystals |
| 44_PEGs_E7 |  | 0.2 M Calcium chloride |  | $20 \%$ (w/v) PEG 3350 |  | multiple crystals |
| 44_PEGs_F12 |  | 0.2 M Lithium acetate |  | $20 \%$ (w/v) PEG 3350 |  | multiple crystals |
| 44_PEGs_G8 |  | 0.2 M Magnesium sulfate |  | 20 \%(w/v) PEG 3350 |  | multiple crystals |
| 44_PEGs_G11 |  | 0.2 M Ammonium sulfate |  | $20 \%$ (w/v) PEG 3350 |  | multiple crystals |
| 45_pHClear_E12 |  |  | 0.1 M BICINE 9.0 | 1.6 M Ammonium sulfate |  | multiple crystals |
| 52_Anions_B10 |  |  | 0.1 M TRIS. HCl pH 8.5 | 0.6 M tri-Sodium citrate |  | multiple crystals |
| 52_Anions_F1 |  |  | 0.1 M HEPES pH 7.5 | 3.5 M Sodium nitrate |  | multiple crystals |
| 53_Cations_H3 |  |  | 0.1 M HEPES pH 7.5 | 2.2 M Potassium chloride |  | multiple crystals |
| 52_Anions_B2 |  |  | 0.1 M HEPES pH 7.5 | 1.25 M Sodium acetate |  | mutiple crystals |
| 53_Cations_C4 |  |  | 0.1 M Sodium acetate pH 4.6 | 1.25 M Lithium acetate |  | single crystals |
| 53_Cations_C6 |  |  | 0.1 M Sodium acetate pH 4.6 | 1.0 M Magnesium acetate |  | single crystals |
| 43_Classics_E11 |  |  | 0.1 M HEPES sodium salt pH 7.5 | 1.5 M Lithium sulfate |  | small crystals |
| 43_Classics_F7 | 0.2 M Calcium acetate |  | 0.1 M Sodium cacodylate pH 6.5 | $18 \%$ (w/v) PEG 8000 |  | small crystals |
| 43_Classics_G8 |  |  |  | $10 \%$ (w/v) PEG 1000 | $10 \%$ (w/v) PEG 8000 | small crystals |
| 43_Classics_G11 | 0.2 M Ammonium sulfate |  | 0.1 M Sodium acetate pH 4.6 | $30 \%$ (w/v) PEG 2000 MME |  | small crystals |
| 44_PEGs_A2 |  |  | 0.1 M Sodium acetate pH 4.6 | $30 \%(\mathrm{v} / \mathrm{v})$ PEG 300 |  | small crystals |
| 44_PEGs_B6 |  |  | 0.1 M Sodium HEPES pH 7.5 | 25 \%(w/v) PEG 2000 MME |  | small crystals |
| 44_PEGs_G6 |  | 0.2 M Ammonium acetate |  | $20 \%(\mathrm{w} / \mathrm{v})$ PEG 3350 |  | small crystals |



Cryo D6 Grid Screen: crystallisation conditions of SCOC (78-159) variants

| well | ScOC ccd | SCOC ccd w/o Tag | SeMet SCOC ccd | Precipitant 1 | Glycerol | pH: MES 0.085 M | $\mathrm{KH}_{2} \mathrm{PO}_{4}$ | $\mathrm{NaH}_{2} \mathrm{PO}_{4}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D1 |  |  | big crystals | NaCl 1.3 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.386 | 0.085 M | 0.085 M |
| D3 |  | crystals | big crystals | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.386 | 0.085 M | 0.085 M |
| F3 | small crystals |  | big crystals | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |
| G1 |  | crystals | big crystals | $\mathrm{NaCl} \mathrm{1.3} \mathrm{M}$ | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| G2 | small crystals |  | big crystals | NaCl 1.364 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| G3 |  | big crystals | big crystals | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| H1 |  |  | big crystals | NaCl 1.3 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.9 | 0.085 M | 0.085 M |
| F1 | crystals | cluster | cluster | NaCl 1.3 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |
| D2 |  |  | crystals | NaCl 1.364 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.386 | 0.085 M | 0.085 M |
| B1 |  |  | microcrystals | NaCl 1.3 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.129 | 0.085 M | 0.085 M |
| B3 |  |  | microcrystals | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.129 | 0.085 M | 0.085 M |
| C1 |  | small crystals | microcrystals | $\mathrm{NaCl} \mathrm{1.3} \mathrm{M}$ | $15 \% \mathrm{v} / \mathrm{v}$ | 6.257 | 0.085 M | 0.085 M |
| G6 |  |  | microcrystals | NaCl 1.618 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| G7 |  |  | microcrystals | NaCl 1.682 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| E3 |  |  | multiple crystals | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.514 | 0.085 M | 0.085 M |
| H2 |  | microcrystals | multiple crystals | NaCl 1.364 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.9 | 0.085 M | 0.085 M |
| H3 |  |  | multiple crystals | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.9 | 0.085 M | 0.085 M |
| E2 |  |  | small crystals | NaCl 1.364 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.514 | 0.085 M | 0.085 M |
| G5 |  |  | small crystals | NaCl 1.555 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| C3 |  |  | spherulites | NaCl 1.427 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.257 | 0.085 M | 0.085 M |
| D4 |  |  | spherulites | NaCl 1.491 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.386 | 0.085 M | 0.085 M |
| D5 |  | crystals | spherulites | NaCl 1.555 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.386 | 0.085 M | 0.085 M |
| F2 | crystals |  | spherulites | NaCl 1.364 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |
| F4 | small crystals |  | spherulites | NaCl 1.491 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |
| F5 | small crystals |  | spherulites | NaCl 1.555 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |
| F6 |  |  | spherulites | NaCl 1.618 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |
| G4 | small crystals |  | spherulites | NaCl 1.491 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.771 | 0.085 M | 0.085 M |
| H4 |  |  | spherulites | NaCl 1.491 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.9 | 0.085 M | 0.085 M |
| F8 | small crystals |  |  | NaCl 1.745 M | $15 \% \mathrm{v} / \mathrm{v}$ | 6.643 | 0.085 M | 0.085 M |


| Cryo D6 Random Screen: crystallisation conditions of SCOC (78-159) |  |  |  |  |  | Salt 1 | Salt 2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| well | plate | crystal characteris | Buffer | Precipitant | Cryoprotectant |  |  |
| C5 | 87/1 | big crystals | MES 0.085 M 6.265 | NaCl 1.461 M |  | NaH2PO4 0.06122 M | KH2PO4 0.1714 M |
| C7 | 87/1 | big crystals | MES 0.085 M 7 | NaCl 1.494 M | Glycerol $14.29 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.04898 M | KH2PO4 0.1673 M |
| F8 | 87/1 | big crystals | MES 0.085 M 6.102 | NaCl 1.314 M | Glycerol 15.1 \%v/v | NaH2PO4 0.06122 M | KH2PO4 0.08163 M |
| B5 | 87/2 | big crystals | MES 0.085 M 6.898 | NaCl 1.706 M | Glycerol $19.59 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.08163 M | KH2PO4 0.09388 M |
| F5 | 87/2 | big crystals | MES 0.085 M 6.857 | NaCl 1.592 M |  | NaH2PO4 0.1878 M | KH2PO4 0.02041 M |
| G3 | 87/2 | big crystals | MES 0.085 M 6.449 | NaCl 1.771 M |  | NaH2PO4 0.01224 M | KH2PO4 0.1469 M |
| A6 | 87/1 | crystal | MES 0.085 M 6.878 | NaCl 1.755 M | Glycerol $11.02 \% \mathrm{~V} / \mathrm{v}$ |  | KH2PO4 0.1265 M |
| D10 | 87/1 | crystal | MES 0.085 M 6.755 | NaCl 1.837 M | Glycerol $6.939 \% \mathrm{v/v}$ |  | KH2PO4 0.1429 M |
| G5 | 87/1 | crystal | MES 0.085 M 6.857 | NaCl 1.69 M | Glycerol 12.24 \%//v | NaH2PO4 0.1755 M |  |
| E3 | 87/2 | crystal | MES 0.085 M 6.551 | NaCl 1.396 M | Glycerol $16.33 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.1959 M |  |
| G10 | 87/2 | crystal | MES 0.085 M 6.469 | NaCl 1.886 M |  |  | KH2PO4 0.1184 M |
| G2 | 87/2 | crystal | MES 0.085 M 6.673 | NaCl 1.69 M |  |  | KH2PO4 0.151 M |
| E5 | 87/1 | crystal clusters | MES 0.085 M 6.592 | NaCl 1.363 M | Glycerol 12.24 \% V/v | NaH2PO4 0.1878 M |  |
| E6 | 87/1 | crystal clusters |  | NaCl 1.853 M |  | NaH2PO4 0.05714 M |  |
| E7 | 87/1 | crystal clusters | MES 0.085 M 6.061 | NaCl 1.347 M |  | NaH2PO4 0.1714 M |  |
| E9 | 87/1 | crystal clusters | MES 0.085 M 6.796 | NaCl2 M |  | NaH2PO4 0.1143 M | KH2PO4 0.06939 M |
| H10 | 87/1 | crystal clusters | MES 0.085 M 6.612 | NaCl 1.412 M |  | NaH2PO4 0.1143 M | KH2PO4 0.1061 M |
| H11 | 87/1 | crystal clusters |  | NaCl 1.494 M |  |  | KH2PO4 0.0449 M |
| H4 | 87/1 | crystal clusters | MES 0.085 M 6.51 | NaCl 1.739 M |  | NaH2PO4 0.06531 M | KH2PO4 0.1224 M |
| D12 | 87/2 | crystal clusters |  |  | Glycerol $0.4082 \% \mathrm{~V} / \mathrm{v}$ |  | KH2PO4 0.0449 M |
| D8 | 87/2 | crystal clusters | MES 0.085 M 6.571 | NaCl 1.396 M |  | NaH2PO4 0.1673 M | KH2PO4 0.07347 M |
| E9 | 87/2 | crystal clusters | MES 0.085 M 6.082 | NaCl 1.314 M |  | NaH2PO4 0.09796 M | KH2PO4 0.1306 M |
| A8 | 87/1 | microcrystals | MES 0.085 M 6.714 | NaCl 1.918 M | Glycerol $16.73 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.1633 M | KH2PO4 0.02041 M |
| D9 | 87/1 | microcrystals | MES 0.085 M 6.673 | NaCl 1.869 M | Glycerol $2.449 \% \mathrm{~V} / \mathrm{v}$ |  | KH2PO4 0.1714 M |
| E8 | 87/1 | microcrystals | MES 0.085 M 6.388 | NaCl 1.461 M |  | NaH2PO4 0.1102 M | KH2PO4 0.1388 M |
| H7 | 87/2 | microcrystals | MES 0.085 M 6.388 | NaCl 1.82 M | Glycerol $5.714 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.1633 M |  |
| D7 | 87/1 | multiple crystals | MES 0.085 M 6.082 | NaCl 1.249 M | Glycerol $3.265 \% \mathrm{v} / \mathrm{v}$ |  | KH2PO4 0.1347 M |
| G12 | 87/1 | multiple crystals | MES 0.085 M 6.49 | NaCl 1.249 M |  | NaH2PO4 0.1959 M |  |
| A4 | 87/1 | spherulites | MES 0.085 M 6.816 | NaCl 1.82 M | Glycerol $15.92 \% \mathrm{~V} / \mathrm{v}$ |  | KH2PO4 0.1755 M |
| C3 | 87/1 | spherulites | MES 0.085 M 6.041 | NaCl 1.918 M |  | NaH2PO4 0.1265 M |  |
| D8 | 87/1 | spherulites | MES 0.085 M 6.51 | NaCl 1.984 M | Glycerol $12.65 \%$ V/v | NaH2PO4 0.04082 M | KH2PO4 0.1102 M |
| F4 | 87/1 | spherulites | MES 0.085 M 6.265 | NaCl 1.869 M | Glycerol $12.65 \% \mathrm{v/v}$ | NaH2PO4 0.08163 M | KH2PO4 0.08163 M |
| G1 | 87/1 | spherulites | MES 0.085 M 6.286 | NaCl 1.739 M | Glycerol $17.55 \%$ v/v | NaH2PO4 0.03673 M | KH2PO4 0.1061 M |
| G11 | 87/1 | spherulites | MES 0.085 M 6.347 | NaCl 1.641 M | Glycerol $13.47 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.1837 M |  |
| G8 | 87/1 | spherulites | MES 0.085 M 6.388 | NaCl 1.38 M | Glycerol $15.51 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.1633 M | KH2PO4 0.06939 M |
| C9 | 87/2 | spherulites | MES 0.085 M 6.694 | NaCl 1.2 M | Glycerol $19.18 \% \mathrm{~V} / \mathrm{v}$ | NaH2PO4 0.08571 M | KH2PO4 0.1714 M |
| D5 | 87/2 | spherulites | MES 0.085 M 6.653 | NaCl 1.804 M | Glycerol $16.73 \%$ v/v | NaH2PO4 0.1265 M | KH2PO4 0.06122 M |
| F1 | 87/2 | spherulites | MES 0.085 M 6.041 | NaCl 1.739 M | Glycerol $17.14 \% \mathrm{~V} / \mathrm{v}$ |  | KH2PO4 0.1061 M |
| F10 | 87/2 | spherulites | MES 0.085 M 6.082 | NaCl 1.673 M | Glycerol 0 \%v/v | NaH2PO4 0.1878 M |  |
| F6 | 87/2 | spherulites | MES 0.085 M 6.51 | NaCl 1.755 M |  | NaH2PO4 0.06531 M | KH2PO4 0.1878 M |
| F7 | 87/2 | spherulites | MES 0.085 M 6.592 | NaCl 1.837 M |  | $\mathrm{NaH2PO} 0.151 \mathrm{M}$ | KH2PO4 0.07347 M |

In situ proteolysis crystallization conditions of SCOC (78-159)

| plate_well | Protease | Native | precipitant | buffer | pH | salt | salt 2 | precipitant 2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 122_Cryo_D6 | TR 1:1000 | crystals | 1.7 M Sodium chloride | 0.085 M MES pH 6.5 | 6.5 | 0.085 M Sodium phosphate | 0.085 M Potassium phosphate | $15 \%$ (V/v) Glycerol |
| 122_Cryo_D7 | TR 1:1000 | crystals | 3.655 M Sodium chloride | 0.085 M HEPES PH 7.5 | 7.5 |  |  | $15 \%$ (V/v) Glycerol |
| 122_Cryo_D11 | TR 1:1000 | crystals | 1.4 M Sodium formate | 0.07 M Sodium acetate pH 4.6 | 4.6 |  |  | $30 \%$ (V/v) Glycerol |
| 122_Cryo_G11 | TR 1:1000 | crystals | $25.5 \%(\mathrm{w} / \mathrm{v})$ PEG 2000 MME | 0.085 M Sodium acetate pH 4.6 | 4.6 | 0.17 M Ammonium sulfate |  | $15 \%$ (V/v) Glycerol |
| 123_Classics_A6 | TR 1:1000 | crystals | $20 \%$ (V/V) Isopropanol | 0.1 M Sodium acetate pH 4.6 | 4.6 | 0.2 M Calcium chloride |  |  |
| 123_Classics_D6 | TR 1:1000 | crystals | 2.0 M Sodium chloride | 0.1 M MES pH 6.5 | 6.5 | 0.1 M Sodium phosphate | 0.1 M Potassium phosphate |  |
| 123_Classics_H1 | TR 1:1000 | crystals | $25 \%(\mathrm{~W} / \mathrm{l})$ PEG 4000 | 0.1 M Sodium acetate pH 4.6 | 4.6 | 0.2 M Ammonium sulfate |  |  |
| 123_Classics_H2 | TR 1:1000 | crystals | $30 \%(\mathrm{w} / \mathrm{l})$ PEG 4000 | 0.1 M Sodium acetate pH 4.6 | 4.6 | 0.2 M Ammonium acetate |  |  |
| 124_Salt_RX_D1 | TR 1:1000 | crystals | 2.5 M Ammonium nitrate | 0,1 M Sodium acetate | 4.6 |  |  |  |
| 124_Salt_RX_D4 | TR 1:1000 | crystals | 6.0 M Ammonium nitrate | 0.1 M Sodium acetate | 4.6 |  |  |  |
| 124_Salt_RX_D5 | TR 1:1000 | crystals | 6.0 M Ammonium nitrate | BIS-TRIS propane | 7.0 |  |  |  |
| 124_Salt_RX_D7 | TR 1:1000 | crystals | 1.5 M Sodium nitrate | 0.1 M Sodium acetate | 4.6 |  |  |  |
| 124_Salt_RX_G7 | TR 1:1000 | crystals | 0.7 Ammonium tartrate dibasic | 0.1 M Sodium acetate | 4.6 |  |  |  |
| 124_Salt_RX_H5 | TR 1:1000 | crystals | 0.5 M Potassium thiocyanate | 0,1 M Sodium acetate | 4.6 |  |  |  |
| 125_Cryo_B10 | SU 1:2000 | crystals | 59.5 \%(V/v) MPD | 0.085 M HEPES PH 7.5 | 7.5 |  |  | $15 \%$ (V/V) Glycerol |
| 125_Cryo_C6 | SU 1:2000 | crystals | 1.5 M Ammonium sulfate | 0.075 M TRIS. HCI pH 8.5 | 8.5 |  |  | $25 \%$ (V/V) Glycerol |
| 125_Cryo_D6 | SU 1:2000 | crystals | 1.7 M Sodium chloride | 0.085 M MES pH 6.5 | 6.5 | 0.085 M Sodium phosphate | 0.085 M Potassium phosphate | $15 \%$ (V/v) Glycerol |
| 125_Cryo_D11 | SU 1:2000 | crystals | 1.4 M Sodium formate | 0.07 M Sodium acetate pH 4.6 | 4.6 |  |  | $30 \%$ (V/v) Glycerol |
| 125_Cryo_D12 | SU 1:2000 | crystals | 3.6 M Sodium formate |  |  |  |  | $10 \%$ (V/V) Glycerol |
| 125_Cryo_E2 | SU 1:2000 | crystals | 1.36 M Ammonium sulfate | 0.085 M MES pH 6.5 | 6.5 |  | $8.5 \%$ (V/v) Dioxane | $15 \%$ (V/v) Glycerol |
| 125_Cryo_E5 | SU 1:2000 | crystals | 1.275 M Ammonium sulfate | 0.085 M TRIS pH 8.5 | 8.5 |  | 10.2 \%(v/v) Glycerol | $15 \%$ (V/v) Glycerol |
| 125_Cryo_F8 | SU 1:2000 | crystals | $16 \%(\mathrm{w} / \mathrm{l})$ PEG 8000 | 0.08 M Sodium cacodylate pH 6.5 | 6.5 | 0.16 M Magnesium acetate |  | $20 \%$ (V/v) Glycerol |
| 125_Cryo_F10 | SU 1:2000 | crystals | $25.5 \%$ (W/v) PEG 8000 | 0.085 M Sodium cacodylate pH 6.5 | 6.5 | 0.17 M Ammonium sulfate |  | $15 \%$ (V/V) Glycerol |
| 125_Cryo_G12 | SU 1:2000 | crystals | 5.6 \%(w/v) PEG 4000 | 0.07 M Sodium acetate pH 4.6 | 4.6 |  |  | $30 \%$ (V/v) Glycerol |
| 126_pHClear_A2 | TR 1:1000 | crystals | 1.0 M Sodium chloride | 0.1 M Citric acid | 5.0 |  |  |  |
| 127_Classics_A6 | SU 1:2000 | crystals | $20 \%(\mathrm{~V} / \mathrm{V})$ Isopropanol | 0.1 M Sodium acetate pH 4.6 | 4.6 | 0.2 M Calcium chloride |  |  |
| 127_Classics_D6 | SU 1:2000 | crystals | 2.0 M Sodium chloride | 0.1 M MES pH 6.5 | 6.5 | 0.1 M Sodium phosphate | 0.1 M Potassium phosphate |  |
| 127_Classics_H1 | SU 1:2000 | crystals | $25 \%(\mathrm{~W} / \mathrm{l})$ PEG 4000 | 0.1 M Sodium acetate pH 4.6 | 4.6 | 0.2 M Ammonium sulfate |  |  |
| 128_JCSG_D12 | SU 1:2000 | crystals | $16 \%$ (w/v) PEG 8000 |  |  |  | 0.04 M Potassium phosphate | $20 \%$ (V/V) Glycerol |
| 128_JCSG_H7 | SU 1:2000 | crystals | $25 \%(\mathrm{w} / \mathrm{l})$ PEG 3350 | 0.1 M BIS-TRIS pH 5.5 | 5.5 | 0.2 M Ammonium sulfate |  |  |
| 129_ComPas_E2 | SU 1:2000 | crystals | $10 \%$ (w/v) Isopropanol | 0.1 M Sodium acetate pH 4.6 | 4.6 |  | 0.2 M Calcium chloride |  |


| 129_ComPas_G9 | SU 1:2000 | crystals | 1.0 M Sodium formate | 0.1 M Sodium acetate pH 4.6 | 4.6 |  | 1.0 M Sodium formate |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 130_Classics_A1 | SU 1:2000 | crystals | 1.0 M 1,6-Hexanediol | 0.1 M Sodium acetate pH 4.6 | 4.6 | 1.0 M 1,6-Hexanediol | 0.01 M Cobalt chloride |  |
| 130_Classics_B3 | SU 1:2000 | crystals | 3.0 M Sodium chloride | 0.1 M MES | 6.0 |  |  |  |
| 130_Classics_B4 | SU 1:2000 | crystals | $30 \%$ (v/v) MPD | 0.1 M Sodium acetate pH 4.6 | 4.6 | $30 \%(\mathrm{v} / \mathrm{v}) \mathrm{MPD}$ | 0.2 M Sodium chloride |  |
| 128_JCSG_G12 | SU 1:2000 | crystals cluster | 3 M Sodium chloride | 0.1 M BIS-TRIS pH 5.5 | 5.5 |  |  |  |
| 122_Cryo_H2 | TR 1:1000 | crystals clusters | 25.5 \%(w/v) PEG 4000 | 0.085 M Sodium acetate pH 4.6 | 4.6 | 0.17 M Ammonium acetate |  | 15 \%(v/v) Glycerol |
| 122_Cryo_D5 | TR 1:1000 | microcrystals | 1.7 M Sodium chloride | 0.085 M Sodium acetate pH 4.6 | 4.6 |  |  | 15 \%(v/v) Glycerol |
| 124_Salt_RX_B1 | TR 1:1000 | microcrystals | 3.2 M Sodium chloride | 0,1 M BIS-TRIS propane | 7.0 |  |  |  |
| 124_Salt_RX_A11 | TR 1:1000 | microcrystals | 2.2 M Sodium chloride | 0,1 M Tris | 8.5 |  |  |  |
| 124_Salt_RX_F7 | TR 1:1000 | microcrystals | 0.8 M Lithium sulfate | 0,1 M Sodium acetate | 4.6 |  |  |  |
| 125_Cryo_C2 | SU 1:2000 | microcrystals | 0.7 M Ammonium phosphate | 0.07 M tri-Sodium citrate pH 5.6 | 5.6 |  |  | $30 \%$ (v/v) Glycerol |
| 125_Cryo_G1 | SU 1:2000 | microcrystals | 1.7 \%(v/v) PEG 400 | 0.085 M HEPES sodium salt pH 7.5 | 7.5 | 1.7 M Ammonium sulfate |  | 15 \%(v/v) Glycerol |
| 126_pHClear_A8 | TR 1:1000 | microcrystals | 2.0 M Sodium chloride | 0.1 M Citric acid | 5.0 |  |  |  |
| 126_pHClear_B3 | TR 1:1000 | microcrystals | 3.0 M Sodium chloride | 0.1 M MES | 6.0 |  |  |  |
| 126_pHClear_B9 | TR 1:1000 | microcrystals | 4.0 M Sodium chloride | 0.1 M MES | 6.0 |  |  |  |
| 127_Classics_C1 | SU 1:2000 | microcrystals | 0.4 M Ammonium phosphate |  |  |  |  |  |
| 127_Classics_C2 | SU 1:2000 | microcrystals | 1.0 M Ammonium phosphate | 0.1 M tri-Sodium citrate pH 5.6 | 5.6 |  |  |  |
| 128_JCSG_C3 | SU 1:2000 | microcrystals | $20 \%$ (W/v) PEG 3350 |  |  | 0.2 M Ammonium nitrate |  |  |
| 128_JCSG_H9 | SU 1:2000 | microcrystals | $25 \%$ (W/v) PEG 3350 | 0.1 M BIS-TRIS pH 5.5 | 5.5 | 0.2 M Lithium sulfate |  |  |
| 128_JCSG_D1 | SU 1:2000 | microcrystals | 24 \%(w/v) PEG 1500 |  |  |  |  | 20\% (w/v) Glycerol |
| 130_Classics_C6 | SU 1:2000 | microcrystals | 2.0 M Ammonium sulfate | 0.1 M TRIS.HCl pH 8.5 | 8.5 | 0.1 M TRIS.HCl pH 8.5 |  |  |
| 122_Cryo_E2 | TR 1:1000 | multiple crystals | 1.36 M Ammonium sulfate | 0.085 M MES pH 6.5 | 6.5 |  | 8.5 \%(v/v) Dioxane | 15 \%(v/v) Glycerol |
| 122_Cryo_H4 | TR 1:1000 | quasicrystalline | 24 \%(W/v) PEG 4000 | 0.08 M TRIS.HCI pH 8.5 | 8.5 | 0.16 M Magnesium chloride |  | 20 \%(v/v) Glycerol |
| 122_Cryo_H5 | TR 1:1000 | quasicrystalline | 25.5 \%(w/v) PEG 4000 | 0.085 M TRIS.HCI pH 8.5 | 8.5 | 0.17 M Lithium sulfate |  | 15 \%(v/v) Glycerol |
| 122_Cryo_H6 | TR 1:1000 | quasicrystalline | 25.5 \%(w/v) PEG 4000 | 0.085 M TRIS.HCI pH 8.5 | 8.5 | 0.17 M Sodium acetate |  | 15 \%(v/v) Glycerol |
| 122_Cryo_H8 | TR 1:1000 | quasicrystalline | 25.5 \%(w/v) PEG 5000 MME | 0.085 M MES pH 6.5 | 6.5 | 0.17 M Ammonium sulfate |  | $15 \%(\mathrm{v} / \mathrm{v})$ Glycerol |
| 122_Cryo_C8 | TR 1:1000 | spherulites | 1.36 M Ammonium sulfate | 0.085 M HEPES pH 7.5 | 7.5 | 0.085 M Sodium chloride |  | $15 \%(\mathrm{v} / \mathrm{v})$ Glycerol |
| 122_Cryo_E5 | TR 1:1000 | spherulites | 1.275 M Ammonium sulfate | 0.085 M TRIS pH 8.5 | 8.5 |  | 10.2 \%(v/v) Glycerol | 15 \%(v/v) Glycerol |
| 123_Classics_H10 | TR 1:1000 | spherulites | 2.0 M Sodium chloride |  |  | $10 \%(W / v)$ PEG 6000 |  |  |
| 124_Salt_RX_G10 | TR 1:1000 | spherulites | 1.0 Ammonium tartrate dibasic | 0.1 M Sodium acetate | 4.6 |  |  |  |
| 131_pHClear_B3 | SU 1:2000 | spherulites | 3.0 M Sodium chloride | 0.1 M MES | 6.0 |  |  |  |

## A. 3 Supplementary Figures

## A.3.1 Elution Profiles



Figure A.1: Elution profiles of SCOC-FEZ1 copurification
(A) Elution profile of StrepTrap chromatography (B) Elution profile of size exclusion chromatography

## A.3.2 Purification of SCOC ccd-FEZ1 ccd complexes

 (see next page)

Figure A.2: Schägger gels of copurifications of mutant SCOC ccd-FEZ1 ccd
(A) Schägger gel of SCOC N125V/N132L with FEZ1 (B) Schägger gel of SCOC E93L/K97V with FEZ1 (C) Schägger gel of SCOC R117E with FEZ1 (D) Schägger gel of SCOC R99E with FEZ1

## A. 4 Computational Methods

## A.4.1 COILS results

(see next page)

Coils output for unknown


NCOILS version 1.0
using MTIDK matrix
\# no weights
Input file is ../wwwtmp/.COILS.25785.6837.seq

| 1 M | d | 0.000 | d | 0.000 | d | 0.000 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2 R | e | 0.000 | e | 0.000 | e | 0.000 |
| 3 R | f | 0.000 | f | 0.000 | f | 0.000 |
| 4 R | g | 0.000 | g | 0.000 | 9 | 0.000 |
| 5 V | a | 0.000 | a | 0.000 | a | 0.000 |
| 6 F | b | 0.000 | b | 0.000 | b | 0.000 |
| 7 S | c | 0.000 | c | 0.000 | c | 0.000 |
| 8 S | d | 0.000 | d | 0.000 | d | 0.000 |
| 9 Q | e | 0.000 | e | 0.000 | e | 0.000 |
| 10 D | f | 0.000 | f | 0.000 | f | 0.000 |
| 11 W | g | 0.000 | g | 0.000 | g | 0.000 |
| 12 R | a | 0.000 | a | 0.000 | a | 0.000 |
| 13 A | b | 0.000 | b | 0.000 | b | 0.000 |
| 14 S | c | 0.000 | c | 0.000 | c | 0.000 |
| 15 G | c | 0.000 | c | 0.000 | c | 0.000 |
| 16 W | d | 0.000 | d | 0.000 | d | 0.000 |
| 17 D | e | 0.000 | e | 0.000 | e | 0.000 |
| 18 G | f | 0.000 | f | 0.000 | f | 0.000 |
| 19 M | g | 0.000 | 9 | 0.000 | 9 | 0.000 |
| 20 G | a | 0.000 | a | 0.000 | a | 0.000 |
| 21 F | b | 0.000 | b | 0.000 | b | 0.000 |
| 22 F | c | 0.000 | c | 0.000 | c | 0.000 |
| 23 S | f | 0.000 | f | 0.000 | f | 0.000 |
| 24 R | g | 0.000 | g | 0.000 | g | 0.000 |
| 25 R | a | 0.000 | a | 0.000 | a | 0.000 |
| 26 T | b | 0.000 | b | 0.000 | b | 0.000 |
| 27 F | c | 0.000 | c | 0.000 | c | 0.000 |
| 28 C | d | 0.000 | d | 0.000 | d | 0.000 |
| 29 G | e | 0.000 | e | 0.000 | e | 0.000 |
| 30 R | f | 0.000 | f | 0.000 | f | 0.000 |
| 31 S | g | 0.000 | g | 0.000 | g | 0.000 |


| 32 | G | a | 0.000 | a | 0.000 | a | 0.000 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 33 | R | b | 0.000 | b | 0.000 | b | 0.000 |
| 34 | S | c | 0.000 | c | 0.000 | c | 0.000 |
| 35 | C | d | 0.000 | d | 0.000 | d | 0.000 |
| 36 | R | e | 0.000 | e | 0.000 | e | 0.000 |
| 37 | G | f | 0.000 | f | 0.000 | f | 0.000 |
| 38 | Q | g | 0.000 | g | 0.000 | g | 0.000 |
| 39 | L | a | 0.000 | a | 0.000 | a | 0.000 |
| 40 | V | b | 0.000 | b | 0.000 | b | 0.000 |
| 41 | Q | c | 0.000 | c | 0.000 | c | 0.000 |
| 42 | V | d | 0.000 | d | 0.000 | d | 0.000 |
| 43 | S | e | 0.000 | e | 0.000 | e | 0.000 |
| 44 | R | f | 0.000 | f | 0.000 | f | 0.000 |
| 45 | P | b | 0.000 | b | 0.000 | b | 0.000 |
| 46 | E | c | 0.000 | c | 0.000 | c | 0.000 |
| 47 | V | d | 0.000 | d | 0.000 | d | 0.000 |
| 48 | S | e | 0.000 | e | 0.000 | e | 0.000 |
| 49 | A | f | 0.000 | f | 0.000 | f | 0.000 |
| 50 | G | b | 0.000 | b | 0.000 | b | 0.000 |
| 51 | S | c | 0.000 | c | 0.000 | c | 0.000 |
| 52 | L | d | 0.000 | d | 0.000 | d | 0.000 |
| 53 | L | e | 0.000 | e | 0.000 | e | 0.000 |
| 54 | L | f | 0.000 | f | 0.000 | f | 0.000 |
| 55 | P | g | 0.000 | g | 0.000 | g | 0.000 |
| 56 | A | a | 0.000 | a | 0.000 | a | 0.000 |
| 57 | P | b | 0.000 | b | 0.000 | b | 0.000 |
| 58 | Q | c | 0.000 | c | 0.000 | c | 0.000 |
| 59 | A | d | 0.000 | d | 0.000 | d | 0.000 |
| 60 | E | e | 0.000 | e | 0.000 | e | 0.000 |
| 61 | D | f | 0.000 | f | 0.000 | f | 0.000 |
| 62 | H | g | 0.000 | g | 0.000 | g | 0.000 |
| 63 | S | a | 0.000 | a | 0.000 | a | 0.000 |
| 64 | S | b | 0.000 | b | 0.000 | b | 0.000 |
| 65 | R | c | 0.000 | c | 0.000 | c | 0.000 |
| 66 | I | d | 0.000 | d | 0.000 | d | 0.000 |
| 67 | L | e | 0.000 | e | 0.000 | e | 0.000 |
| 68 | Y | a | 0.000 | a | 0.000 | a | 0.000 |
| 69 | P | b | 0.000 | b | 0.000 | b | 0.000 |
| 70 | R | c | 0.000 | c | 0.000 | c | 0.000 |
| 71 | P | d | 0.000 | d | 0.000 | d | 0.000 |
| 72 | K | e | 0.000 | e | 0.002 | e | 0.003 |
| 73 | S | f | 0.000 | f | 0.003 | f | 0.003 |
| 74 | L | g | 0.000 | g | 0.003 | g | 0.003 |
| 75 | L | a | 0.000 | a | 0.003 | a | 0.003 |
| 76 | P | f | 0.000 | f | 0.003 | f | 0.003 |
| 77 | K | g | 0.084 | g | 0.657 | g | 0.351 |
| 78 | M | a | 0.110 | a | 0.657 | a | 0.351 |
| 79 | M | b | 0.110 | b | 0.657 | b | 0.351 |
| 80 | N | c | 0.434 | c | 0.657 | c | 0.612 |
| 81 | A | d | 0.434 | d | 0.657 | d | 0.745 |
| 82 | D | e | 0.434 | e | 0.657 | e | 0.745 |
| 83 | M | f | 0.434 | f | 0.657 | f | 0.745 |
| 84 | D | g | 0.610 | g | 0.657 | g | 0.745 |
| 85 | A | a | 0.610 | a | 0.657 | a | 0.745 |
| 86 | V | b | 0.610 | b | 0.657 | b | 0.745 |
| 87 | D | c | 0.610 | c | 0.657 | c | 0.956 |
| 88 | A | d | 0.610 | d | 0.657 | d | 0.961 |
| 89 | E | e | 0.610 | e | 0.657 | e | 0.961 |
| 90 | N | f | 0.610 | f | 0.657 | f | 0.961 |
| 91 | Q | g | 0.610 | g | 0.657 | g | 0.961 |
| 92 | V | a | 0.610 | a | 0.657 | a | 0.961 |
| 93 | E | b | 0.610 | b | 0.680 | b | 0.982 |
| 94 | L | c | 0.610 | c | 0.953 | c | 0.985 |
| 95 | E | f | 0.690 | f | 0.973 | f | 0.998 |
| 96 | E | g | 0.690 | g | 0.973 | g | 0.998 |
| 97 | K | a | 0.690 | a | 0.973 | a | 0.998 |
| 98 | T | b | 0.690 | b | 0.973 | b | 0.998 |
| 99 | R | c | 0.690 | c | 0.975 | c | 0.998 |
| 100 | L | d | 0.690 | d | 0.975 | d | 0.998 |
| 101 | I | e | 0.690 | e | 0.975 | e | 0.998 |
| 102 | N | f | 0.748 | f | 0.975 | f | 1.000 |
| 103 | Q | g | 0.748 | g | 0.975 | g | 1.000 |
| 104 | V | a | 0.748 | a | 0.982 | a | 1.000 |
| 105 | L | b | 0.748 | b | 0.982 | b | 1.000 |
| 106 | E | c | 0.943 | c | 0.982 | c | 1.000 |
| 107 | L | d | 0.943 | d | 0.982 | d | 1.000 |
| 108 | Q | e | 0.943 | e | 0.982 | e | 1.000 |
| 109 | H | f | 0.943 | f | 0.982 | f | 1.000 |


| 110 T | g | 0.943 | 9 | 0.982 | 9 | 1.000 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 111 L | a | 0.968 | a | 0.996 | a | 1.000 |
| 112 E | b | 0.968 | b | 0.996 | b | 1.000 |
| 113 D | c | 0.968 | c | 0.996 | c | 1.000 |
| 114 L | d | 0.968 | d | 0.996 | d | 1.000 |
| 115 S | e | 0.968 | e | 0.996 | e | 1.000 |
| 116 A | f | 0.968 | f | 0.996 | f | 1.000 |
| 117 R | g | 0.968 | g | 0.996 | g | 1.000 |
| 118 V | a | 0.968 | a | 0.996 | a | 1.000 |
| 119 D | b | 0.968 | b | 0.996 | b | 1.000 |
| 120 A | c | 0.968 | c | 0.996 | c | 1.000 |
| 121 V | d | 0.968 | d | 0.996 | d | 1.000 |
| 122 K | e | 0.968 | e | 0.996 | e | 1.000 |
| 123 E | f | 0.968 | f | 0.996 | f | 1.000 |
| 124 E | g | 0.968 | g | 0.996 | g | 1.000 |
| 125 N | a | 0.871 | a | 0.996 | a | 1.000 |
| 126 L | b | 0.628 | b | 0.996 | b | 1.000 |
| 127 K | c | 0.628 | c | 0.996 | c | 1.000 |
| 128 L | d | 0.628 | d | 0.996 | d | 1.000 |
| 129 K | e | 0.628 | e | 0.996 | e | 1.000 |
| 130 S | f | 0.628 | f | 0.996 | f | 1.000 |
| 131 E | g | 0.628 | g | 0.996 | g | 1.000 |
| 132 N | a | 0.628 | a | 0.982 | a | 1.000 |
| 133 Q | b | 0.628 | b | 0.967 | b | 1.000 |
| 134 V | c | 0.628 | c | 0.758 | c | 0.998 |
| 135 L | d | 0.628 | d | 0.758 | d | 0.998 |
| 136 G | e | 0.050 | e | 0.482 | e | 0.982 |
| 137 Q | f | 0.038 | f | 0.482 | f | 0.982 |
| 138 Y | g | 0.027 | g | 0.482 | 9 | 0.731 |
| 139 I | a | 0.027 | a | 0.482 | a | 0.731 |
| 140 E | b | 0.027 | b | 0.482 | b | 0.731 |
| 141 N | c | 0.027 | c | 0.482 | c | 0.731 |
| 142 L | d | 0.027 | d | 0.482 | d | 0.731 |
| 143 M | b | 0.012 | b | 0.163 | b | 0.677 |
| 144 S | c | 0.012 | c | 0.044 | c | 0.529 |
| 145 A | d | 0.012 | d | 0.042 | d | 0.303 |
| 146 S | e | 0.005 | e | 0.028 | e | 0.148 |
| 147 S | f | 0.004 | f | 0.028 | f | 0.069 |
| 148 V | g | 0.004 | 9 | 0.005 | g | 0.023 |
| 149 F | a | 0.004 | a | 0.001 | a | 0.007 |
| 150 Q | b | 0.004 | b | 0.001 | b | 0.007 |
| 151 T | f | 0.001 | f | 0.001 | f | 0.001 |
| 152 T | g | 0.001 | 9 | 0.001 | 9 | 0.001 |
| 153 D | e | 0.001 | e | 0.000 | e | 0.000 |
| 154 T | f | 0.000 | f | 0.000 | f | 0.000 |
| 155 K | g | 0.000 | 9 | 0.000 | g | 0.000 |
| 156 S | a | 0.000 | a | 0.000 | a | 0.000 |
| 157 K | b | 0.000 | b | 0.000 | b | 0.000 |
| 158 R | c | 0.000 | c | 0.000 | C | 0.000 |
| 159 K | d | 0.000 | d | 0.000 | d | 0.000 |

## A.4.2 HHpred results

(see next page)
HMM


窑

 0
$\stackrel{0}{0}$
0
0
0
 へ

 0
$\stackrel{y}{4}$
0

 $\stackrel{0}{3}$




$\stackrel{\circ}{0}$














[^1]
## A.4.3 XDS input file

```
! Settings for PILATUS6M @ SLS generated by GO.COM
! job control
JOB= ALL
!JOB=XYCORR INIT COLSPOT IDXREF DEFPIX INTEGRATE CORRECT
MAXIMUM_NUMBER_OF_JOBS=4
MAXIMUM NUMBER OF PROCESSORS=12
!MINUTE=0 !how long to wait (minutes), inplies only one JOBS
! for this experiment:
ORGX= 1252
ORGY= 1238
DETECTOR_DISTANCE= 520.19
OSCILLATION_RANGE= 0.5
X-RAY WAVELENGTH= 0.97936
NAME_\overline{TEMPLATE_OF_DATA_FRAMES=../../dts6_8_?????.cbf CBF}
DATA_RANGE= 1 360
SPOT_RANGE= 1 29
BACK\overline{GROUND RANGE= 19}
SPACE_GROUP_NUMBER=20
UNIT CELL CONSTANTS=70.99 114.8 93.27 90 90 90
! REI\overline{D}X= -0
REFINE(IDXREF)=BEAM AXIS ORIENTATION CELL !DISTANCE
REFINE(INTEGRATE)=DISTANCE BEAM ORIENTATION CELL !AXIS
REFINE(CORRECT)=DISTANCE BEAM ORIENTATION CELL AXIS
FRIEDEL'S_LAW=FALSE
STRICT_ABSORPTION_CORRECTION=FALSE ! but read Tips_and_Tricks in XDSwiki
! parameters with changes wrt default values:
TRUSTED_REGION=0.00 1.15
VALUE RANGE FOR_TRUSTED_DETECTOR_PIXELS=8000. 30000.
!MINIMUM ZETA=0.05
CORRECTIONS=DECAY MODULATION ABSORP !default value
INCLUDE_RESOLUTION_RANGE=50 2.7
STRONG_P
! parameters specifically for this detector and beamline:
DETECTOR=PILATUS NX=2463 NY=2527 QX=0.172 QY=0.172 !PILATUS 6M
MINIMUM_VALID_PIXEL_VALUE=0 OVERLOAD=1048500
DIRECTION OF DETECTO
DIRECTION OF DETECTOR Y-AXIS=0 1 0
INCIDENT_\overline{BEAM}_DIRECTION=0 0 1
ROTATION AXIS=1 0 0
FRACTION_OF_POLARIZATION=0.99
POLARIZATION
SENSOR THICKNESS=0.32
!UNTRUSTED_RECTANGLE= 487 495 1 2527
!UNTRUSTED_RECTANGLE= 981 989 1 2527
!UNTRUSTED_RECTANGLE=1475 1483 1 2527
!UNTRUSTED_RECTANGLE=1969 1977 1 2527
!UNTRUSTED RECTANGLE= 1 2463 195 213
!UNTRUSTED_RECTANGLE= 1 2463 407 425
!UNTRUSTED RECTANGLE= 1 2463 619 637
!UNTRUSTED_RECTANGLE= 12463 831 849
!UNTRUSTED_RECTANGLE= 1 2463 1043 1061
!UNTRUSTED_RECTANGLE= 1 2463 1255 1273
!UNTRUSTED_RECTANGLE= 1 2463 1467 1485
!UNTRUSTED RECTANGLE= 1 2463 1679 1697
```



```
!UNTRUSTED RECTANGLE= 1 2463 2103 2121
!UNTRUSTED_RECTANGLE= 1 2463 2315 2333
NUMBER_OF_PROFILE_GRID_POINTS_ALONG_ALPHA/BETA=13 !used by: INTEGRATE
```


## A.4.4 Systematic absences by CORRECT.LP

(see next page)
STATISTICS OF SAVED DATA SET "XDS_ASCII.HKL" (DATA_RANGE= 11360 )
FILE TYPE: XDSASCII MERGE=FALSE - FRIEDEL'S LAW=FALSE

REFLECTIONS OF TYPE $\mathrm{H}, 0,0$ 0, $\mathrm{K}, 0$ 0,0,L OR EXPECTED TO BE ABSENT (*)




AVERAGE INTENSITY FOR 31 REFLECTIONS WHICH SHOULD
BE SYSTEMATICALLY ABSENT IS $00.1 \%$ OF MEAN INTENSITY

## COMPLETENESS AND QUALITY OF DATA SET

[^2]COMPARED
I/SIGMA
Sigma(I)
number of reflections used for calculating R-FACTOR
mean of intensity/Sigma(I) of unique reflections (after merging symmetry-related observations) $\begin{aligned}= & \text { standard deviation of reflection intensity I } \\ & \text { estimated from sample statistics }\end{aligned}$
redundancy independent R -factor (intensities)

## R-meas

= percentage of correlation between intensities from
andom half-datasets. Correlation signif
"
Karplus \& Diederichs (2012), Science 336, 1030-33

CC (1/2)

Anomal = percentage of correlation between random half-sets
Anomal
Corr
SigAno
Nano

Number of unique reflections used to calculate
Anomal_Corr \& SigAno. At least two observations
for each (+ and -) parity are required.

$$
\begin{aligned}
& \text { Friedel pairs are treated as diffe } \\
& \text { Fried }
\end{aligned}
$$

## NOTE: Friedel pairs are treated as different reflections.

$\begin{array}{llllllll}\text { OBSET OF INTENSITY DATA WITH SIGNAL/NOISE }>=-3.0 \text { AS FUNCTION OF RESOLUTION } \\ \text { RESOLUTION } & \text { NUMBER OF REFLECTIONS COMPLETENESS R-FACTOR R-FACTOR COMPARE }\end{array}$

| SOLUTION | NUMBER | OF REFLE | ECTIONS | COMPLETENESS | R-FACTOR | R-FACTOR | COMPARED | I / SIGMA |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| IMIT | OBSERVED | UNIQUE | POSSIBLE | OF DATA | observed | expected |  |  |
| 8.01 | 2582 | 764 | 779 | 98.1\% | 2. $7 \%$ | 3.0\% | 2576 | 37.44 |
| 5.70 | 4645 | 1369 | 1377 | 99.4\% | 3.9\% | 3.9\% | 4635 | 24.54 |
| 4.67 | 6184 | 1757 | 1769 | 99.3\% | $4.0 \%$ | 3.9\% | 6167 | 25.58 |
| 4.05 | 7137 | 2078 | 2097 | $99.1 \%$ | 4.0\% | 4.0\% | 7103 | 25.74 |
| 3.62 | 8293 | 2370 | 2379 | 99.6\% | $5.4 \%$ | 5.5\% | 8275 | 19.65 |
| 3.31 | 8870 | 2614 | 2624 | 99.6\% | 8.7\% | 9.2\% | 8821 | 12.47 |
| 3.06 | 10159 | 2830 | 2838 | 99.7\% | 15.8\% | $17.2 \%$ | 10123 | 7.71 |
| 2.87 | 10666 | 3065 | 3072 | 99.8\% | $23.9 \%$ | $25.8 \%$ | 10607 | 5.30 |
| 2.70 | 10768 | 3200 | 3251 | 98.4\% | 45.9\% | $48.9 \%$ | 10652 | 2.78 |
| total | 69304 | 20047 | 20186 | 99.3\% | 5.7\% | $6.0 \%$ | 68959 | 14.30 |

70473
1138 31
69304
20047

NUMBER OF REFLECTIONS IN SELECTED SUBSET OF IMAGES NUMBER OF REJECTED MISFITS NUMBER OF SYSTEMATIC ABSENT REFLECTIONS NUMBER OF ACCEPTED OBSERVATIONS

## A.4.5 List of Se positions by Phenix

| CRYST1 | 70.984 | 114 | . 75 |  | 93.27390 .0 | 0090.0 | 90.00 | C 22 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HETATM | 1 SE | SE | Z | 1 | 18.124 | -8.556 | -68.382 | 1.33 | 24.22 | SE |
| HETATM | 2 SE | SE | Z | 2 | 29.566 | -46.380 | -18.613 | 0.78 | 24.98 | SE |
| HETATM | 3 SE | SE | Z | 3 | 31.938 | -5.731 | -64.424 | 0.81 | 24.88 | SE |
| HETATM | 4 SE | SE | Z | 4 | 22.513 | -18.294 | -9.542 | 0.18 | 20.19 | SE |
| HETATM | 5 SE | SE | Z | 5 | 25.560 | -30.104 | -36.916 | 0.15 | 20.41 | SE |
| HETATM | 6 SE | SE | Z | 6 | 34.482 | 12.241 | -63.311 | 0.15 | 20.13 | SE |
| HETATM | 7 SE | SE | Z | 7 | 9.465 | -14.196 | -38.506 | 0.23 | 20.64 | SE |
| HETATM | 8 SE | SE | Z | 8 | 31.491 | -0.764 | -16.316 | 0.20 | 20.50 | SE |
| HETATM | 9 SE | SE | Z | 9 | 19.459 | -14.048 | -15.544 | 0.22 | 20.06 | SE |
| HETATM | 10 SE | SE | Z | 10 | 18.011 | 6.285 | -28.540 | 0.21 | 21.05 | SE |
| TER |  |  |  |  |  |  |  |  |  |  |
| END |  |  |  |  |  |  |  |  |  |  |

## A.4.6 T-COFFEE alignment across species

(see next page)



## A. 5 Mass spectrometry results

(see next page)


## Bibliography

1. Clark, S. L. "Cellular Differentiation In the Kidneys of Newborn Mice Studied With the Electron Microscope". Journal of Biophysical and Biochemical Cytology 3, 349 (1957) (cit. on p. 1).
2. Novikoff, A. B. "The Proximal Tubule Cell In Experimental Hydronephrosis". Journal of Biophysical and Biochemical Cytology 6, 136 (1959) (cit. on p. 1).
3. Ashford, T. P. \& Porter, K. R. "Cytoplasmic Components In Hepatic Cell Lysosomes". Journal of Cell Biology 12, 198 (1962) (cit. on p. 1).
4. Deduve, C. \& Wattiaux, R. "Functions of Lysosomes". Annual Review of Physiology 28, 435 (1966) (cit. on p. 1).
5. Tsukada, M. \& Ohsumi, Y. "Isolation and Characterization of Autophagydefective Mutants of Saccharomyces-cerevisiae". FEBS Letters 333, 169-174 (1993) (cit. on p. 1).
6. Titorenko, V. I., Keizer, I., Harder, W. \& Veenhuis, M. "Isolation and Characterization of Mutants Impaired In the Selective Degradation of Peroxisomes In the Yeast Hansenula-polymorpha". Journal of Bacteriology 177, 357-363 (1995) (cit. on p. 1).
7. Harding, T. M., Morano, K. A., Scott, S. V. \& Klionsky, D. J. "Isolation and Characterization of Yeast Mutants In the Cytoplasm To Vacuole Protein Targeting Pathway". Journal of Cell Biology 131, 591-602 (1995) (cit. on p. 1).
8. Thumm, M. et al. "Isolation of Autophagocytosis Mutants of Saccharomycescerevisiae". FEBS Letters 349, 275-280 (1994) (cit. on p. 1).
9. Motley, A. M., Nuttall, J. M. \& Hettema, E. H. "Pex3-anchored Atg36 tags peroxisomes for degradation in Saccharomyces cerevisiae". The EMBO Journal 31, 2852-2868 (2012) (cit. on pp. 1, 2).
10. Mizushima, N., Yoshimori, T. \& Ohsumi, Y. "The Role of Atg Proteins in Autophagosome Formation". Annual Review of Cell and Developmental Biology 27, 107-132 (2011) (cit. on pp. 1, 3).
11. Kraft, C. \& Martens, S. "Mechanisms and regulation of autophagosome formation". Current Opinion in Cell Biology 24, 496-501 (2012) (cit. on pp. 2, 4).
12. Yang, Z. \& Klionsky, D. J. "Mammalian autophagy: core molecular machinery and signaling regulation". Current Opinion in Cell Biology 22, 124-131 (2010) (cit. on pp. 1, 2, 4, 6).
13. Mizushima, N., Levine, B., Cuervo, A. M. \& Klionsky, D. J. "Autophagy fights disease through cellular self-digestion". Nature 451, 1069-1075 (2008) (cit. on p. 2).
14. Rambold, A. S. \& Lippincott-Schwartz, J. "Mechanisms of mitochondria and autophagy crosstalk". Cell Cycle 10, 4032-4038 (2011) (cit. on p. 2).
15. Kraft, C., Deplazes, A., Sohrmann, M. \& Peter, M. "Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease". Nature Cell Biology 10, 602-610 (2008) (cit. on p. 2).
16. Hutchins, M. U. \& Klionsky, D. J. "Vacuolar localization of oligomeric alphamannosidase requires the cytoplasm to vacuole targeting and autophagy pathway components in Saccharomyces cerevisiae". Journal of Biological Chemistry 276, 20491-20498 (2001) (cit. on p. 2).
17. Behrends, C. \& Fulda, S. "Receptor proteins in selective autophagy." International Journal of Cell Biology 2012, 673290 (2012) (cit. on p. 2).
18. Arias, E. \& Cuervo, A. M. "Chaperone-mediated autophagy in protein quality control". Current Opinion in Cell Biology 23, 184-189 (2011) (cit. on p. 4).
19. Li, W.-w., Li, J. \& Bao, J.-k. "Microautophagy: lesser-known self-eating". Cellular and Molecular Life Sciences 69, 1125-1136 (2012) (cit. on p. 4).
20. Rubinsztein, D. C., Shpilka, T. \& Elazar, Z. "Mechanisms of Autophagosome Biogenesis". Current Biology 22, R29-R34 (2012) (cit. on p. 4).
21. Longatti, A. \& Tooze, S. A. "Vesicular trafficking and autophagosome formation". Cell Death and Differentiation 16, 956-965 (2009) (cit. on p. 4).
22. Tooze, S. A. \& Yoshimori, T. "The origin of the autophagosomal membrane". Nature Cell Biology 12, 831-835 (2010) (cit. on p. 4).
23. Hayashi-Nishino, M. et al. "A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation". Nature Cell Biology 11, 1433 (2009) (cit. on p. 4).
24. Yla-Anttila, P., Vihinen, H., Jokita, E. \& Eskelinen, E.-L. "3D tomography reveals connections between the phagophore and endoplasmic reticulum". $A u$ tophagy 5, 1180-1185 (2009) (cit. on p. 4).
25. Axe, E. L. et al. "Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3 -phosphate and dynamically connected to the endoplasmic reticulum". Journal of Cell Biology 182, 685-701 (2008) (cit. on p. 4).
26. Hailey, D. W. et al. "Mitochondria Supply Membranes for Autophagosome Biogenesis during Starvation". Cell 141, 656-667 (2010) (cit. on p. 4).
27. Ohashi, Y. \& Munro, S. "Membrane Delivery to the Yeast Autophagosome from the Golgi-Endosomal System". Molecular Biology of the Cell 21, 39984008 (2010) (cit. on p. 4).
28. Ravikumar, B., Moreau, K., Jahreiss, L., Puri, C. \& Rubinsztein, D. C. "Plasma membrane contributes to the formation of pre-autophagosomal structures". Nature Cell Biology 12, 747 (2010) (cit. on p. 4).
29. Weidberg, H., Shvets, E. \& Elazar, Z. "Biogenesis and Cargo Selectivity of Autophagosomes". Annual Review of Biochemistry, Vol 80 80, 125-156 (2011) (cit. on pp. 5, 6).
30. Itakura, E., Kishi, C., Inoue, K. \& Mizushima, N. "Beclin 1 Forms Two Distinct Phosphatidylinositol 3-Kinase Complexes with Mammalian Atg14 and UVRAG". Molecular Biology of the Cell 19, 5360-5372 (2008) (cit. on p. 4).
31. Matsunaga, K. et al. "Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages". Nature Cell Biology 11, 385 (2009) (cit. on p. 4).
32. Zhong, Y. et al. "Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex". Nature Cell Biology 11, 468 (2009) (cit. on p. 4).
33. Takahashi, Y. et al. "Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis". Nature Cell Biology 9, 1142-1151 (2007) (cit. on p. 4).
34. Liang, C. et al. "Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking". Nature Cell Biology 10, 776-787 (2008) (cit. on p. 4).
35. McKnight, N. C. et al. "Genome-wide siRNA screen reveals amino acid star-vation-induced autophagy requires SCOC and WAC". The EMBO Journal 31, 1931-1946 (2012) (cit. on pp. 6, 7, 9, 99, 111-114).
36. Van Valkenburgh, H., Shern, J. F., Sharer, J. D., Zhu, X. J. \& Kahn, R. A. "ADP-ribosylation factors (ARFs) and ARF-like 1 (ARL1) have both specific and shared effectors: Characterizing ARL1-binding proteins". Journal of Biological Chemistry 276, 22826-22837 (2001) (cit. on pp. 7, 8, 104, 107, 114).
37. $\mathrm{Su}, \mathrm{C} .-\mathrm{W}$. et al. "The short coiled-coil domain-containing protein UNC-69 cooperates with UNC-76 to regulate axonal outgrowth and normal presynaptic organization in Caenorhabditis elegans." Journal of Biology 5, 9 (2006) (cit. on pp. 7, 9, 89, 111).
38. Panic, B., Whyte, J. R. C. \& Munro, S. "The ARF-like GTPases Arl1p and Arl3p act in a pathway that interacts with vesicle-tethering factors at the Golgi apparatus". Current Biology 13, 405-410 (2003) (cit. on p. 7).
39. Panic, B., Perisic, O., Veprintsev, D. B., Williams, R. L. \& Munro, S. "Structural basis for Arl1-dependent targeting of homodimeric GRIP domains to the Golgi apparatus". Molecular Cell 12, 863-874 (2003) (cit. on pp. 7, 8, 104).
40. Chen, K.-Y., Tsai, P.-C., Liu, Y.-W. \& Lee, F.-J. S. "Competition between the golgin Imh1p and the GAP Gcs1p stabilizes activated Arl1p at the lateGolgi". Journal of Cell Science 125, 4586-4596 (2012) (cit. on p. 7).
41. Christis, C. \& Munro, S. "The small G protein Arl1 directs the trans-Golgispecific targeting of the Arf1 exchange factors BIG1 and BIG2". Journal of Cell Biology 196, 327-335 (2012) (cit. on p. 7).
42. Wu, M. S., Lu, L., Hong, W. J. \& Song, H. W. "Structural basis for recruitment of GRIP domain golgin-245 by small GTPase Arl1". Nature Structural छ Molecular Biology 11, 86-94 (2004) (cit. on pp. 8, 104).
43. Nakamura, K. et al. "Structural Basis for Membrane Binding Specificity of the Bin/Amphiphysin/Rvs (BAR) Domain of Arfaptin-2 Determined by Arl1 GTPase". Journal of Biological Chemistry 287, 25478-25489 (2012) (cit. on p. 8).
44. Assmann, E. M., Alborghetti, M. R., Camargo, M. E. R. \& Kobarg, J. "FEZ1 dimerization and interaction with transcription regulatory proteins involves its coiled-coil region". Journal of Biological Chemistry 281, 9869-9881 (2006) (cit. on pp. 8, 9, 102, 111).
45. Lanza, D. C. F. et al. "Human FEZ1 has characteristics of a natively unfolded protein and dimerizes in solution". Proteins-structure Function and Bioinformatics 74, 104-121 (2009) (cit. on pp. 9, 99, 102).
46. Blasius, T. L., Cai, D., Jih, G. T., Toret, C. P. \& Verhey, K. J. "Two binding partners cooperate to activate the molecular motor Kinesin-1". Journal of Cell Biology 176, 11-17 (2007) (cit. on p. 9).
47. Gindhart, J. G. et al. "The kinesin-associated protein UNC-76 is required for axonal transport in the Drosophila nervous system". Molecular Biology of the Cell 14, 3356-3365 (2003) (cit. on p. 9).
48. Chua, J. J. E. et al. "Phosphorylation-regulated axonal dependent transport of syntaxin 1 is mediated by a Kinesin-1 adapter". Proceedings of the National Academy of Sciences of the United States of America 109, 5862-5867 (2012) (cit. on pp. 9, 112).
49. Toda, H. et al. "UNC-51/ATG1 kinase regulates axonal transport by mediating motor-cargo assembly". Genes $\mathcal{F}$ Development 22, 3292-3307 (2008) (cit. on p. 9).
50. Bloom, L. \& Horvitz, H. R. "The Caenorhabditis elegans gene unc-76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation". Proceedings of the National Academy of Sciences of the United States of America 94, 3414-3419 (1997) (cit. on p. 9).
51. Mochizuki, H. et al. "Unc-51/ATG1 Controls Axonal and Dendritic Development via Kinesin-Mediated Vesicle Transport in the Drosophila Brain". PLoS ONE 6, e19632 (2011) (cit. on p. 9).
52. Rackham, O. J. L. et al. "The Evolution and Structure Prediction of Coiled Coils across All Genomes". Journal of Molecular Biology 403, 480-493 (2010) (cit. on p. 10).
53. Wang, Y. et al. "Coiled-coil networking shapes cell molecular machinery". Molecular Biology of the Cell 23, 3911-3922 (2012) (cit. on p. 10).
54. Lupas, A. N. \& Gruber, M. "The structure of alpha-helical coiled coils". Fibrous Proteins: Coiled-coils, Collagen and Elastomers 70, 37 (2005) (cit. on p. 10).
55. Woolfson, D. N. "The design of coiled-coil structures and assemblies". Fibrous Proteins: Coiled-coils, Collagen and Elastomers 70, 79 (2005) (cit. on pp. 10, 110).
56. Grigoryan, G. \& Keating, A. E. "Structural specificity in coiled-coil interactions". Current Opinion in Structural Biology 18, 477-483 (2008) (cit. on p. 10).
57. Mason, J. M. \& Arndt, K. M. "Coiled coil domains: Stability, specificity, and biological implications". Chembiochem 5, Boehringer Ingelheim Fonds (2004) (cit. on p. 10).
58. Gruber, M., Soeding, J. \& Lupas, A. N. "Comparative analysis of coiled-coil prediction methods". Journal of Structural Biology 155, 140-145 (2006) (cit. on p. 10).
59. Harbury, P. B., Zhang, T., Kim, P. S. \& Alber, T. "A Switch Between 2stranded, 3 -stranded and 4-stranded Coiled Coils In Gcn4 Leucine-zipper Mutants". Science 262, 1401-1407 (1993) (cit. on pp. 10, 91, 110).
60. Levine, B., Mizushima, N. \& Virgin, H. W. "Autophagy in immunity and inflammation". Nature 469, 323-335 (2011) (cit. on p. 11).
61. Deretic, V. \& Levine, B. "Autophagy, Immunity, and Microbial Adaptations". Cell Host $\mathcal{E}^{2}$ Microbe 5, 527-549 (2009) (cit. on p. 11).
62. Lamark, T., Kirkin, V., Dikic, I. \& Johansen, T. "NBR1 and p62 as cargo receptors for selective autophagy of ubiquitinated targets". Cell Cycle 8, 19861990 (2009) (cit. on p. 12).
63. Thurston, T. L. M., Ryzhakov, G., Bloor, S., von Muhlinen, N. \& Randow, F. "The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria". Nature Immunology 10, 1215 (2009) (cit. on p. 12).
64. Mostowy, S. et al. "p62 and NDP52 Proteins Target Intracytosolic Shigella and Listeria to Different Autophagy Pathways". Journal of Biological Chemistry 286, 26987-26995 (2011) (cit. on pp. 12, 13).
65. Von Muhlinen, N. et al. "LC3C, Bound Selectively by a Noncanonical LIR Motif in NDP52, Is Required for Antibacterial Autophagy". Molecular Cell 48, 329-342 (2012) (cit. on p. 12).
66. Korac, J. et al. "Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates". Journal of Cell Science 126, 580-592 (2013) (cit. on p. 12).
67. Wild, P. et al. "Phosphorylation of the Autophagy Receptor Optineurin Restricts Salmonella Growth". Science 333, 228-233 (2011) (cit. on p. 12).
68. Kirkin, V. et al. "A Role for NBR1 in Autophagosomal Degradation of Ubiquitinated Substrates". Molecular Cell 33, 505-516 (2009) (cit. on p. 12).
69. Jo, E.-K., Yuk, J.-M., Shin, D.-M. \& Sasakawa, C. "Roles of autophagy in elimination of intracellular bacterial pathogens." Frontiers in Immunology 4, 97 (2013) (cit. on p. 12).
70. Shaid, S., Brandts, C. H., Serve, H. \& Dikic, I. "Ubiquitination and selective autophagy". Cell Death and Differentiation 20, 21-30 (2013) (cit. on p. 12).
71. Harriff, M. J., Purdy, G. E. \& Lewinsohn, D. M. "Escape from the Phagosome: The Explanation for MHC-I Processing of Mycobacterial Antigens?" Frontiers in Immunology 3, 40 (2012) (cit. on p. 12).
72. Huynh, K. K., Joshi, S. A. \& Brown, E. J. "A delicate dance: host response to mycobacteria". Current Opinion in Immunology 23, 464-472 (2011) (cit. on p. 12).
73. Deretic, V. et al. "Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism". Cellular Microbiology 8, 719-727 (2006) (cit. on p. 12).
74. Basu, J., Shin, D.-M. \& Jo, E.-K. "Mycobacterial signaling through toll-like receptors." Frontiers in Cellular and Infection Microbiology 2, 145 (2012) (cit. on p. 12).
75. Bakowski, M. A., Braun, V. \& Brumell, J. H. "Salmonella-Containing Vacuoles: Directing Traffic and Nesting to Grow". Traffic 9, 2022-2031 (2008) (cit. on p. 12).
76. Ashida, H. et al. "Shigella are versatile mucosal pathogens that circumvent the host innate immune system". Current Opinion in Immunology 23, 448455 (2011) (cit. on p. 12).
77. Egile, C. et al. "Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility". Journal of Cell Biology 146, 1319-1332 (1999) (cit. on pp. 12, 14, 131).
78. Ogawa, M. et al. "Escape of intracellular Shigella from autophagy". Science 307, 727-731 (2005) (cit. on p. 12).
79. Lee, M.-S. et al. "Shiga toxins induce autophagy leading to differential signalling pathways in toxin-sensitive and toxin-resistant human cells". Cellular Microbiology 13, 1479-1496 (2011) (cit. on p. 13).
80. Dupont, N. et al. "Shigella Phagocytic Vacuolar Membrane Remnants Participate in the Cellular Response to Pathogen Invasion and Are Regulated by Autophagy". Cell Host $\mathcal{F}$ Microbe 6, 137-149 (2009) (cit. on p. 13).
81. Mostowy, S. et al. "Entrapment of Intracytosolic Bacteria by Septin Cage-like Structures". Cell Host $\mathcal{E}^{2}$ Microbe 8, 433-444 (2010) (cit. on pp. 13, 131).
82. Junker, M. et al. "Pertactin beta-helix folding mechanism suggests common themes for the secretion and folding of autotransporter proteins". Proceedings of the National Academy of Sciences of the United States of America 103, 4918-4923 (2006) (cit. on p. 14).
83. Janakiraman, A., Fixen, K. R., Gray, A. N., Niki, H. \& Goldberg, M. B. "A Genome-Scale Proteomic Screen Identifies a Role for DnaK in Chaperoning of Polar Autotransporters in Shigella". Journal of Bacteriology 191, 6300-6311 (2009) (cit. on p. 13).
84. Wagner, J. K., Heindl, J. E., Gray, A. N., Jain, S. \& Goldberg, M. B. "Contribution of the Periplasmic Chaperone Skp to Efficient Presentation of the Autotransporter IcsA on the Surface of Shigella flexneri". Journal of Bacteriology 191, 815-821 (2009) (cit. on p. 14).
85. Kühnel, K. \& Diezmann, D. "Crystal Structure of the Autochaperone Region from the Shigella flexneri Autotransporter IcsA". Journal of Bacteriology 193, 2042-2045 (2011) (cit. on pp. 14, 120, 130).
86. Benz, I. \& Schmidt, M. A. "Structures and functions of autotransporter proteins in microbial pathogens". International Journal of Medical Microbiology 301, 461-468 (2011) (cit. on p. 14).
87. May, K. L. \& Morona, R. "Mutagenesis of the Shigella flexneri autotransporter IcsA reveals novel functional regions involved in IcsA biogenesis and recruitment of host neural Wiscott-Aldrich syndrome protein". Journal of Bacteriology 190, 4666-4676 (2008) (cit. on pp. 14, 131).
88. Allaoui, A., Mounier, J., Prevost, M. C., Sansonetti, P. J. \& Parsot, C. "icsB: a Shigella-flexneri Virulence Gene Necessary For the Lysis of Protrusions During Intercellular Spread". Molecular Microbiology 6, 1605-1616 (1992) (cit. on p. 15).
89. Ogawa, M., Suzuki, T., Tatsuno, I., Abe, H. \& Sasakawa, C. "IcsB, secreted via the type III secretion system, is chaperoned by $\operatorname{Ipg} A$ and required at the post-invasion stage of Shigella pathogenicity". Molecular Microbiology 48, 913-931 (2003) (cit. on pp. 15, 124).
90. Studier, F. W. "Protein production by auto-induction in high-density shaking cultures". Protein Expression and Purification 41, 207-234 (2005) (cit. on pp. 20-23).
91. Laemmli, U. K. "Cleavage of Structural Proteins During Assembly of Head of Bacteriophage-t4". Nature 227, 680 (1970) (cit. on p. 47).
92. Schägger, H. \& von Jagow, G. "Tricine Sodium Dodecyl-sulfate Polyacrylamidegel Electrophoresis For the Separation of Proteins In the Range From 1-kda To 100-kda". Analytical Biochemistry 166, 368-379 (1987) (cit. on p. 47).
93. Towbin, H., Staehelin, T. \& Gordon, J. "Electrophoretic Transfer of Proteins From Polyacrylamide Gels To Nitrocellulose Sheets: Procedure and Some Applications". Proceedings of the National Academy of Sciences of the United States of America 76, 4350-4354 (1979) (cit. on p. 48).
94. Einarson, M. B. "Detection of protein-protein interactions using the GST fusion protein pull-down technique". Nature Methods 1, 275-276 (2004) (cit. on p. 49).
95. Kabsch, W. "Automatic Processing of Rotation Diffraction Data From Crystals of Initially Unknown Symmetry and Cell Constants". Journal of Applied Crystallography 26, 795-800 (1993) (cit. on pp. 53, 82).
96. Adams, P. D. et al. "PHENIX: a comprehensive Python-based system for macromolecular structure solution". Acta Crystallographica Section D 66, 213-221 (2010) (cit. on pp. 54, 82).
97. Emsley, P. \& Cowtan, K. "Coot: model-building tools for molecular graphics". Acta Crystallographica Section D 60, 2126-2132 (2004) (cit. on pp. 54, 85).
98. Schrödinger, LLC. The PyMOL Molecular Graphics System, Version 1.3r1. 2010 (cit. on p. 55).
99. Livingstone, C. D. \& Barton, G. J. "Protein-sequence Alignments-A Strategy For the Hierarchical Analysis of Residue Conservation". Computer Applications in the Biosciences 9, 745-756 (1993) (cit. on pp. 55, 92).
100. Lupas, A., van Dyke, M. \& Stock, J. "Predicting Coiled Coils From Protein Sequences". Science 252, 1162-1164 (1991) (cit. on p. 57).
101. Dosztányi, Z., Csizmók, V., Tompa, P. \& Simon, I. "The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins". Journal of Molecular Biology 347, 827-839 (2005) (cit. on pp. 57, 58).
102. Dosztányi, Z., Csizmók, V., Tompa, P. \& Simon, I. "IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content". Bioinformatics 21, 3433-3434 (2005) (cit. on pp. 57, 58).
103. Remmert, M., Biegert, A., Hauser, A. \& Söding, J. "HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment". Nature Methods 9, 173-175 (2012) (cit. on p. 59).
104. Söding, J. "Protein homology detection by HMM-HMM comparison". Bioinformatics 21, 951-960 (2005) (cit. on p. 59).
105. Söding, J., Biegert, A. \& Lupas, A. N. "The HHpred interactive server for protein homology detection and structure prediction". Nucleic Acids Research 33, W244-W248 (2005) (cit. on p. 59).
106. Overton, I. M. et al. "TarO: a target optimisation system for structural biology". Nucleic Acids Research 36, W190-W196 (2008) (cit. on p. 60).
107. Evans, G. \& Pettifer, R. F. "CHOOCH: a program for deriving anomalousscattering factors from X-ray fluorescence spectra". Journal of Applied Crystallography 34, 82-86 (2001) (cit. on p. 81).
108. Strelkov, S. V. \& Burkhard, P. "Analysis of alpha-helical coiled coils with the program TWISTER reveals a structural mechanism for stutter compensation". Journal of Structural Biology 137, 54-64 (2002) (cit. on p. 89).
109. Notredame, C., Higgins, D. G. \& Heringa, J. "T-Coffee: A novel method for fast and accurate multiple sequence alignment". Journal of Molecular Biology 302, 205-217 (2000) (cit. on p. 89).
110. Suzuki, T. et al. "Identification of FEZ1 as a protein that interacts with JC virus agnoprotein and microtubules: Role of agnoprotein-induced dissociation of FEZ1 from microtubules in viral propagation". Journal of Biological Chemistry 280, 24948-24956 (2005) (cit. on p. 99).
111. Alborghetti, M. R. et al. "Human FEZ1 Protein Forms a Disulfide Bond Mediated Dimer: Implications for Cargo Transport". Journal of Proteome Research 9, 4595-4603 (2010) (cit. on p. 102).
112. Smith, S. J. M. \& Rittinger, K. "Preparation of GTPases for structural and biophysical analysis." Methods in molecular biology (Clifton, N.J.) 189, 1324 (2002) (cit. on p. 104).
113. Li, X. et al. "Imperfect interface of Beclin1 coiled-coil domain regulates homodimer and heterodimer formation with Atg14L and UVRAG". Nature Communications 3, 662 (2012) (cit. on p. 110).
114. Lanza, D. C. F. et al. "FEZ1 interacts with CLASP2 and NEK1 through coiled-coil regions and their cellular colocalization suggests centrosomal functions and regulation by PKC". Molecular and Cellular Biochemistry 338, 3545 (2010) (cit. on p. 112).
115. Di Bartolomeo, S. et al. "The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy". Journal of Cell Biology 191, 155-168 (2010) (cit. on p. 113).
116. Russell, R. C. et al. "ULK1 induces autophagy by phosphorylating Beclin1 and activating VPS34 lipid kinase". Nature Cell Biology. advance online publication (2013) (cit. on p. 113).
117. Wirth, M., Joachim, J. \& Tooze, S. A. "Autophagosome formation-The role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage". Seminars in Cancer Biology. in press (cit. on p. 113).
118. Kayath, C. A. et al. "Escape of intracellular Shigella from autophagy requires binding to cholesterol through the type III effector, IcsB". Microbes and Infection 12, 956-966 (2010) (cit. on p. 131).
119. Suzuki, T. et al. "Neural Wiskott-Aldrich syndrome protein (N-WASP) is the specific ligand for Shigella VirG among the WASP family and determines the host cell type allowing actin-based spreading". Cellular Microbiology 4, 223233 (2002) (cit. on p. 131).
120. Ashida, H. et al. "A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKK gamma to dampen the host NF-kappa B-mediated inflammatory response". Nature Cell Biology 12, 66 (2010) (cit. on p. 131).

[^0]:    Materials and Methods

[^1]:    
    
    ld3_A Myosin VI; molecular mo nlw-A MAD protein, MAX dimeri
    
     2v66_B Nuclear distribution pr 1jnm_A Proto-oncogene C-JUN; B
    2 v 4 h A NF -kappa-B essential mo 3u59_A Tropomyosin beta chain; 2p90-A Hypothetical protein CG 1gk7-A Vimentin; intermediate 3hnw_A Uncharacterized protein 1m1j_C Fibrinogen gamma chain; 2oqq_A Transcription factor HY
    1ses A Seryl-tRNA synthetase; Ises_A Seryl-tRNA synthetase; $3 u 0 c$ _A Invasin IPAB, 62 kDa an
     3caz_A BAR protein; thermo-aci 3vrp-A Signal transduction pro
    
     Fibritin, gpwac M; bact
    Spectrin alpha chain, e
     E3 ubiquitin-protein li
    Fibrinogen beta chain; Fibrinogen beta chain; Catenin alpha-1; four $h$ Myotonin-protein kinase Myosin heavy chain, str Myosin heavy chain, car Iropomyosin; contractIl
    DNA repair protein XRCC DNA repair protein XRCC
    Striated-muscle alpha $t$ Prefoldin beta subunit Coronin-1A; coiled coil Spindle assembly abnorm
    Centriole protein; cent Centriole protein; cent
    DNA repair protein XRCC Fibrinogen beta chain; Uncharacterized protein RHO-associated protein
    
    
    

[^2]:    $=(\operatorname{SUM}(\operatorname{ABS}(I(h, i)-I(h)))) /(\operatorname{SUM}(I(h, i)))$
    $=\operatorname{expected} R-$ FACTOR derived from Sigma(I)
    R-FACIOR
    expected

    ## R-FACTOR

